data_2lrj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lrj _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.419 HD22 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 . . . . . 0 N--CA 1.449 -0.513 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.476 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.662 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.822 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.414 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.662 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.441 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.588 HG12 HD12 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.647 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.831 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.831 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.623 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.522 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.647 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.474 ' CG1' HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.762 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.451 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.452 ' HG2' HG21 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.607 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.588 HD12 HG12 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.639 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.481 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.481 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.639 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.476 ' CB ' HD13 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.443 HG21 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.607 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.742 HG23 HG23 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.876 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 98' ' ' ARG . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.854 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.431 ' HE2' HG21 ' A' ' 95' ' ' VAL . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.64 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.822 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.64 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.442 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.431 HG21 ' HE2' ' A' ' 86' ' ' MET . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.854 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.638 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.876 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.559 ' HB3' HG21 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.451 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.762 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.623 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.758 ' H ' HD11 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.636 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.473 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.546 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.466 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.443 HG23 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.636 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.529 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.4 ' HE1' ' O ' ' A' ' 28' ' ' ILE . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.735 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.511 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.735 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.423 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.487 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.608 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.488 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.487 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.602 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG21 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.513 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.585 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.837 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.616 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.608 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.71 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.616 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.585 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.591 HG11 HG23 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.696 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.476 HG21 HD21 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.784 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.466 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.784 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.908 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.445 ' HB3' HD13 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.696 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.44 ' HB2' HG21 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.504 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.513 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.816 HG21 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.432 HD22 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.448 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.563 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.448 ' HD1' ' CB ' ' A' ' 11' ' ' TYR . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.588 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.588 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.464 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.435 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 7.0 t30 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.662 ' CH2' HG22 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.496 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.405 HE21 HG23 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.597 ' CD2' HD13 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.677 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.585 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HG1' ' C ' ' A' ' 51' ' ' HIS . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.637 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.662 HG22 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.566 ' H ' HG21 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.831 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . 0.478 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.491 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.831 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.559 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.639 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.458 ' HA ' HG23 ' A' ' 58' ' ' ILE . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.737 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.637 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.957 HG21 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.737 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.549 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.728 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.479 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.99 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.4 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.99 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.479 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.728 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.549 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.957 ' HB ' HG21 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.46 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.641 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.677 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.597 HD13 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.562 HD21 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.562 ' N ' HD21 ' A' ' 9' ' ' ASN . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.544 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.457 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.544 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 12.8 mm100 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.779 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.599 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.585 HG12 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.532 HG13 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.429 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.618 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.588 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.518 HG22 ' HB3' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.618 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.473 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.523 HD22 ' HA ' ' A' ' 66' ' ' PHE . 4.3 t30 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.5 t30 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.604 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.413 ' HB3' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.628 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.852 HG23 HG21 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 52.8 m-20 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.691 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.463 ' HG1' ' C ' ' A' ' 51' ' ' HIS . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB3' ' HZ1' ' A' ' 55' ' ' LYS . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.579 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.664 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.443 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.57 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.664 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.599 HG21 HG22 ' A' ' 17' ' ' THR . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.54 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.625 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.6 HG23 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.877 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.821 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.507 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.779 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.507 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.821 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.877 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.411 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.6 ' HB ' HG23 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.444 ' CD2' HD21 ' A' ' 59' ' ' LEU . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.691 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.852 HG21 HG23 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.556 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 . . . . . 0 N--CA 1.449 -0.476 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.544 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.544 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 22.0 mm-40 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.965 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.437 HG23 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.556 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.448 ' CD1' ' HE2' ' A' ' 86' ' ' MET . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.419 HG13 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.566 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.587 HG22 HG13 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.609 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.609 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.438 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.795 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.568 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.602 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CD2' HD11 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.459 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.496 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.458 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.606 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.795 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.864 ' HG2' HD21 ' A' ' 109' ' ' ASN . 0.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.827 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.827 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.418 ' HB3' HD11 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.553 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.426 HG21 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.553 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.786 HG21 HG23 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.825 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.436 HD13 HD13 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.627 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.991 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.965 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.407 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.991 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.627 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.825 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.491 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.864 HD21 ' HG2' ' A' ' 60' ' ' GLN . 0.6 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.602 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 15.7 m-70 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.587 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.652 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.46 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.46 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.403 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.682 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.744 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.406 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.682 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.581 ' CD1' ' HE3' ' A' ' 86' ' ' MET . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.583 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.53 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.53 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.631 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.631 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.404 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.593 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.667 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.72 ' HD2' HD13 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.493 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.478 ' CG1' HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 1.049 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.792 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.593 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.583 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.708 HD12 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.471 ' N ' HD13 ' A' ' 59' ' ' LEU . 0.0 OUTLIER -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.542 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.721 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.428 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . 0.533 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.721 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.542 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.667 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.53 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.412 HG23 HG21 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.593 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.561 HG13 HG23 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.429 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.845 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.412 HG21 HG23 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.638 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.699 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.744 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.699 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.638 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.845 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.61 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.792 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.708 ' CD2' HD12 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.43 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 1.049 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.72 HD13 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.493 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.449 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 . . . . . 0 CA--C 1.522 -0.111 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.595 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.595 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.598 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HG22 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.546 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.662 HG11 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.495 HG12 HD11 ' A' ' 58' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.46 HD12 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.424 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.563 ' HB3' HG12 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.473 ' ND2' ' HB3' ' A' ' 41' ' ' ALA . 11.3 t30 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.698 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.578 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.552 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.435 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.447 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.662 HG12 HG11 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.574 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.692 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.692 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.499 ' HB3' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.409 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.454 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.661 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.769 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.768 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.598 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.47 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.768 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.711 ' HB2' HD12 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.769 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.441 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.541 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.467 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.435 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.732 HD13 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 23.1 p80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.771 ' H ' HD11 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 110.47 -0.196 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.437 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.44 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.44 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.483 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.549 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 20.0 mm-40 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.716 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.549 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.409 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.595 ' HH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.486 HG21 HD11 ' A' ' 28' ' ' ILE . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.437 ' H ' HG22 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.706 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.706 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.595 ' HB3' ' HH ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.55 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.666 ' HA3' HD22 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.54 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.6 m120 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.422 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.666 HD22 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.726 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.447 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.623 ' CD2' HD11 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.485 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.968 HG11 HG21 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 50' ' ' ASN . 0.0 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.629 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.629 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.667 ' HG3' HD13 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.4 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.726 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.667 HD13 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.443 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.791 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.685 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.422 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.791 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.613 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.606 HG23 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.625 HG22 HG21 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.535 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.625 HG21 HG22 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.613 HD12 ' HB1' ' A' ' 70' ' ' ALA . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.491 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.594 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.716 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.475 ' HB3' HD13 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.535 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.521 HD11 HD11 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.448 ' HB2' HG21 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.506 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.443 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.589 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.968 HG21 HG11 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.515 HD22 ' HB2' ' A' ' 22' ' ' ASP . 85.1 m-20 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.432 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.652 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.914 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.482 HG22 HG23 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.652 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.817 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . 0.515 ' HB2' HD22 ' A' ' 9' ' ' ASN . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HD2' ' HA ' ' A' ' 23' ' ' LYS . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.443 HG22 HD11 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.443 HD11 HG22 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.732 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.732 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.409 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.418 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.52 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.426 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.565 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD13 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.436 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.408 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.502 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.817 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.613 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.469 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.588 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.402 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.735 ' HA ' HG21 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.658 HG22 HG23 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.685 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.735 HG21 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.547 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.667 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.701 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.914 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.701 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.667 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.547 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.685 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.555 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.507 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.559 ' CG ' HD12 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.502 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.553 HD13 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.497 HD12 ' HB2' ' A' ' 30' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.659 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.54 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.54 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 10.8 mm100 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.659 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.52 ' CG1' HD11 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.525 HG11 HD13 ' A' ' 58' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.497 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.564 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.462 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.486 ' HA ' HG22 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.533 ' CE2' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.509 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.41 ' CD2' HD11 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.52 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.497 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.653 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.513 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.42 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.605 ' HB3' ' HZ2' ' A' ' 55' ' ' LYS . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.525 HD13 HG11 ' A' ' 24' ' ' VAL . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.498 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.558 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG12 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.561 ' HB3' HD13 ' A' ' 83' ' ' ILE . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.457 ' HA ' HG22 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.581 HG13 HG21 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.553 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.664 HD12 HD12 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.886 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.775 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.964 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.466 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.775 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.886 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.555 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.553 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.664 HD12 HD12 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.513 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.497 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.52 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.895 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.58 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.529 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.481 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.651 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 1.043 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.651 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.743 HG11 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.529 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.458 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.495 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.657 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.535 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.579 ' CD2' HG13 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.657 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.456 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' HD11 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.534 ' HB ' ' CE1' ' A' ' 112' ' ' HIS . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.515 HG13 HG21 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.743 HG12 HG11 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.522 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.677 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.505 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.579 HG13 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.712 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.669 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.609 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.669 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.481 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.793 HG21 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.712 HD13 ' HB1' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.735 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.655 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.562 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 1.043 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.562 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.735 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.627 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.793 ' HB ' HG21 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.411 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.522 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.674 HD11 ' HD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.534 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 29.6 p80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.52 HD21 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 . . . . . 0 C--O 1.233 0.199 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.525 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.424 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 1.041 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.457 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.525 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.435 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.874 HG12 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.643 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.577 HG22 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.643 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.735 HD11 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.827 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.552 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . 0.483 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.827 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.554 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.7 m120 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.661 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.554 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.664 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.457 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.665 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.699 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.717 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 31.9 m-20 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.83 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.493 ' HG2' HG13 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.541 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.874 HG12 HG12 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.614 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.57 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.725 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.424 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.725 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.661 HG13 ' HB1' ' A' ' 35' ' ' ALA . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.551 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.427 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.441 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.541 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.829 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.645 HD12 HD13 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.748 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.684 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.439 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 1.041 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.495 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.748 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.483 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.829 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.454 ' O ' HG21 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.403 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.408 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.408 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.496 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.83 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.717 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.699 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.543 ' HE2' ' ND2' ' A' ' 50' ' ' ASN . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.405 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 . . . . . 0 N--CA 1.455 -0.207 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.476 HD11 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.428 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.412 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.412 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.507 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.979 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.428 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.517 HG21 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.564 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.542 HG23 HD11 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.542 HD11 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.709 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.476 ' HB3' HD11 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.709 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.411 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.411 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.526 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.46 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.645 ' CD2' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.453 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.564 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.453 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.657 ' HD2' HD13 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.552 HG12 HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.913 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.628 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.457 ' HB2' HG13 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.568 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.588 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.607 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.526 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.645 HG12 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.509 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG23 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.568 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.687 HG23 HG21 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.495 ' HB3' HG23 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.723 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.647 HG23 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.926 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.709 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.52 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.979 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.435 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.709 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.926 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.568 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.495 HG23 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.723 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.45 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.628 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.913 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.509 HD11 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.793 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.709 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.481 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.793 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.79 HD13 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.772 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' SER . . . . . 0.509 ' HB2' HD11 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.79 ' HZ3' HD13 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.445 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.603 ' HB2' HG12 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.711 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.58 ' HB2' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.712 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.603 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.598 HG22 ' CH2' ' A' ' 38' ' ' TRP . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.578 ' H ' HG21 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.54 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.745 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.678 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.437 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.671 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.533 HD13 HD23 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.875 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.422 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.709 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.422 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.875 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.671 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.527 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.603 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.711 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.821 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.554 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.826 0.346 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.527 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 14.7 mm-40 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.509 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.527 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.813 HG11 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.554 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.771 ' HB ' HD13 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.545 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.566 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.523 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.477 ' ND2' ' HB3' ' A' ' 41' ' ' ALA . 13.4 t30 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.613 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.566 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.472 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.491 ' NE2' HG11 ' A' ' 49' ' ' VAL . 16.2 mm-40 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.682 ' HD2' HD11 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.726 HG12 HG21 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 1.033 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.535 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.426 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.454 ' CG ' ' HB2' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.813 HG12 HG11 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.535 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.443 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.446 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.651 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.431 ' HB2' HG21 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.465 HG21 HG23 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.796 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.573 HD12 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 1.02 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.729 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.651 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.729 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 1.02 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.47 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.573 ' HB2' HD12 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.796 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.499 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.413 ' CD2' HD22 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.535 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 1.033 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.726 HG21 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.771 HD13 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.63 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.556 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.613 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.726 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.411 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.63 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.558 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.419 ' CG1' HD13 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.416 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.416 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.54 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.409 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.573 ' HB1' HG11 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.435 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.6 t30 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.805 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.46 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.648 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.804 HG23 HG23 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.7 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 31.0 m-20 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.43 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.57 ' HG2' HG23 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.498 ' H ' ' HB2' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.498 ' HB2' ' H ' ' A' ' 54' ' ' SER . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.805 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.625 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.452 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.592 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.435 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.592 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.647 HG13 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.541 HG22 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.512 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.57 HG23 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.462 HD11 HD21 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.797 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.609 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.58 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.797 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.512 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.43 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.7 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.804 HG23 HG23 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.473 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.571 0.224 . . . . 0.0 110.512 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.455 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.455 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.437 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.428 HG21 HG23 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.49 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.43 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.672 HG12 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.586 HG23 HD12 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.419 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.631 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.829 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.829 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.441 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.616 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.516 ' HB2' HG23 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.598 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.424 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.67 ' HD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' THR . . . . . 0.817 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.877 HG11 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.652 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.548 ' HB2' HG13 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.672 HG12 HG12 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.7 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.642 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.984 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.984 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.642 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.684 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.451 HG23 HG23 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.571 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.422 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.631 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.451 HG23 HG23 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.569 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.593 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.569 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.422 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.631 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.486 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.7 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.652 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.877 HG22 HG11 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.817 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.685 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.506 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 1.017 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.685 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.611 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.611 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.404 HG21 HD11 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.549 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.639 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.492 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.483 ' HA ' HG23 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.659 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.48 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 9.0 t30 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.878 ' HH2' HG22 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.639 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.474 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.664 HG13 HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.933 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.666 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.629 ' HB2' HG12 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.878 HG22 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.587 ' H ' HG21 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.689 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.571 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.659 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.689 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.566 HG22 HG22 ' A' ' 17' ' ' THR . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.793 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.445 ' HA ' HG23 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.793 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.744 HG23 HG21 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.496 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.744 HG21 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.629 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.893 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.408 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 1.017 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.893 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.629 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.689 HD12 HD11 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.486 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.486 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.483 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.666 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.933 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.664 HG23 HG13 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.412 HD12 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.632 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.496 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.418 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.418 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.428 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.529 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 22.3 mm-40 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.701 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.551 HG21 HG23 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.632 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.53 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.405 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.45 HG22 HD12 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.405 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.656 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.633 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.633 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.534 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.454 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.58 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.615 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.438 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.656 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.754 HG13 HG23 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.703 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.47 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.404 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.541 HG23 ' CH2' ' A' ' 38' ' ' TRP . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.681 HD13 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.609 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.881 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.409 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.881 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.614 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . 0.509 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.587 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.837 HG21 HG23 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.837 HG23 HG21 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.499 HD13 ' HB1' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.666 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.449 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.701 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.666 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.49 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.572 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . 0.486 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.681 ' CD2' HD13 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.47 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.703 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.754 HG23 HG13 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . 0.418 ' HE2' ' ND2' ' A' ' 50' ' ' ASN . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.562 HD22 ' HB2' ' A' ' 22' ' ' ASP . 83.9 m-20 . . . . . 0 CA--C 1.518 -0.253 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . 0.524 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.525 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.412 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.933 ' HA2' ' HE2' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.525 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 9.6 mm100 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.777 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TYR . . . . . 0.452 ' CD1' ' HE1' ' A' ' 86' ' ' MET . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 9' ' ' ASN . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.569 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.412 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.407 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . 0.482 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.542 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 12.7 t30 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' TRP . . . . . 0.791 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.481 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLN . . . . . 0.481 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PHE . . . . . 0.753 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASN . . . . . 0.645 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.667 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.46 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LYS . . . . . 0.576 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.692 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.791 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.601 ' H ' HG23 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLN . . . . . 0.498 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.65 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.442 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.429 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.482 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.65 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.571 HG12 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.617 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.454 HG21 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.617 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' SER . . . . . 0.576 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.599 HG21 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.54 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.571 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.933 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.533 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.777 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' GLY . . . . . 0.533 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' PRO . . . . . 0.504 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.571 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.599 ' HB ' HG21 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.417 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' SER . . . . . 0.578 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.606 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.417 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.606 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASN . . . . . 0.745 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' TYR . . . . . 0.692 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ILE . . . . . 0.847 HG22 HG23 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.572 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.9 m -129.34 131.78 46.96 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.0 p -61.07 -57.99 10.26 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 123.485 0.49 . . . . 0.0 111.154 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.7 mt 48.36 72.81 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.7 0.762 . . . . 0.0 110.836 -177.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -142.71 -60.24 0.44 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.035 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -83.62 64.91 8.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.745 0.783 . . . . 0.0 109.001 170.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.0 p -143.86 -67.21 0.34 Allowed 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.837 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 58.31 -94.89 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.31 -0.859 . . . . 0.0 113.478 173.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.419 HD22 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 -81.4 136.06 35.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 -176.811 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.476 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.662 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.822 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.414 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.662 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.575 HG11 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.441 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.588 HG12 HD12 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.647 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.831 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.831 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.623 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.522 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.647 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.474 ' CG1' HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.762 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.451 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.452 ' HG2' HG21 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.607 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.588 HD12 HG12 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.623 HD22 HD12 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.639 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.481 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.481 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.639 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.588 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.476 ' CB ' HD13 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.443 HG21 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.607 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.742 HG23 HG23 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.876 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.638 HD11 ' HB3' ' A' ' 98' ' ' ARG . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.854 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.431 ' HE2' HG21 ' A' ' 95' ' ' VAL . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.64 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.822 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.64 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.442 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.431 HG21 ' HE2' ' A' ' 86' ' ' MET . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.854 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.638 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.876 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.559 ' HB3' HG21 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.451 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.762 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.623 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.758 ' H ' HD11 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.777 0 N-CA-C 111.914 -0.475 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 m -80.27 94.39 6.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.961 0.41 . . . . 0.0 110.896 -178.06 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 p -104.47 167.41 9.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.843 175.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 66.6 mt -62.97 -62.05 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.968 0.413 . . . . 0.0 110.511 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.2 m -154.61 104.16 2.52 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 34.4 m170 67.16 -81.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.681 0.613 . . . . 0.0 110.225 -173.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 32.3 t -154.78 146.23 23.07 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -140.8 -48.41 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.978 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.636 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 -140.35 147.69 40.2 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.473 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.546 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.466 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.443 HG23 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.636 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.529 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.4 ' HE1' ' O ' ' A' ' 28' ' ' ILE . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.735 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.511 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.735 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.491 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.423 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.837 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.487 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.608 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.488 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.487 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.602 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.816 HG22 HG21 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.513 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.585 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.837 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.616 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.608 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.71 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.71 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.616 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.585 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.591 HG11 HG23 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.696 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.476 HG21 HD21 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.784 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.466 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.784 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.908 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.445 ' HB3' HD13 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.696 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.44 ' HB2' HG21 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.504 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.513 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.816 HG21 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.5 t -87.07 104.91 16.77 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 178.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.2 m -79.73 -30.52 40.92 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.084 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -101.6 129.17 53.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.323 0.582 . . . . 0.0 111.266 -178.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 m -123.07 -47.53 2.03 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.289 179.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.91 113.42 25.23 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.323 171.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.2 t -63.34 -36.61 84.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.072 0.463 . . . . 0.0 110.114 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.15 -36.95 2.29 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.51 175.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.432 HD22 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 -110.32 146.64 35.37 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 -176.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.448 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.516 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.563 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.448 ' HD1' ' CB ' ' A' ' 11' ' ' TYR . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.588 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.402 ' O ' ' HB3' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.588 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.464 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.435 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.491 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 7.0 t30 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.662 ' CH2' HG22 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.496 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.405 HE21 HG23 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.597 ' CD2' HD13 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.544 HG13 HG23 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.677 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.585 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HG1' ' C ' ' A' ' 51' ' ' HIS . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.637 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.662 HG22 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.566 ' H ' HG21 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.831 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.478 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.478 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.491 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.831 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.559 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.639 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.458 ' HA ' HG23 ' A' ' 58' ' ' ILE . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.737 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.637 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.549 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.957 HG21 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.737 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.549 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.728 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.479 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.99 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.4 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.99 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.479 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.728 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.549 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.467 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.957 ' HB ' HG21 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.46 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.641 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.677 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.597 HD13 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.644 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.2 m -96.03 -24.45 16.34 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.222 0.534 . . . . 0.0 110.027 179.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -153.76 167.61 29.06 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 54.1 mt -104.44 97.53 5.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.186 0.517 . . . . 0.0 111.752 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -130.06 -39.15 1.39 Allowed 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.71 90.46 1.63 Allowed 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 172.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.3 t -86.92 -26.68 23.78 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.092 -176.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.9 44.44 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 -175.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.562 HD21 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -134.36 127.86 32.5 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -176.305 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.562 ' N ' HD21 ' A' ' 9' ' ' ASN . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.544 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.457 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.426 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.544 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 12.8 mm100 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.779 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.599 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.487 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.585 HG12 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.588 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 23' ' ' LYS . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.532 HG13 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.429 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.618 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.588 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.518 HG22 ' HB3' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.618 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.473 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.523 HD22 ' HA ' ' A' ' 66' ' ' PHE . 4.3 t30 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.5 t30 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.604 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.413 ' HB3' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . 0.518 ' HB3' HG22 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.628 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.852 HG23 HG21 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 52.8 m-20 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.691 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.463 ' HG1' ' C ' ' A' ' 51' ' ' HIS . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HB3' ' HZ1' ' A' ' 55' ' ' LYS . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.579 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.664 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.443 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.57 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.664 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.599 HG21 HG22 ' A' ' 17' ' ' THR . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.54 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.625 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.6 HG23 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.877 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.821 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.507 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.779 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.507 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.821 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.877 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.411 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.6 ' HB ' HG23 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.444 ' CD2' HD21 ' A' ' 59' ' ' LEU . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.691 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.852 HG21 HG23 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 t -73.52 -47.52 40.32 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.663 0.268 . . . . 0.0 110.298 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.6 m 59.33 63.02 1.65 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.477 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 pt -99.55 168.49 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.929 176.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 t -113.19 -84.34 0.59 Allowed 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -122.73 -30.99 3.77 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.4 t -124.36 149.89 46.14 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.522 175.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.86 49.79 4.19 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.306 176.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.556 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 -124.67 144.86 49.97 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 -176.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.544 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.544 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 22.0 mm-40 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.965 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.437 HG23 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.556 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.448 ' CD1' ' HE2' ' A' ' 86' ' ' MET . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.419 HG13 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.566 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.587 HG22 HG13 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.609 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.457 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.609 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.438 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.795 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.568 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.602 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.579 ' CD2' HD11 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.459 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.496 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.458 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.606 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.795 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.609 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.864 ' HG2' HD21 ' A' ' 109' ' ' ASN . 0.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.827 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.468 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.827 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.418 ' HB3' HD11 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.553 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.426 HG21 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.553 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.786 HG21 HG23 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.825 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.436 HD13 HD13 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.627 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.991 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.965 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.407 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.991 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.627 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.825 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.491 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.864 HD21 ' HG2' ' A' ' 60' ' ' GLN . 0.6 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.602 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 15.7 m-70 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.587 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.1 t -125.82 -44.89 1.77 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.004 0.431 . . . . 0.0 110.333 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -94.28 25.36 3.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.108 0.48 . . . . 0.0 110.368 -178.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.1 mm -92.32 -16.25 7.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.025 -174.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 15.0 m -60.43 -60.62 3.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.751 -175.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -140.05 20.62 2.45 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.2 m 59.87 84.51 0.12 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.866 -173.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.65 -29.66 75.63 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.746 -0.661 . . . . 0.0 113.06 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 -157.95 149.83 21.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.652 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.46 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.46 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.403 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.682 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.744 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.406 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.682 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.581 ' CD1' ' HE3' ' A' ' 86' ' ' MET . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.583 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.53 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.53 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.631 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.631 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.404 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.593 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.667 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.72 ' HD2' HD13 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.493 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.478 ' CG1' HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 1.049 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.792 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.593 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.583 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.708 HD12 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.471 ' N ' HD13 ' A' ' 59' ' ' LEU . 0.0 OUTLIER -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.542 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.721 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.428 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.533 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . 0.533 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.721 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.542 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.667 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.53 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.412 HG23 HG21 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.593 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.561 HG13 HG23 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.429 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.845 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.412 HG21 HG23 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.638 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.699 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.463 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.744 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.463 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.405 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.699 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.638 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.845 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.61 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.792 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.708 ' CD2' HD12 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.43 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 1.049 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.72 HD13 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.493 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.449 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.676 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.5 t -167.1 -31.34 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.753 0.311 . . . . 0.0 110.318 -177.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.5 m -76.28 55.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.202 0.525 . . . . 0.0 111.708 -177.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tp -97.6 3.67 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 122.063 0.935 . . . . 0.0 109.116 176.36 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.9 m -107.51 -159.91 0.71 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.691 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -72.41 -25.36 61.46 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.6 0.238 . . . . 0.0 110.799 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 30.7 p 52.78 51.4 16.03 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 123.595 0.758 . . . . 0.0 112.851 173.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.75 -68.67 2.8 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.515 172.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 -142.51 149.04 38.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 -175.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.595 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.595 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.598 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HG22 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.546 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.662 HG11 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.495 HG12 HD11 ' A' ' 58' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.46 HD12 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.424 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.563 ' HB3' HG12 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.473 ' ND2' ' HB3' ' A' ' 41' ' ' ALA . 11.3 t30 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.698 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.578 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.732 ' HD2' HD13 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.552 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.435 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.447 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.662 HG12 HG11 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.611 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.574 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.692 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.692 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.611 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.499 ' HB3' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.409 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.454 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.661 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.769 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.711 HD12 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.768 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.598 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.47 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.768 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.432 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.711 ' HB2' HD12 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.769 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.441 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.441 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.541 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.467 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.435 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.732 HD13 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 23.1 p80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.771 ' H ' HD11 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 111.936 -0.466 . . . . 0.0 111.936 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.0 p -69.42 -22.27 63.69 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 p -77.45 -5.35 49.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.916 0.388 . . . . 0.0 110.779 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mm 54.5 75.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.26 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.4 m -121.45 -50.26 2.11 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -133.0 128.94 37.46 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.491 170.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.1 m -112.24 141.82 45.48 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.412 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.28 -114.32 2.75 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.706 176.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -117.34 -158.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.517 0 O-C-N 122.838 -0.213 . . . . 0.0 110.47 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.437 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.44 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.44 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.549 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 20.0 mm-40 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.716 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.549 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.409 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.595 ' HH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.486 HG21 HD11 ' A' ' 28' ' ' ILE . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.437 ' H ' HG22 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.706 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.706 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.595 ' HB3' ' HH ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.55 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.666 ' HA3' HD22 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.54 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.6 m120 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.685 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.422 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.666 HD22 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.726 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.447 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.623 ' CD2' HD11 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.485 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.968 HG11 HG21 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 50' ' ' ASN . 0.0 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.629 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.629 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.667 ' HG3' HD13 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.4 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.726 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.667 HD13 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.443 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.791 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.685 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.422 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.791 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.613 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.606 HG23 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.42 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.625 HG22 HG21 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.535 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.625 HG21 HG22 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.613 HD12 ' HB1' ' A' ' 70' ' ' ALA . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.491 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.594 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.438 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.716 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.438 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.445 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.475 ' HB3' HD13 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.535 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.521 HD11 HD11 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.448 ' HB2' HG21 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.506 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.443 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.589 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.968 HG21 HG11 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 111.782 -0.527 . . . . 0.0 111.782 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t 55.7 -100.33 0.11 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.076 0.55 . . . . 0.0 111.359 -178.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.1 m -95.37 -18.52 20.69 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.117 0.484 . . . . 0.0 110.611 -178.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.2 mm -73.96 92.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.444 0.64 . . . . 0.0 110.497 -177.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.416 ' C ' ' H ' ' A' ' 7' ' ' SER . 50.5 m -150.2 -48.46 0.13 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.175 175.775 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -76.84 10.0 2.52 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.255 172.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.416 ' H ' ' C ' ' A' ' 5' ' ' SER . 3.7 m -105.09 30.2 5.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.729 -179.577 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.1 134.44 39.94 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.456 -0.793 . . . . 0.0 113.219 -175.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.515 HD22 ' HB2' ' A' ' 22' ' ' ASP . 85.1 m-20 -85.34 -171.31 3.55 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.432 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.652 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.914 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.482 HG22 HG23 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.652 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.507 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.817 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.515 ' HB2' HD22 ' A' ' 9' ' ' ASN . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HD2' ' HA ' ' A' ' 23' ' ' LYS . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.443 HG22 HD11 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.443 HD11 HG22 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.732 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.732 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.409 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.418 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.449 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.52 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.426 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.565 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD13 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.461 ' HB ' HG23 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.436 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.408 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.502 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.817 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.613 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.469 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.588 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.402 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.588 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.718 ' HB3' HD11 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.735 ' HA ' HG21 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.658 HG22 HG23 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.474 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.685 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.735 HG21 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.547 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.667 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.701 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.914 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.701 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.667 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.547 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.578 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.685 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.555 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.507 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.555 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.559 ' CG ' HD12 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.502 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.553 HD13 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.104 -0.399 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.4 m -87.38 5.54 38.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.128 0.49 . . . . 0.0 110.818 -178.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -66.89 -21.6 66.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.074 177.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.3 pt -126.09 143.85 38.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.324 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 t -132.55 -72.63 0.52 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.93 0.395 . . . . 0.0 110.277 178.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 m170 -107.63 10.51 29.05 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.502 ' HB3' HD22 ' A' ' 10' ' ' LEU . 4.4 m -64.89 -42.64 94.62 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.883 -1.053 . . . . 0.0 111.382 -176.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.98 -122.93 17.27 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.426 -176.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 -90.82 132.8 35.66 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 176.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.502 HD22 ' HB3' ' A' ' 7' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.659 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.54 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.54 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 10.8 mm100 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.964 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.659 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.52 ' CG1' HD11 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.525 HG11 HD13 ' A' ' 58' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.497 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.564 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.462 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.486 ' HA ' HG22 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.533 ' CE2' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.509 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.41 ' CD2' HD11 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.52 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.497 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.653 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.513 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.42 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.605 ' HB3' ' HZ2' ' A' ' 55' ' ' LYS . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.525 HD13 HG11 ' A' ' 24' ' ' VAL . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.418 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.498 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.558 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG12 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.561 ' HB3' HD13 ' A' ' 83' ' ' ILE . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.457 ' HA ' HG22 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.581 HG13 HG21 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.553 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.585 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.664 HD12 HD12 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.886 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.775 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.964 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.466 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.775 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.886 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.555 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.553 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.664 HD12 HD12 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.513 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.653 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.497 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.52 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.895 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.788 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.4 m -142.45 -177.04 5.08 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 p -79.37 85.61 5.17 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.012 0.434 . . . . 0.0 110.548 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.6 mm -71.87 -66.39 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.364 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.6 t -147.22 -38.83 0.2 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.07 0.462 . . . . 0.0 110.067 177.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -141.78 80.74 1.73 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.06 176.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.9 m -103.45 -80.42 0.52 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 175.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.78 -94.8 0.21 Allowed Glycine 0 C--N 1.333 0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 113.757 173.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.58 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 -75.09 159.89 31.13 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 -171.585 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.529 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.481 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.651 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 1.043 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.651 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.743 HG11 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.529 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.458 ' O ' HD12 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.495 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.657 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.535 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.579 ' CD2' HG13 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.657 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.456 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' HD11 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.534 ' HB ' ' CE1' ' A' ' 112' ' ' HIS . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.515 HG13 HG21 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.481 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.743 HG12 HG11 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.5 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.522 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.677 ' O ' ' HB2' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.505 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.579 HG13 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.712 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.669 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.609 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.669 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.481 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.661 HG21 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.793 HG21 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.712 HD13 ' HB1' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.735 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.655 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.562 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 1.043 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.562 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.655 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.735 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.627 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.793 ' HB ' HG21 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.411 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.522 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.674 HD11 ' HD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.534 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 29.6 p80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.74 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.3 t -94.9 105.92 17.88 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.7 m -78.43 99.3 6.35 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.19 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.7 pt -110.35 61.78 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.787 0.804 . . . . 0.0 109.579 174.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 p -87.12 45.77 1.3 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.57 -175.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 m80 68.4 -72.29 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.515 -175.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 41.2 m -152.31 14.72 0.6 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.277 0.56 . . . . 0.0 109.814 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.01 -80.62 0.34 Allowed Glycine 0 N--CA 1.444 -0.813 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.592 -177.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.52 HD21 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 -173.81 167.3 4.41 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.525 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.424 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 1.041 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.457 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.525 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.435 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.874 HG12 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.643 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.577 HG22 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.643 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.735 HD11 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.827 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.552 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . 0.483 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.827 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.554 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.458 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.7 m120 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.661 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.554 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.664 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.457 ' HB2' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.665 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.699 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.717 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 31.9 m-20 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.83 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.493 ' HG2' HG13 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.541 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.874 HG12 HG12 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.614 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.57 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.725 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.424 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.725 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.661 HG13 ' HB1' ' A' ' 35' ' ' ALA . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.551 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.427 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.441 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.541 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.829 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.645 HD12 HD13 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.748 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.684 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.439 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 1.041 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.495 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.684 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.748 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.483 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.829 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.454 ' O ' HG21 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.403 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.408 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.403 ' HB2' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.408 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.496 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.83 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.717 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.699 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.543 ' HE2' ' ND2' ' A' ' 50' ' ' ASN . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.405 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.818 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 m -108.37 -48.74 3.29 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.905 0.353 . . . . 0.0 110.922 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.3 t -162.05 118.11 2.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.962 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.0 mt -108.95 98.17 6.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.21 0.529 . . . . 0.0 110.453 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.6 m -152.68 -59.48 0.14 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 14.1 p80 -164.73 33.19 0.07 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 167.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.6 m -78.14 41.85 0.38 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.983 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 163.03 -160.75 33.29 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 -168.81 161.75 11.14 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.476 HD11 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.428 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.412 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.412 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.507 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.979 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.428 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.517 HG21 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.564 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.542 HG23 HD11 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.542 HD11 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.709 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.476 ' HB3' HD11 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.709 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.411 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.411 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.526 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.46 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.645 ' CD2' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.453 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.564 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.453 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.657 ' HD2' HD13 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.552 HG12 HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.913 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.628 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.434 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.457 ' HB2' HG13 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.568 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.588 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.607 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.526 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.645 HG12 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.509 ' HB1' HD12 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.542 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG23 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.568 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.687 HG23 HG21 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.495 ' HB3' HG23 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.723 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.647 HG23 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.926 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.709 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.52 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.979 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.435 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.709 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.926 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.568 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.495 HG23 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.723 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.45 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.628 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.913 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.657 HD13 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.3 p 48.49 46.81 20.68 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.279 0.631 . . . . 0.0 111.61 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -82.76 111.47 18.71 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.051 0.453 . . . . 0.0 110.555 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 tt -114.56 142.06 28.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.894 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.5 t -87.56 94.92 9.86 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 65.07 -81.42 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.657 -176.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.9 m -162.63 176.18 10.62 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.5 -34.1 63.63 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.068 175.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -105.48 -173.89 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 176.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.509 HD11 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.793 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.709 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.481 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.793 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.79 HD13 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.772 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.509 ' HB2' HD11 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.79 ' HZ3' HD13 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.603 ' HB2' HG12 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.711 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.58 ' HB2' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.712 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.603 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.527 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.598 HG22 ' CH2' ' A' ' 38' ' ' TRP . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.578 ' H ' HG21 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.54 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.745 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.745 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.678 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.437 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.671 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.533 HD13 HD23 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.875 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.422 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.709 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.422 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.875 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.671 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.435 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.527 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.603 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.711 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.821 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.803 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.9 t -149.71 161.86 41.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 -179.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -122.32 84.43 2.26 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.222 0.534 . . . . 0.0 110.192 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.5 mt -97.38 111.65 27.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.803 177.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 p -139.33 -58.61 0.59 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.204 0.526 . . . . 0.0 109.692 -177.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.7 t-80 -126.45 86.84 2.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.05 172.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.5 m -134.38 94.78 3.27 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.976 179.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.57 170.22 52.77 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.884 -0.598 . . . . 0.0 113.417 -174.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.554 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 -79.91 145.45 32.66 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.156 -179.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.527 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.401 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 14.7 mm-40 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.509 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.527 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.813 HG11 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.554 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.771 ' HB ' HD13 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.545 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.566 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.523 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.477 ' ND2' ' HB3' ' A' ' 41' ' ' ALA . 13.4 t30 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.613 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.566 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.472 ' CB ' HG22 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.491 ' NE2' HG11 ' A' ' 49' ' ' VAL . 16.2 mm-40 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.682 ' HD2' HD11 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.726 HG12 HG21 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 1.033 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.535 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.426 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.454 ' CG ' ' HB2' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.813 HG12 HG11 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.535 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.443 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.446 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.523 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.651 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.419 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.431 ' HB2' HG21 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.465 HG21 HG23 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.445 HG22 HG23 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.796 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.573 HD12 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 1.02 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.729 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.651 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.729 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 1.02 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.47 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.573 ' HB2' HD12 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.796 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.499 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HB1' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.413 ' CD2' HD22 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.535 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 1.033 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.726 HG21 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.771 HD13 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 m -72.34 115.42 11.56 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 178.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.6 t -102.35 91.13 4.13 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.006 0.431 . . . . 0.0 110.282 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 51.2 mm -111.45 -42.14 4.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.8 178.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 t 72.31 152.75 0.12 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.313 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 m80 62.7 17.26 9.63 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.936 175.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.4 m 61.21 20.17 10.74 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.118 -177.339 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.11 -148.25 18.05 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.604 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.63 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 -128.12 6.23 5.92 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.556 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.613 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.613 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.726 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.411 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.63 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.558 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.419 ' CG1' HD13 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.416 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.416 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.479 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.54 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.409 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.573 ' HB1' HG11 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.435 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.6 t30 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.805 ' CH2' HG23 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.54 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.46 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.648 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.804 HG23 HG23 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.7 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 31.0 m-20 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.43 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.57 ' HG2' HG23 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.498 ' H ' ' HB2' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.498 ' HB2' ' H ' ' A' ' 54' ' ' SER . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.805 HG23 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.625 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.452 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.592 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.435 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.592 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.647 HG13 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.464 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.541 HG22 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.512 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.57 HG23 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.462 HD11 HD21 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.797 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.609 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.726 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.445 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.58 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.797 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.512 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.462 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.43 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.7 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.804 HG23 HG23 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.4 m -70.7 -24.79 62.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.028 0.442 . . . . 0.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 t -143.93 99.68 3.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.65 176.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.5 tt -151.0 -42.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.872 179.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.2 m -95.08 -131.66 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.262 173.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -66.99 116.91 8.35 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 176.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.539 ' O ' ' HA3' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -58.31 131.47 50.75 Favored 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.215 0.322 . . . . 0.0 111.269 -177.888 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.58 -71.18 0.78 Allowed Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.994 -174.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.473 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 -158.79 129.67 6.17 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.512 176.498 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.455 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.455 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.437 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.428 HG21 HG23 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.49 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.43 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.672 HG12 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.586 HG23 HD12 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.539 ' HA3' ' O ' ' A' ' 7' ' ' SER . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.631 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.829 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.829 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.441 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.616 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.516 ' HB2' HG23 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.598 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.424 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.67 ' HD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' THR . . . . . 0.817 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.877 HG11 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.652 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.548 ' HB2' HG13 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.672 HG12 HG12 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.7 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.642 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.984 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.984 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.642 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.684 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.451 HG23 HG23 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.571 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.422 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.631 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.451 HG23 HG23 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.684 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.569 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.593 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.437 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.569 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.422 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.631 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.486 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.7 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.652 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.877 HG22 HG11 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.817 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.779 0 N-CA-C 112.06 -0.416 . . . . 0.0 112.06 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.5 t -167.97 133.49 1.9 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.5 0.191 . . . . 0.0 110.654 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.1 m 66.83 -174.58 0.19 Allowed 'General case' 0 C--O 1.233 0.23 0 O-C-N 123.862 0.727 . . . . 0.0 112.332 172.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.401 ' O ' HG22 ' A' ' 4' ' ' ILE . 22.0 mm -103.64 35.43 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.89 0.853 . . . . 0.0 108.9 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.9 m -63.85 -49.7 71.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.295 -178.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -79.87 -69.11 0.61 Allowed 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 171.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 36.9 t -177.41 158.58 1.44 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.241 -0.89 . . . . 0.0 109.411 174.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.84 6.81 58.81 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 175.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 -112.19 138.38 48.95 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -178.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.685 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.506 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 1.017 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG22 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.685 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.611 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.611 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.404 HG21 HD11 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.549 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.639 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.492 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.483 ' HA ' HG23 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.659 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.48 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 9.0 t30 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.878 ' HH2' HG22 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.639 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.474 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.564 ' CD2' HD11 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.664 HG13 HG23 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.933 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.666 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.629 ' HB2' HG12 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.878 HG22 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.587 ' H ' HG21 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.689 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.571 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.659 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.689 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.566 HG22 HG22 ' A' ' 17' ' ' THR . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.793 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.445 ' HA ' HG23 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.793 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.744 HG23 HG21 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.496 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.744 HG21 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.689 HD11 HD12 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.629 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.893 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.408 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 1.017 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.893 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.629 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' THR . . . . . 0.519 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.689 HD12 HD11 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.486 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.486 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.483 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.666 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.933 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.664 HG23 HG13 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.412 HD12 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 112.067 -0.413 . . . . 0.0 112.067 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 p -85.0 0.24 52.1 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.709 0.29 . . . . 0.0 111.512 -178.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -77.61 80.38 4.09 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.227 0.537 . . . . 0.0 111.526 -177.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.4 pt -128.49 147.56 33.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.318 174.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.8 t -157.38 122.29 4.46 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.42 -176.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 50.2 m80 67.21 15.35 10.0 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.288 177.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.0 t -98.98 127.57 44.93 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.72 -10.6 84.03 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.611 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.632 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 -116.09 153.77 31.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 -178.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.496 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.418 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.418 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.428 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.529 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 22.3 mm-40 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.701 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.551 HG21 HG23 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.632 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.53 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.405 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.45 HG22 HD12 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.405 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.656 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.633 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.633 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.534 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.515 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.454 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.58 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.615 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.438 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.656 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.754 HG13 HG23 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.703 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.47 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.404 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.587 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.541 HG23 ' CH2' ' A' ' 38' ' ' TRP . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.681 HD13 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.609 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.881 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.409 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.409 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.881 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.614 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . 0.509 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.587 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.837 HG21 HG23 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.837 HG23 HG21 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.499 HD13 ' HB1' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.666 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.637 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.449 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.701 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.449 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.666 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.49 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.572 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . 0.486 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.681 ' CD2' HD13 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.47 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.703 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.754 HG23 HG13 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . 0.418 ' HE2' ' ND2' ' A' ' 50' ' ' ASN . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.692 ' H ' HD12 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.599 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 p -122.42 17.45 10.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.98 0.419 . . . . 0.0 111.029 -178.103 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.0 m -84.82 106.76 16.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.3 tt -172.07 110.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.68 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 p -109.98 62.03 0.6 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.83 176.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 42.44 78.44 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 122.109 0.957 . . . . 0.0 110.715 -170.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.5 m -79.2 6.32 10.04 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.667 -173.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 95.79 159.62 32.71 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.724 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.562 HD22 ' HB2' ' A' ' 22' ' ' ASP . 83.9 m-20 -125.29 172.23 9.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . 0.524 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.525 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.412 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.933 ' HA2' ' HE2' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.525 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 9.6 mm100 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.777 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . 0.452 ' CD1' ' HE1' ' A' ' 86' ' ' MET . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 9' ' ' ASN . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.454 HD11 HG23 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.569 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.412 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.407 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.429 ' HB1' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . 0.482 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.542 ' ND2' ' HB1' ' A' ' 41' ' ' ALA . 12.7 t30 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' TRP . . . . . 0.791 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.481 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLN . . . . . 0.481 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PHE . . . . . 0.753 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' VAL . . . . . 0.847 HG23 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASN . . . . . 0.645 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.667 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.46 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.576 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.692 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.791 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.601 ' H ' HG23 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLN . . . . . 0.498 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.65 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.442 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.429 ' O ' ' HB1' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.482 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.65 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.571 HG12 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.617 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.454 HG21 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.617 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . 0.576 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.599 HG21 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.54 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.571 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.933 ' HE2' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.533 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.777 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.533 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.504 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.571 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.599 ' HB ' HG21 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.417 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' SER . . . . . 0.578 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.606 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.417 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.606 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASN . . . . . 0.745 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.692 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ILE . . . . . 0.847 HG22 HG23 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.459 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 . . . . . 0 N--CA 1.449 -0.513 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.498 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.686 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.827 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.686 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.605 HG11 HD11 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.667 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.847 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.847 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.49 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.617 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.667 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.759 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.481 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.471 ' HB2' HG11 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.619 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.605 HD11 HG11 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.663 HD22 HD13 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.497 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.579 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.48 ' CB ' HD12 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.417 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.733 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.894 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.663 HD13 HD22 ' A' ' 59' ' ' LEU . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.868 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.647 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.827 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.444 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.868 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.644 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.894 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.551 ' HB3' HG23 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.759 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 47' ' ' PHE . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.847 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.663 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.47 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.564 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.446 HG22 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.663 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.561 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.728 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.728 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.475 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.422 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.522 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.844 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.516 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.482 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.618 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.825 HG22 HG22 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 1.051 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.582 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.844 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.632 ' H ' HG22 ' A' ' 58' ' ' ILE . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.629 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.755 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.522 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.755 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.621 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.409 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.582 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.617 HG13 HG22 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.715 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.49 HG21 HD22 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.927 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.795 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 15' ' ' GLN . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.795 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.927 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.451 ' HB3' HD11 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.715 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.525 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 1.051 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.825 HG22 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.472 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.48 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.437 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.527 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.561 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.476 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.48 ' HA ' HD21 ' A' ' 9' ' ' ASN . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.411 ' O ' ' HG2' ' A' ' 23' ' ' LYS . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 19' ' ' TYR . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.473 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.603 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.421 ' O ' ' HB1' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.603 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.454 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.491 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.513 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.491 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 12.5 t-20 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.689 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.49 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.417 HE21 HG22 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.601 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.575 HG12 HG22 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.676 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.689 HG21 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.637 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 11.8 tp60 -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.886 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.513 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.886 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.567 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.652 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.435 ' HB2' HG22 ' A' ' 20' ' ' VAL . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.76 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.645 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.967 HG22 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.561 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.745 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.506 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.971 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.971 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.506 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.561 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.464 ' H ' HD11 ' A' ' 83' ' ' ILE . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.967 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.479 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.654 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.676 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.601 HD12 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 48' ' ' THR . 0.1 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.536 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.529 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.536 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 69.6 mm-40 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.778 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.626 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.523 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.618 HG13 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.594 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.556 HG11 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.434 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.634 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.594 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.581 HG21 ' HB2' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.634 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.632 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HA ' HE22 ' A' ' 60' ' ' GLN . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.627 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.44 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.581 ' HB2' HG21 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.635 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.9 m120 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.701 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HB2' HG11 ' A' ' 81' ' ' VAL . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.618 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.665 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.556 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.665 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 35' ' ' ALA . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.548 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.662 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.662 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.87 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.822 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.517 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.778 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.822 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.87 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.428 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.459 ' HE2' HD12 ' A' ' 100' ' ' ILE . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.701 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.581 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 . . . . . 0 N--CA 1.449 -0.476 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.583 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.583 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 13.6 mm100 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.952 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.447 HG22 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.581 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.426 HG11 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.62 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.623 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.434 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.628 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.806 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.628 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.593 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.549 ' CD2' HD12 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.51 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.602 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.806 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 1.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.855 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.855 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.44 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.567 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.567 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.787 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.841 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.463 HD13 HD11 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.661 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' MET . . . . . 1.01 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.505 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.952 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.421 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.01 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.661 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.841 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.543 ' HB3' ' CG ' ' A' ' 60' ' ' GLN . 0.5 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.733 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.593 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.595 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.453 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.656 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.406 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.716 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.759 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.423 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.716 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.424 ' CE2' ' HG3' ' A' ' 23' ' ' LYS . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.602 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.646 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.432 ' HG ' ' C ' ' A' ' 29' ' ' GLY . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.646 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 42.0 m-20 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.596 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.669 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.727 ' HD2' HD12 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.498 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 1.057 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.454 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.812 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.599 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.602 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.72 HD11 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.484 ' N ' HD13 ' A' ' 59' ' ' LEU . 2.2 tp60 -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.593 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.732 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLY . . . . . 0.632 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.732 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.593 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.669 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB2' ' OE1' ' A' ' 85' ' ' GLU . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.599 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.446 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.867 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.444 HG22 HG22 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.662 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.693 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.759 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.459 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.693 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.662 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.867 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.618 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.812 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.72 ' CD2' HD11 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.454 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 1.057 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.727 HD12 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.504 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.458 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 . . . . . 0 CA--C 1.522 -0.111 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.64 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.64 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG21 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.456 ' HB3' ' H ' ' A' ' 15' ' ' GLN . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.579 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.698 HG13 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.541 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.541 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.581 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.603 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.413 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.516 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.591 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.437 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.455 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.698 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.615 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.595 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.74 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.74 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.545 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.401 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.483 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.651 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.782 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.74 HD11 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.461 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.753 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.582 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.482 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.753 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.461 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.74 ' HB2' HD11 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.782 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.446 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.449 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.446 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.449 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.555 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.473 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.437 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.743 HD12 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.841 ' H ' HD12 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 110.47 -0.196 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.447 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.402 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.402 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.5 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.575 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 15.1 mm100 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.41 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.424 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.511 ' CZ ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.531 HG23 ' H ' ' A' ' 26' ' ' GLY . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.729 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.41 ' H ' ' HZ ' ' A' ' 47' ' ' PHE . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.511 ' HB3' ' CZ ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.564 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.687 ' HA3' HD21 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.522 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 85.6 m-20 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.428 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.687 HD21 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.732 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.564 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.534 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.62 ' CD2' HD12 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.492 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 1.012 HG12 HG22 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 52' ' ' THR . 0.1 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.642 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.642 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.707 ' HG3' HD12 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.732 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.707 HD12 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.794 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.794 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.686 HG11 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.607 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.588 HG23 HG22 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.548 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG23 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 HG22 ' A' ' 72' ' ' VAL . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.497 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.58 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.721 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 92' ' ' PRO . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 91' ' ' GLY . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.445 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.512 ' HB3' HD11 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.548 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.488 HD11 HD13 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' SER . . . . . 0.401 ' HB3' ' OE2' ' A' ' 104' ' ' GLU . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.462 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 1.012 HG22 HG12 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.492 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.401 ' C ' ' H ' ' A' ' 11' ' ' TYR . 14.3 m120 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.683 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.892 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.495 HG22 HG21 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.683 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.541 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.869 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.456 HG21 HD13 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.456 HD13 HG21 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.753 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.753 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.442 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.563 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.596 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.436 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD12 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.452 ' HB ' HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.437 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.402 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.423 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.554 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.869 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.608 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.442 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.736 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.663 HG23 HG22 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.708 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.774 HG22 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.576 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.672 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.708 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.892 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.672 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.576 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.584 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.708 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.405 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.463 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.566 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.554 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.553 HD12 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.3 p-80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.407 ' H ' HG12 ' A' ' 113' ' ' ILE . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.533 HD12 ' HB2' ' A' ' 30' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.661 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.548 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.43 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.548 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 61.6 mm-40 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.983 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.495 HG21 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.661 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.576 HG21 HD13 ' A' ' 28' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.904 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.58 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.533 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.621 ' HZ3' HD11 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.495 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.518 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.434 ' CD2' HD12 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.531 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.509 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.65 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.428 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.599 HG21 ' CH2' ' A' ' 38' ' ' TRP . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.572 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.492 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.572 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.554 HG11 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.555 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.469 ' HA ' HG23 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.575 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.598 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.641 HD13 HD11 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.777 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.983 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.476 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.777 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.882 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.575 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.641 HD11 HD13 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.522 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.65 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.509 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.531 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.904 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.595 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.542 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.451 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.451 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.499 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.688 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.412 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.536 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.459 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.511 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.684 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.52 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.684 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.665 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.534 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 27.4 m-70 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 110' ' ' TYR . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.512 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.538 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.512 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.591 HG11 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.738 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.674 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.674 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.494 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.644 HG23 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.738 HD12 ' HB3' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.759 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.597 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 1.036 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.597 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.759 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.633 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.811 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.432 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.538 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.43 ' HD2' ' HB1' ' A' ' 57' ' ' ALA . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.665 HD12 ' CD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 39.0 p-80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 28' ' ' ILE . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.575 HD22 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 . . . . . 0 C--O 1.233 0.199 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.523 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.401 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.486 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 1.045 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HA ' HD22 ' A' ' 9' ' ' ASN . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.899 HG13 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.653 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.585 HG21 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.653 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.721 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.837 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.555 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.837 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.488 ' HA ' HG21 ' A' ' 17' ' ' THR . 29.7 m-80 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.59 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.695 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.476 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.712 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.712 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.8 m120 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.481 ' HG2' HG11 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.899 HG12 HG13 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.586 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.454 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.613 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.557 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.428 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.549 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.868 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.596 HD13 HD11 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.677 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.443 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 1.045 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.788 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.868 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.455 ' O ' HG22 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.484 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.42 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.842 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.712 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.712 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.493 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 . . . . . 0 N--CA 1.455 -0.207 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.492 HD12 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.44 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.523 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.967 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 38' ' ' TRP . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.44 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.629 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.629 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.723 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.492 ' HB3' HD12 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.723 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.409 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.475 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.648 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.438 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.656 ' HD2' HD12 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.546 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.904 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.661 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.437 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HB2' HG11 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.73 ' H ' HG22 ' A' ' 58' ' ' ILE . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.525 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.556 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.563 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.683 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.505 ' HB3' HG22 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.738 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.949 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.69 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.532 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.967 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.436 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.69 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.949 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.599 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.505 HG22 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.738 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.409 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.661 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.904 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.656 HD12 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.402 HD11 HG22 ' A' ' 28' ' ' ILE . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.532 HD12 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.79 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.723 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.476 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.79 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' CE2' ' A' ' 71' ' ' TYR . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.789 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.786 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' SER . . . . . 0.532 ' HB2' HD12 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.789 ' HZ3' HD12 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.431 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.639 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.706 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.718 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.594 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.407 ' HG2' HG21 ' A' ' 81' ' ' VAL . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 59' ' ' LEU . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.706 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.551 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.456 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.699 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.439 ' HB2' HG22 ' A' ' 20' ' ' VAL . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.585 HG23 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.69 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.57 HD13 HD22 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.899 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.43 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.723 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.43 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.507 ' HA ' ' HG3' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.899 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 85' ' ' GLU . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.69 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.44 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.594 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.706 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.877 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.567 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.826 0.346 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.541 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.414 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 12.1 mm100 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.506 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.541 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.86 HG13 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.4 HG22 ' HA ' ' A' ' 21' ' ' TYR . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.794 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.56 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.533 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.607 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.679 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.73 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.431 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.457 ' CG ' ' HB1' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 74' ' ' SER . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.86 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.55 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.467 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.471 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.533 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.663 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.607 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.482 ' HB2' HG22 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.49 HG22 HG22 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 55' ' ' LYS . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.818 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.592 HD11 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.488 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' MET . . . . . 1.058 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.76 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.663 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.76 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 1.058 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.488 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.592 ' HB2' HD11 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.818 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.536 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.42 ' CD2' HD21 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.56 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.73 HG22 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.794 HD11 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.564 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.658 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.658 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.741 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.68 ' HA ' HD22 ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.591 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.429 ' CG1' HD12 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.432 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.492 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.597 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.449 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.807 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.498 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.654 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.831 HG22 HG22 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 7.1 m120 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.591 ' HG2' HG21 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.525 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.571 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.807 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.468 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.64 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.449 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.66 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.489 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.548 HG23 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.532 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG21 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.476 HD13 HD22 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.827 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.741 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.599 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.424 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.827 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.532 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.481 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.437 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.713 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.831 HG22 HG22 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.488 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.571 0.224 . . . . 0.0 110.512 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.408 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.408 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.524 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.428 ' O ' HG23 ' A' ' 20' ' ' VAL . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.453 HG22 HG21 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.707 HG13 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.488 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.598 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.435 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.644 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.841 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.841 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.428 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.651 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.65 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.675 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' THR . . . . . 0.844 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.863 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.658 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.55 ' HB2' HG11 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.578 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.707 HG12 HG13 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.707 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.626 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . 1.001 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 1.001 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.452 HG22 HG22 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.578 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.443 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.638 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.452 HG22 HG22 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.719 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.577 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.595 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.425 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.577 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.443 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.638 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.505 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.707 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.863 HG22 HG12 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' HIS . . . . . 0.844 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.692 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.538 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.692 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.606 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.606 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.462 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.555 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.656 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.474 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.517 ' HA ' HG21 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.65 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.896 ' HH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.656 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.573 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.678 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.93 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.699 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.66 ' HB2' HG11 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.896 HG21 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.65 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.707 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.591 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.65 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.707 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.565 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.795 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.457 ' HA ' HG22 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.795 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.747 HG23 HG22 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.513 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.747 HG22 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.695 HD13 HD11 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.646 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.905 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 1.01 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.905 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.646 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.695 HD11 HD13 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.501 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.699 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.93 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.678 HG22 HG12 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.44 HD13 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.653 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.51 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.442 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.551 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 15.1 mm100 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.698 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.588 HG22 HG21 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.653 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG13 HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.42 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' HB3' ' A' ' 23' ' ' LYS . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.42 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.41 ' H ' HG23 ' A' ' 24' ' ' VAL . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.678 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.639 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.522 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' HG21 ' A' ' 17' ' ' THR . 18.8 p30 -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.522 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.414 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.576 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.678 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.699 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.413 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.597 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.569 HG12 HG13 ' A' ' 20' ' ' VAL . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.678 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.633 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.922 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.404 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.922 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . 0.538 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.597 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.811 HG23 HG22 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 HG23 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.62 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.698 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.704 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.512 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.594 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ASN . . . . . 0.498 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.678 ' CD2' HD11 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.699 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.78 HG22 HG12 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.768 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m120 . . . . . 0 CA--C 1.518 -0.253 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' TYR . . . . . 0.53 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.52 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.445 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.504 ' HA2' ' HE3' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.52 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 53.2 mm-40 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.771 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.53 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.51 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.51 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.583 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.583 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.405 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASN . . . . . 0.486 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.478 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.415 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLN . . . . . 0.478 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' VAL . . . . . 0.846 HG22 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASN . . . . . 0.662 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.674 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.686 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.804 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.599 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLN . . . . . 0.517 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.684 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.486 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.684 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.584 HG11 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.632 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.468 HG22 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.632 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.415 HG23 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.611 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.549 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' MET . . . . . 0.504 ' HE3' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.771 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' PRO . . . . . 0.494 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.595 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.402 ' HB2' HD11 ' A' ' 83' ' ' ILE . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.611 ' HB ' HG22 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' SER . . . . . 0.59 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.621 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.506 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.621 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASN . . . . . 0.748 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 110' ' ' TYR . . . . . 0.686 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ILE . . . . . 0.846 HG22 HG22 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.413 ' H ' HG12 ' A' ' 113' ' ' ILE . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.572 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.9 m -129.34 131.78 46.96 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.0 p -61.07 -57.99 10.26 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 123.485 0.49 . . . . 0.0 111.154 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.7 mt 48.36 72.81 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.7 0.762 . . . . 0.0 110.836 -177.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -142.71 -60.24 0.44 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.035 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -83.62 64.91 8.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.745 0.783 . . . . 0.0 109.001 170.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.0 p -143.86 -67.21 0.34 Allowed 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.837 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 58.31 -94.89 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.31 -0.859 . . . . 0.0 113.478 173.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.459 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 -81.4 136.06 35.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 -176.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.498 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.686 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.827 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.686 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.605 HG11 HD11 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.667 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.847 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.847 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.49 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.617 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.667 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.759 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.481 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.471 ' HB2' HG11 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.619 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.605 HD11 HG11 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.663 HD22 HD13 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.497 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.579 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.48 ' CB ' HD12 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.417 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.733 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.894 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.663 HD13 HD22 ' A' ' 59' ' ' LEU . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.868 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.647 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.827 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.444 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.868 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.644 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.894 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.551 ' HB3' HG23 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.759 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 47' ' ' PHE . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.847 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.777 0 N-CA-C 111.914 -0.475 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 m -80.27 94.39 6.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.961 0.41 . . . . 0.0 110.896 -178.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 p -104.47 167.41 9.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.843 175.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 66.6 mt -62.97 -62.05 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.968 0.413 . . . . 0.0 110.511 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.2 m -154.61 104.16 2.52 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 34.4 m170 67.16 -81.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.681 0.613 . . . . 0.0 110.225 -173.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 32.3 t -154.78 146.23 23.07 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -140.8 -48.41 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.978 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.663 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 -140.35 147.69 40.2 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.47 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.564 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.446 HG22 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.663 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.561 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.728 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.728 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.422 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.522 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.844 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.516 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.482 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.618 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.825 HG22 HG22 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 1.051 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.582 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.844 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.632 ' H ' HG22 ' A' ' 58' ' ' ILE . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.629 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.755 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.522 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.755 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.621 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.409 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.582 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.617 HG13 HG22 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.715 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.49 HG21 HD22 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.927 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.795 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 15' ' ' GLN . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.795 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.927 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.451 ' HB3' HD11 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.715 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.525 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 1.051 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.825 HG22 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.472 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.5 t -87.07 104.91 16.77 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 178.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.2 m -79.73 -30.52 40.92 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.084 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -101.6 129.17 53.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.323 0.582 . . . . 0.0 111.266 -178.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 m -123.07 -47.53 2.03 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.289 179.07 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.91 113.42 25.23 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.323 171.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.2 t -63.34 -36.61 84.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.072 0.463 . . . . 0.0 110.114 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.15 -36.95 2.29 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.51 175.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.48 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 -110.32 146.64 35.37 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 -176.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.437 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.527 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.561 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.476 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.48 ' HA ' HD21 ' A' ' 9' ' ' ASN . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.411 ' O ' ' HG2' ' A' ' 23' ' ' LYS . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 19' ' ' TYR . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.473 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.603 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.421 ' O ' ' HB1' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.603 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.454 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.491 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.513 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.491 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 12.5 t-20 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.689 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.49 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.417 HE21 HG22 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.601 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.575 HG12 HG22 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.676 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.689 HG21 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.637 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 11.8 tp60 -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.886 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.513 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.886 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.567 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.652 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.435 ' HB2' HG22 ' A' ' 20' ' ' VAL . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.76 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.645 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.967 HG22 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.561 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.745 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.506 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.971 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.971 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.506 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.561 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.464 ' H ' HD11 ' A' ' 83' ' ' ILE . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.967 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.479 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.654 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.676 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.601 HD12 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 48' ' ' THR . 0.1 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.644 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.2 m -96.03 -24.45 16.34 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.222 0.534 . . . . 0.0 110.027 179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -153.76 167.61 29.06 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 54.1 mt -104.44 97.53 5.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.186 0.517 . . . . 0.0 111.752 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -130.06 -39.15 1.39 Allowed 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.71 90.46 1.63 Allowed 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 172.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.3 t -86.92 -26.68 23.78 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.092 -176.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.9 44.44 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 -175.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -134.36 127.86 32.5 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -176.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.536 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.529 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.536 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 69.6 mm-40 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.778 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.626 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.523 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.618 HG13 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.594 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.556 HG11 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.434 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.634 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.594 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.581 HG21 ' HB2' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.634 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 11.0 t-20 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.632 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HA ' HE22 ' A' ' 60' ' ' GLN . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.627 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.44 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.581 ' HB2' HG21 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.635 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.9 m120 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.701 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HB2' HG11 ' A' ' 81' ' ' VAL . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.618 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.665 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.556 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.665 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 35' ' ' ALA . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.548 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.662 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.662 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.87 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.822 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.517 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.778 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.822 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.87 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.428 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.459 ' HE2' HD12 ' A' ' 100' ' ' ILE . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.701 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 t -73.52 -47.52 40.32 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.663 0.268 . . . . 0.0 110.298 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.6 m 59.33 63.02 1.65 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.477 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 pt -99.55 168.49 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.929 176.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 t -113.19 -84.34 0.59 Allowed 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -122.73 -30.99 3.77 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.4 t -124.36 149.89 46.14 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.522 175.309 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.86 49.79 4.19 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.306 176.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.581 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 -124.67 144.86 49.97 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 -176.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.583 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.583 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 13.6 mm100 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.952 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.447 HG22 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.581 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.426 HG11 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.62 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.623 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.434 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.628 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.806 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.628 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.593 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.549 ' CD2' HD12 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.51 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.602 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.806 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 1.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.855 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.855 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.44 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.567 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.567 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.787 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.841 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.463 HD13 HD11 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.661 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' MET . . . . . 1.01 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.505 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.952 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.421 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.01 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.661 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.841 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.543 ' HB3' ' CG ' ' A' ' 60' ' ' GLN . 0.5 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.733 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.593 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 m80 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.595 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.1 t -125.82 -44.89 1.77 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.004 0.431 . . . . 0.0 110.333 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -94.28 25.36 3.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.108 0.48 . . . . 0.0 110.368 -178.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.1 mm -92.32 -16.25 7.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.025 -174.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 15.0 m -60.43 -60.62 3.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.751 -175.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -140.05 20.62 2.45 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.2 m 59.87 84.51 0.12 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.866 -173.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.65 -29.66 75.63 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.746 -0.661 . . . . 0.0 113.06 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 -157.95 149.83 21.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.656 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.406 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.716 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.759 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.423 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.716 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.424 ' CE2' ' HG3' ' A' ' 23' ' ' LYS . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.602 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.646 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.432 ' HG ' ' C ' ' A' ' 29' ' ' GLY . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.646 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 42.0 m-20 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.596 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.669 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.727 ' HD2' HD12 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.498 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 1.057 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.454 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.812 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.599 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.602 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.72 HD11 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.484 ' N ' HD13 ' A' ' 59' ' ' LEU . 2.2 tp60 -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.593 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.732 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.632 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.732 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.593 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.669 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB2' ' OE1' ' A' ' 85' ' ' GLU . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.599 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.446 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.867 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.444 HG22 HG22 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.662 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.693 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.759 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.459 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.693 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.662 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.867 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.618 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.812 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.72 ' CD2' HD11 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.454 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 1.057 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.727 HD12 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.504 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.458 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.676 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.5 t -167.1 -31.34 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.753 0.311 . . . . 0.0 110.318 -177.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.5 m -76.28 55.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.202 0.525 . . . . 0.0 111.708 -177.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tp -97.6 3.67 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 122.063 0.935 . . . . 0.0 109.116 176.36 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.9 m -107.51 -159.91 0.71 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.691 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -72.41 -25.36 61.46 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.6 0.238 . . . . 0.0 110.799 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 30.7 p 52.78 51.4 16.03 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 123.595 0.758 . . . . 0.0 112.851 173.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.75 -68.67 2.8 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.515 172.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 -142.51 149.04 38.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 -175.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.64 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.64 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG21 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.456 ' HB3' ' H ' ' A' ' 15' ' ' GLN . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.579 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.698 HG13 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.541 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.541 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.581 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.603 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.413 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.516 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.591 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.437 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.455 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.698 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.615 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.595 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.74 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.74 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.545 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.401 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.483 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.651 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.782 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.74 HD11 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.461 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.753 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.582 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.482 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.753 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.461 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.74 ' HB2' HD11 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.782 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.446 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.449 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.446 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.449 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.555 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.473 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.437 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.743 HD12 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 50.0 p-80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.841 ' H ' HD12 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 111.936 -0.466 . . . . 0.0 111.936 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.0 p -69.42 -22.27 63.69 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 p -77.45 -5.35 49.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.916 0.388 . . . . 0.0 110.779 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mm 54.5 75.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.26 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.4 m -121.45 -50.26 2.11 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -133.0 128.94 37.46 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.491 170.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.1 m -112.24 141.82 45.48 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.412 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.28 -114.32 2.75 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.706 176.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -117.34 -158.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.517 0 O-C-N 122.838 -0.213 . . . . 0.0 110.47 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.447 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.402 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.402 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.5 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.575 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 15.1 mm100 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.41 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.424 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.511 ' CZ ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.531 HG23 ' H ' ' A' ' 26' ' ' GLY . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.729 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.41 ' H ' ' HZ ' ' A' ' 47' ' ' PHE . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.511 ' HB3' ' CZ ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.564 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.687 ' HA3' HD21 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.522 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 85.6 m-20 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.428 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.687 HD21 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.732 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.564 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.534 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.62 ' CD2' HD12 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.492 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 1.012 HG12 HG22 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.404 ' O ' ' N ' ' A' ' 52' ' ' THR . 0.1 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.642 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.642 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.707 ' HG3' HD12 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.732 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.707 HD12 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.794 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.794 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.686 HG11 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.607 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.588 HG23 HG22 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.548 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG23 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 HG22 ' A' ' 72' ' ' VAL . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.497 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.58 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.721 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 92' ' ' PRO . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 91' ' ' GLY . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.445 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.512 ' HB3' HD11 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.548 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.488 HD11 HD13 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' SER . . . . . 0.401 ' HB3' ' OE2' ' A' ' 104' ' ' GLU . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.462 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 1.012 HG22 HG12 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.492 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 111.782 -0.527 . . . . 0.0 111.782 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t 55.7 -100.33 0.11 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.076 0.55 . . . . 0.0 111.359 -178.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.1 m -95.37 -18.52 20.69 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.117 0.484 . . . . 0.0 110.611 -178.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.2 mm -73.96 92.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.444 0.64 . . . . 0.0 110.497 -177.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -150.2 -48.46 0.13 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.175 175.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -76.84 10.0 2.52 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.255 172.046 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.7 m -105.09 30.2 5.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.729 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.1 134.44 39.94 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.456 -0.793 . . . . 0.0 113.219 -175.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.401 ' C ' ' H ' ' A' ' 11' ' ' TYR . 14.3 m120 -85.34 -171.31 3.55 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.683 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.892 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.495 HG22 HG21 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.683 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.541 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.869 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.456 HG21 HD13 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.456 HD13 HG21 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.753 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.753 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.442 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.563 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.596 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.436 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD12 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.452 ' HB ' HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.437 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.402 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.423 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.554 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.869 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.608 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.442 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.736 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.663 HG23 HG22 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.708 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.774 HG22 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.576 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.672 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.708 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.892 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.672 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.576 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.584 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.708 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.405 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.463 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.566 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.554 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.553 HD12 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.3 p-80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.407 ' H ' HG12 ' A' ' 113' ' ' ILE . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.104 -0.399 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.4 m -87.38 5.54 38.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.128 0.49 . . . . 0.0 110.818 -178.037 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -66.89 -21.6 66.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.074 177.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.3 pt -126.09 143.85 38.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.324 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 t -132.55 -72.63 0.52 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.93 0.395 . . . . 0.0 110.277 178.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 m170 -107.63 10.51 29.05 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.519 ' HB3' HD21 ' A' ' 10' ' ' LEU . 4.4 m -64.89 -42.64 94.62 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.883 -1.053 . . . . 0.0 111.382 -176.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.98 -122.93 17.27 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.426 -176.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 -90.82 132.8 35.66 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 176.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.533 HD12 ' HB2' ' A' ' 30' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.661 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.548 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.43 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.548 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 61.6 mm-40 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.983 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.495 HG21 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.661 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.576 HG21 HD13 ' A' ' 28' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.904 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.58 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.533 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.621 ' HZ3' HD11 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.495 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.518 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.434 ' CD2' HD12 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.531 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.509 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.65 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.428 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.599 HG21 ' CH2' ' A' ' 38' ' ' TRP . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.572 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.492 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.572 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.554 HG11 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.555 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.469 ' HA ' HG23 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.575 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.598 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.641 HD13 HD11 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.777 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.983 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.476 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.777 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.882 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.575 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.641 HD11 HD13 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.522 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.65 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.509 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.531 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.904 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.788 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.4 m -142.45 -177.04 5.08 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 p -79.37 85.61 5.17 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.012 0.434 . . . . 0.0 110.548 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.6 mm -71.87 -66.39 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.364 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.6 t -147.22 -38.83 0.2 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.07 0.462 . . . . 0.0 110.067 177.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -141.78 80.74 1.73 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.06 176.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.9 m -103.45 -80.42 0.52 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 175.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.78 -94.8 0.21 Allowed Glycine 0 C--N 1.333 0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 113.757 173.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.595 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 -75.09 159.89 31.13 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 -171.585 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.542 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.451 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.451 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.499 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.688 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.412 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.536 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.459 HD13 ' O ' ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.511 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.684 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.52 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.684 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.665 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.534 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 27.4 m-70 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 110' ' ' TYR . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.512 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.538 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.512 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.591 HG11 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.738 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.674 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.674 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.494 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.644 HG23 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.738 HD12 ' HB3' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.759 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.597 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 1.036 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.597 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.759 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.633 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.811 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.432 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.538 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.43 ' HD2' ' HB1' ' A' ' 57' ' ' ALA . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.665 HD12 ' CD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 39.0 p-80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 28' ' ' ILE . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.74 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.3 t -94.9 105.92 17.88 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.7 m -78.43 99.3 6.35 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.19 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.7 pt -110.35 61.78 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.787 0.804 . . . . 0.0 109.579 174.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 p -87.12 45.77 1.3 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.57 -175.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 m80 68.4 -72.29 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.515 -175.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 41.2 m -152.31 14.72 0.6 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.277 0.56 . . . . 0.0 109.814 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.01 -80.62 0.34 Allowed Glycine 0 N--CA 1.444 -0.813 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.592 -177.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.575 HD22 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 -173.81 167.3 4.41 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.523 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.401 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.486 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 1.045 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HA ' HD22 ' A' ' 9' ' ' ASN . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.899 HG13 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.653 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.585 HG21 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.653 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.721 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.837 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.555 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.837 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.488 ' HA ' HG21 ' A' ' 17' ' ' THR . 29.7 m-80 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.59 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.695 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.476 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.712 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.712 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.8 m120 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.481 ' HG2' HG11 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.899 HG12 HG13 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.586 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.454 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.613 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.557 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.428 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.549 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.868 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.596 HD13 HD11 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.677 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.443 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 1.045 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.788 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.868 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.455 ' O ' HG22 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.484 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.42 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.842 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.712 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.712 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.493 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.818 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 m -108.37 -48.74 3.29 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.905 0.353 . . . . 0.0 110.922 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.3 t -162.05 118.11 2.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.962 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.0 mt -108.95 98.17 6.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.21 0.529 . . . . 0.0 110.453 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.6 m -152.68 -59.48 0.14 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 14.1 p80 -164.73 33.19 0.07 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 167.264 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.6 m -78.14 41.85 0.38 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.983 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 163.03 -160.75 33.29 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 -168.81 161.75 11.14 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.492 HD12 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.44 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.523 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.967 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 38' ' ' TRP . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.44 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.629 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.629 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.723 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.492 ' HB3' HD12 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.723 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.409 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.475 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.648 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.438 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.656 ' HD2' HD12 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.546 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.904 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.661 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.437 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HB2' HG11 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.73 ' H ' HG22 ' A' ' 58' ' ' ILE . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.525 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.556 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.563 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.683 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.505 ' HB3' HG22 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.738 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.949 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.69 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.532 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.967 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.436 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.69 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.949 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.599 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.505 HG22 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.738 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.409 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.661 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.904 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.656 HD12 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.402 HD11 HG22 ' A' ' 28' ' ' ILE . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.3 p 48.49 46.81 20.68 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.279 0.631 . . . . 0.0 111.61 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -82.76 111.47 18.71 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.051 0.453 . . . . 0.0 110.555 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 tt -114.56 142.06 28.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.894 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.5 t -87.56 94.92 9.86 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 65.07 -81.42 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.657 -176.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.9 m -162.63 176.18 10.62 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.5 -34.1 63.63 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.068 175.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -105.48 -173.89 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 176.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.532 HD12 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.79 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.723 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.476 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.79 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' CE2' ' A' ' 71' ' ' TYR . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.789 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.786 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.532 ' HB2' HD12 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.789 ' HZ3' HD12 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.431 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.639 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.706 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.718 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.594 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.407 ' HG2' HG21 ' A' ' 81' ' ' VAL . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 59' ' ' LEU . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.706 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.551 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.456 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.699 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.439 ' HB2' HG22 ' A' ' 20' ' ' VAL . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.585 HG23 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.69 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.57 HD13 HD22 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.899 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.43 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.723 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.43 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.507 ' HA ' ' HG3' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.899 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 85' ' ' GLU . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.69 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.44 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.594 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.706 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.877 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.803 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.9 t -149.71 161.86 41.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 -179.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -122.32 84.43 2.26 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.222 0.534 . . . . 0.0 110.192 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.5 mt -97.38 111.65 27.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.803 177.04 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 p -139.33 -58.61 0.59 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.204 0.526 . . . . 0.0 109.692 -177.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.7 t-80 -126.45 86.84 2.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.05 172.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.5 m -134.38 94.78 3.27 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.976 179.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.57 170.22 52.77 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.884 -0.598 . . . . 0.0 113.417 -174.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.567 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 -79.91 145.45 32.66 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.156 -179.259 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.541 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.414 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 12.1 mm100 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.506 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.541 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.86 HG13 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.4 HG22 ' HA ' ' A' ' 21' ' ' TYR . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.794 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.56 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.533 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.607 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 12.6 mm100 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.679 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.73 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.431 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.457 ' CG ' ' HB1' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 74' ' ' SER . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.86 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.55 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.467 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.471 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.533 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.663 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.607 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.482 ' HB2' HG22 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.49 HG22 HG22 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 55' ' ' LYS . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.818 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.592 HD11 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.488 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' MET . . . . . 1.058 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.76 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.663 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.76 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 1.058 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.488 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.592 ' HB2' HD11 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.818 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.536 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.42 ' CD2' HD21 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.56 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.73 HG22 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.794 HD11 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 m -72.34 115.42 11.56 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 178.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.6 t -102.35 91.13 4.13 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.006 0.431 . . . . 0.0 110.282 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 51.2 mm -111.45 -42.14 4.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.8 178.28 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 t 72.31 152.75 0.12 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.313 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 m80 62.7 17.26 9.63 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.936 175.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.4 m 61.21 20.17 10.74 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.118 -177.339 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.11 -148.25 18.05 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.604 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 -128.12 6.23 5.92 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.564 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.658 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.658 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.741 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.68 ' HA ' HD22 ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.591 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.429 ' CG1' HD12 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.432 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.492 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.597 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.449 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.807 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.498 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.654 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.831 HG22 HG22 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 7.1 m120 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.591 ' HG2' HG21 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.525 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.571 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.807 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.468 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.64 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.449 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.66 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.489 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.548 HG23 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.532 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG21 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.476 HD13 HD22 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.827 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.741 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.599 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.424 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.827 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.532 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.481 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.437 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.713 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.831 HG22 HG22 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.4 m -70.7 -24.79 62.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.028 0.442 . . . . 0.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 t -143.93 99.68 3.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.65 176.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.5 tt -151.0 -42.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.872 179.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.2 m -95.08 -131.66 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.262 173.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -66.99 116.91 8.35 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 176.125 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.555 ' O ' ' HA3' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -58.31 131.47 50.75 Favored 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.215 0.322 . . . . 0.0 111.269 -177.888 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.58 -71.18 0.78 Allowed Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.994 -174.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.488 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 -158.79 129.67 6.17 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.512 176.498 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.408 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.408 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.524 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.428 ' O ' HG23 ' A' ' 20' ' ' VAL . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.453 HG22 HG21 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.707 HG13 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.488 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.598 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.555 ' HA3' ' O ' ' A' ' 7' ' ' SER . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.644 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.841 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.841 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.428 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 86.9 m-20 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.651 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.65 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.675 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' THR . . . . . 0.844 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.863 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.658 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.55 ' HB2' HG11 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.578 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.707 HG12 HG13 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.707 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.626 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . 1.001 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 1.001 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.452 HG22 HG22 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.578 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.443 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.638 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.452 HG22 HG22 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.719 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.577 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.595 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.425 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.577 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.443 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.638 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.505 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.707 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.863 HG22 HG12 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' HIS . . . . . 0.844 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.779 0 N-CA-C 112.06 -0.416 . . . . 0.0 112.06 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.5 t -167.97 133.49 1.9 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.5 0.191 . . . . 0.0 110.654 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.1 m 66.83 -174.58 0.19 Allowed 'General case' 0 C--O 1.233 0.23 0 O-C-N 123.862 0.727 . . . . 0.0 112.332 172.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -103.64 35.43 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.89 0.853 . . . . 0.0 108.9 179.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.9 m -63.85 -49.7 71.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.295 -178.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -79.87 -69.11 0.61 Allowed 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 171.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 36.9 t -177.41 158.58 1.44 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.241 -0.89 . . . . 0.0 109.411 174.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.84 6.81 58.81 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 175.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 -112.19 138.38 48.95 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -178.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.692 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.538 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.692 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.606 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.606 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.462 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.555 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.656 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.474 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.517 ' HA ' HG21 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.65 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.896 ' HH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.656 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.573 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.678 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.93 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.699 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.66 ' HB2' HG11 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.896 HG21 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.65 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.707 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.591 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.65 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.707 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.565 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.795 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.457 ' HA ' HG22 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.795 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.747 HG23 HG22 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.513 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.747 HG22 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.695 HD13 HD11 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.646 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.905 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 1.01 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.905 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.646 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.695 HD11 HD13 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.501 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.699 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.93 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.678 HG22 HG12 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.44 HD13 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 112.067 -0.413 . . . . 0.0 112.067 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 p -85.0 0.24 52.1 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.709 0.29 . . . . 0.0 111.512 -178.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -77.61 80.38 4.09 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.227 0.537 . . . . 0.0 111.526 -177.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.4 pt -128.49 147.56 33.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.318 174.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.8 t -157.38 122.29 4.46 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.42 -176.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 50.2 m80 67.21 15.35 10.0 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.288 177.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.0 t -98.98 127.57 44.93 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.72 -10.6 84.03 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.611 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.653 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 -116.09 153.77 31.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 -178.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.51 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.442 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.551 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 15.1 mm100 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.698 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.588 HG22 HG21 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.653 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG13 HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.42 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' HB3' ' A' ' 23' ' ' LYS . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.42 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.41 ' H ' HG23 ' A' ' 24' ' ' VAL . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.678 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.639 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.522 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' HG21 ' A' ' 17' ' ' THR . 18.8 p30 -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.522 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.414 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.576 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.678 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.699 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.413 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.597 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.569 HG12 HG13 ' A' ' 20' ' ' VAL . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.678 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.633 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.922 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.404 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.922 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . 0.538 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.597 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.811 HG23 HG22 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 HG23 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.62 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.698 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.704 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.512 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.594 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ASN . . . . . 0.498 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.678 ' CD2' HD11 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.699 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.78 HG22 HG12 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.768 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.599 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 p -122.42 17.45 10.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.98 0.419 . . . . 0.0 111.029 -178.103 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.0 m -84.82 106.76 16.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.3 tt -172.07 110.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.68 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 p -109.98 62.03 0.6 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.83 176.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 42.44 78.44 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 122.109 0.957 . . . . 0.0 110.715 -170.479 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.5 m -79.2 6.32 10.04 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.667 -173.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 95.79 159.62 32.71 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.724 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.29 172.23 9.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' TYR . . . . . 0.53 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.52 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.445 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' HA2' ' HE3' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.52 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 53.2 mm-40 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.771 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.53 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.51 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.51 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.583 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.583 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.405 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASN . . . . . 0.486 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.478 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.415 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLN . . . . . 0.478 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' VAL . . . . . 0.846 HG22 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASN . . . . . 0.662 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.674 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.686 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.804 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.599 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLN . . . . . 0.517 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.684 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.486 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.684 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.584 HG11 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.632 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.468 HG22 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.632 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.415 HG23 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.611 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.549 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' MET . . . . . 0.504 ' HE3' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.771 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.494 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.595 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.402 ' HB2' HD11 ' A' ' 83' ' ' ILE . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.611 ' HB ' HG22 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' SER . . . . . 0.59 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.621 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.506 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.621 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASN . . . . . 0.748 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.686 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ILE . . . . . 0.846 HG22 HG22 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.413 ' H ' HG12 ' A' ' 113' ' ' ILE . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.459 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 . . . . . 0 N--CA 1.449 -0.513 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.498 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.686 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.827 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.686 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.605 HG11 HD11 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.667 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.847 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.847 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.49 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.617 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.667 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.759 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.481 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.471 ' HB2' HG11 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.619 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.605 HD11 HG11 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.663 HD22 HD13 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.497 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.579 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.48 ' CB ' HD12 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.417 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.733 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.894 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.663 HD13 HD22 ' A' ' 59' ' ' LEU . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.868 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.647 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.827 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.444 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.868 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.644 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.894 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.551 ' HB3' HG23 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.759 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 47' ' ' PHE . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.847 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.663 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 . . . . . 0 N--CA 1.451 -0.396 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.47 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.564 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.446 HG22 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.663 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.561 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.728 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.728 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.475 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.422 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.522 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.844 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.516 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.482 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.618 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.825 HG22 HG22 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 1.051 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.582 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.844 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.632 ' H ' HG22 ' A' ' 58' ' ' ILE . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.629 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.755 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.522 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.755 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.621 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.409 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.582 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.617 HG13 HG22 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.715 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.49 HG21 HD22 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.927 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.795 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 15' ' ' GLN . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.795 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.927 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.451 ' HB3' HD11 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.715 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.525 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 1.051 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.825 HG22 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.472 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.48 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.437 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.527 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.561 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.476 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.48 ' HA ' HD21 ' A' ' 9' ' ' ASN . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.411 ' O ' ' HG2' ' A' ' 23' ' ' LYS . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 19' ' ' TYR . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.603 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.421 ' O ' ' HB1' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.603 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.454 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.491 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.513 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.491 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 7.0 t30 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.689 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.49 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.417 HE21 HG22 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.601 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.575 HG12 HG22 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.676 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.689 HG21 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.637 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.886 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.513 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.886 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.567 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.652 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.435 ' HB2' HG22 ' A' ' 20' ' ' VAL . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.76 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.645 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.967 HG22 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.561 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.745 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.506 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.971 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.971 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.506 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.561 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.464 ' H ' HD11 ' A' ' 83' ' ' ILE . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.967 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.479 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.654 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.676 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.601 HD12 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 48' ' ' THR . 0.2 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.601 HD22 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER . . . . . 0 N--CA 1.453 -0.304 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.601 ' N ' HD22 ' A' ' 9' ' ' ASN . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.536 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.529 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.536 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 12.8 mm100 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.778 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.626 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.523 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.618 HG13 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.594 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.556 HG11 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.434 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.634 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.594 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.581 HG21 ' HB2' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.634 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.571 HD21 ' HA ' ' A' ' 66' ' ' PHE . 4.3 t30 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.632 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HA ' HE22 ' A' ' 60' ' ' GLN . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.5 t30 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.627 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.44 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.581 ' HB2' HG21 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.635 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 52.8 m-20 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.701 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HB2' HG11 ' A' ' 81' ' ' VAL . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.618 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.665 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.571 ' HA ' HD21 ' A' ' 34' ' ' ASN . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.665 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 35' ' ' ALA . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.548 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.662 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.662 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.87 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.822 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.517 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.778 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.822 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.87 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.428 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.459 ' HE2' HD12 ' A' ' 100' ' ' ILE . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.701 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.581 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 . . . . . 0 N--CA 1.449 -0.476 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.583 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.583 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 22.0 mm-40 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.952 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.447 HG22 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.581 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.426 HG11 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.62 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.623 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.434 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.628 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.806 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.628 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.593 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.549 ' CD2' HD12 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.51 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.602 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.806 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.891 ' HG2' HD22 ' A' ' 109' ' ' ASN . 0.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.855 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.855 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.44 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.567 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.567 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.787 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.841 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.463 HD13 HD11 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.661 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 1.01 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.505 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.952 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.421 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.01 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.661 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.841 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.891 HD22 ' HG2' ' A' ' 60' ' ' GLN . 0.6 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.733 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.593 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 15.7 m-70 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.595 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.453 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 . . . . . 0 N--CA 1.452 -0.327 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.656 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.406 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.716 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.759 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.423 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.716 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.424 ' CE2' ' HG3' ' A' ' 23' ' ' LYS . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.602 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.646 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.432 ' HG ' ' C ' ' A' ' 29' ' ' GLY . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.646 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.596 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.669 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.727 ' HD2' HD12 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.498 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 1.057 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.454 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.812 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.599 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.602 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.72 HD11 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.484 ' N ' HD13 ' A' ' 59' ' ' LEU . 0.0 OUTLIER -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.593 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.732 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . 0.632 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.732 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.593 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.669 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB2' ' OE1' ' A' ' 85' ' ' GLU . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.599 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.446 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.867 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.444 HG22 HG22 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.662 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.693 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.759 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.459 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.693 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.662 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.867 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.618 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.812 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.72 ' CD2' HD11 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.454 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 1.057 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.727 HD12 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.504 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.458 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 . . . . . 0 CA--C 1.522 -0.111 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.64 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.64 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG21 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.456 ' HB3' ' H ' ' A' ' 15' ' ' GLN . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.579 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.698 HG13 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.541 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.541 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.581 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.603 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.413 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.516 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.3 t30 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.591 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.437 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.455 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.698 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.615 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.595 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.74 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.74 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.545 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.401 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.483 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.651 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.782 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.74 HD11 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.461 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.753 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.582 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.482 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.753 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.461 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.74 ' HB2' HD11 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.782 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.446 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.449 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.446 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.449 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.555 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.473 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.437 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.743 HD12 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 23.1 p80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.841 ' H ' HD12 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 . . . . . 0 CA--C 1.529 0.172 0 N-CA-C 110.47 -0.196 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.447 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.402 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.402 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.5 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.575 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 20.0 mm-40 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.41 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.424 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.511 ' CZ ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.531 HG23 ' H ' ' A' ' 26' ' ' GLY . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.729 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.41 ' H ' ' HZ ' ' A' ' 47' ' ' PHE . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.511 ' HB3' ' CZ ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.564 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.687 ' HA3' HD21 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.522 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.6 m120 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.428 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.687 HD21 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.732 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.564 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.534 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.62 ' CD2' HD12 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.492 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 1.012 HG12 HG22 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 50' ' ' ASN . 0.0 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.642 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.642 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.707 ' HG3' HD12 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.732 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.707 HD12 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.794 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.794 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.686 HG11 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.607 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.588 HG23 HG22 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.548 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG23 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 HG22 ' A' ' 72' ' ' VAL . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.497 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.58 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.721 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 92' ' ' PRO . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 91' ' ' GLY . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.445 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.512 ' HB3' HD11 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.548 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.488 HD11 HD13 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . 0.401 ' HB3' ' OE2' ' A' ' 104' ' ' GLU . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.462 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 1.012 HG22 HG12 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.492 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.562 HD21 ' HB2' ' A' ' 22' ' ' ASP . 85.1 m-20 . . . . . 0 CA--C 1.521 -0.165 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.683 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.892 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.495 HG22 HG21 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.683 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.541 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.869 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . 0.562 ' HB2' HD21 ' A' ' 9' ' ' ASN . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.456 HG21 HD13 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.456 HD13 HG21 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.753 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.753 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.442 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.563 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.596 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.436 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD12 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.452 ' HB ' HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.437 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.402 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.423 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.554 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.869 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.608 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.442 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.736 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.663 HG23 HG22 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.708 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.774 HG22 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.576 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.672 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.708 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.892 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.672 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.576 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.584 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.708 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.405 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.463 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.566 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.554 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.553 HD12 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.407 ' H ' HG12 ' A' ' 113' ' ' ILE . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 . . . . . 0 N--CA 1.454 -0.248 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.533 HD12 ' HB2' ' A' ' 30' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.661 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.548 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.43 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.548 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 10.8 mm100 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.983 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.495 HG21 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.661 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.576 HG21 HD13 ' A' ' 28' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.904 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.58 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.533 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.621 ' HZ3' HD11 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.495 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.518 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.434 ' CD2' HD12 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.531 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.509 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.65 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.428 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.599 HG21 ' CH2' ' A' ' 38' ' ' TRP . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.572 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.492 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.572 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.554 HG11 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.555 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.469 ' HA ' HG23 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.575 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.598 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.641 HD13 HD11 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.777 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.983 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.476 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.777 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.882 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.575 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.641 HD11 HD13 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.522 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.65 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.509 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.531 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.904 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.595 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.542 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.451 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.451 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.499 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.688 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.412 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.536 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.511 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.684 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.52 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.684 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.665 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.537 ' HB ' ' CE1' ' A' ' 112' ' ' HIS . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.534 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 110' ' ' TYR . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.512 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.538 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.512 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.591 HG11 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.738 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.674 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.674 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.494 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.644 HG23 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.738 HD12 ' HB3' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.759 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.597 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 1.036 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.597 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.759 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.633 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.811 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.432 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.538 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.43 ' HD2' ' HB1' ' A' ' 57' ' ' ALA . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.665 HD12 ' CD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.537 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 29.6 p80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 28' ' ' ILE . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.575 HD22 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 . . . . . 0 C--O 1.233 0.199 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.523 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.401 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.486 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 1.045 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HA ' HD22 ' A' ' 9' ' ' ASN . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.899 HG13 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.653 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.585 HG21 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.653 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.721 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.837 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.555 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.837 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.488 ' HA ' HG21 ' A' ' 17' ' ' THR . 15.7 m120 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.59 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.695 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.476 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.712 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.712 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 31.9 m-20 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.481 ' HG2' HG11 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.899 HG12 HG13 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.586 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.454 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.613 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.557 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.428 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.549 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.868 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.596 HD13 HD11 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.677 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.443 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 1.045 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.788 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.868 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.455 ' O ' HG22 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.484 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.42 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.842 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.712 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.712 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.493 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 . . . . . 0 N--CA 1.455 -0.207 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.492 HD12 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.44 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.523 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.967 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 38' ' ' TRP . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.44 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.629 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.629 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.723 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.492 ' HB3' HD12 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.723 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.409 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.475 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.648 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.438 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.656 ' HD2' HD12 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.546 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.904 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.661 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.437 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HB2' HG11 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.73 ' H ' HG22 ' A' ' 58' ' ' ILE . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.525 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.556 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.563 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.683 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.505 ' HB3' HG22 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.738 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.949 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.69 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.532 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.967 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.436 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.69 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.949 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.599 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.505 HG22 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.738 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.409 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.661 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.904 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.656 HD12 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.402 HD11 HG22 ' A' ' 28' ' ' ILE . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 . . . . . 0 N--CA 1.453 -0.319 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.532 HD12 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.79 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.723 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.476 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.79 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' CE2' ' A' ' 71' ' ' TYR . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.789 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.786 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . 0.532 ' HB2' HD12 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.789 ' HZ3' HD12 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.431 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.639 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.706 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.718 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.594 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.407 ' HG2' HG21 ' A' ' 81' ' ' VAL . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 59' ' ' LEU . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.706 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.551 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.456 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.699 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.439 ' HB2' HG22 ' A' ' 20' ' ' VAL . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.585 HG23 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.69 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.57 HD13 HD22 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.899 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.43 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.723 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.43 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.507 ' HA ' ' HG3' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.899 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 85' ' ' GLU . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.69 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.44 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.594 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.706 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.877 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.567 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.826 0.346 . . . . 0.0 110.156 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.541 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.414 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 14.7 mm-40 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.506 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.541 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.86 HG13 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.4 HG22 ' HA ' ' A' ' 21' ' ' TYR . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.794 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.56 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.533 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.441 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 13.4 t30 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.607 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.507 ' NE2' HG13 ' A' ' 49' ' ' VAL . 16.2 mm-40 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.679 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.73 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.431 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.457 ' CG ' ' HB1' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 74' ' ' SER . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.86 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.55 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.467 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.471 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.533 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.663 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.607 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.482 ' HB2' HG22 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.49 HG22 HG22 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 55' ' ' LYS . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.818 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.592 HD11 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.488 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 1.058 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.76 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.663 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.76 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 1.058 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.488 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.592 ' HB2' HD11 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.818 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.536 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.42 ' CD2' HD21 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.56 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.73 HG22 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.794 HD11 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.564 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.658 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.658 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.741 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.68 ' HA ' HD22 ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.591 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.429 ' CG1' HD12 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.432 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.492 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.597 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.449 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.421 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.6 t30 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.807 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.498 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.654 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.831 HG22 HG22 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 31.0 m-20 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.591 ' HG2' HG21 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.525 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.571 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.807 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.468 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.64 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.449 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.66 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.489 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.548 HG23 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.532 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.591 HG21 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.476 HD13 HD22 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.827 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.501 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.741 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.599 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.424 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.827 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.532 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.481 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.437 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.713 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.831 HG22 HG22 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.488 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 . . . . . 0 N--CA 1.453 -0.323 0 CA-C-O 120.571 0.224 . . . . 0.0 110.512 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.408 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.408 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.524 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.428 ' O ' HG23 ' A' ' 20' ' ' VAL . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.453 HG22 HG21 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.707 HG13 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.488 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.598 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.435 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.644 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.841 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.841 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.428 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.651 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.65 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.675 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . 0.844 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.863 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.658 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.55 ' HB2' HG11 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.578 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.707 HG12 HG13 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.707 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.626 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 1.001 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 1.001 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.452 HG22 HG22 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.578 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.443 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.638 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.452 HG22 HG22 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.719 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.577 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.595 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.425 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.577 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.443 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.638 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.505 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.707 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.863 HG22 HG12 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . 0.844 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 . . . . . 0 N--CA 1.45 -0.46 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.692 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.538 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.692 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.606 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.606 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.462 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.555 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.656 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.474 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.517 ' HA ' HG21 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.65 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.477 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 9.0 t30 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.896 ' HH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.656 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.573 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.678 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.93 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.699 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.66 ' HB2' HG11 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.896 HG21 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.65 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.707 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.591 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.65 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.707 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.565 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.795 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.457 ' HA ' HG22 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.795 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.747 HG23 HG22 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.513 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.747 HG22 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.695 HD13 HD11 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.646 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.905 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 1.01 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.905 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.646 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.695 HD11 HD13 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.501 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.699 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.93 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.678 HG22 HG12 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.44 HD13 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.653 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 . . . . . 0 N--CA 1.455 -0.2 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.51 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.442 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.551 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 22.3 mm-40 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.698 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.588 HG22 HG21 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.653 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.569 HG13 HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.42 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' HB3' ' A' ' 23' ' ' LYS . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.42 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.41 ' H ' HG23 ' A' ' 24' ' ' VAL . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.678 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.639 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.522 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.522 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.414 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.576 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.678 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.699 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.413 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.597 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.569 HG12 HG13 ' A' ' 20' ' ' VAL . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.678 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.633 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.922 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.404 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.922 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . 0.538 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.597 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.811 HG23 HG22 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 HG23 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.62 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.698 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.704 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.512 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.594 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . 0.498 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.678 ' CD2' HD11 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.699 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.78 HG22 HG12 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.768 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.616 HD21 ' HB2' ' A' ' 22' ' ' ASP . 83.9 m-20 . . . . . 0 CA--C 1.518 -0.253 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . 0.53 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.52 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.445 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.504 ' HA2' ' HE3' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.52 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 9.6 mm100 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.771 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.53 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASP . . . . . 0.616 ' HB2' HD21 ' A' ' 9' ' ' ASN . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.51 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.51 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.583 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.583 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.405 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . 0.486 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.533 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.7 t30 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.478 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.415 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLN . . . . . 0.478 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' VAL . . . . . 0.846 HG22 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASN . . . . . 0.662 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.674 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.686 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.804 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.599 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLN . . . . . 0.517 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.684 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.486 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.684 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.584 HG11 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.632 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.468 HG22 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.632 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.415 HG23 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.611 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.549 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . 0.504 ' HE3' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.771 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' PRO . . . . . 0.494 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.595 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.402 ' HB2' HD11 ' A' ' 83' ' ' ILE . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.611 ' HB ' HG22 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' SER . . . . . 0.59 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.621 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.506 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.621 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASN . . . . . 0.748 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' TYR . . . . . 0.686 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ILE . . . . . 0.846 HG22 HG22 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.413 ' H ' HG12 ' A' ' 113' ' ' ILE . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.572 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.9 m -129.34 131.78 46.96 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.0 p -61.07 -57.99 10.26 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 123.485 0.49 . . . . 0.0 111.154 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.7 mt 48.36 72.81 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.7 0.762 . . . . 0.0 110.836 -177.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.7 m -142.71 -60.24 0.44 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.375 -0.83 . . . . 0.0 109.035 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.3 t60 -83.62 64.91 8.2 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-O 121.745 0.783 . . . . 0.0 109.001 170.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.0 p -143.86 -67.21 0.34 Allowed 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.837 177.291 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 58.31 -94.89 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.334 0 CA-C-N 115.31 -0.859 . . . . 0.0 113.478 173.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.459 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.1 t-20 -81.4 136.06 35.68 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.051 0.453 . . . . 0.0 110.215 -176.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 93.1 mt -76.21 -10.24 59.25 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.762 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.498 ' HB2' ' HD1' ' A' ' 18' ' ' TRP . 3.8 m-85 -76.75 -172.07 2.13 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.952 -177.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.08 -137.43 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.728 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -126.73 19.19 7.27 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 121.57 0.7 . . . . 0.0 110.283 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 172.91 77.32 0.05 OUTLIER Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.084 -177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.686 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 18.9 mm-40 -130.89 156.22 45.43 Favored 'General case' 0 C--N 1.319 -0.746 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.827 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 0.1 OUTLIER -61.37 -43.8 98.25 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.322 0.582 . . . . 0.0 109.68 177.74 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.429 ' CG2' HG21 ' A' ' 69' ' ' VAL . 1.2 p -86.96 2.57 49.01 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.002 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.686 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 79.7 t90 -90.32 -57.88 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 174.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 66.3 t80 -56.75 -45.46 82.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.415 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 58' ' ' ILE . 38.9 t -52.14 -50.71 34.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.822 176.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.447 ' CD1' ' HA3' ' A' ' 29' ' ' GLY . 67.3 t80 -62.84 -40.7 98.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.115 -175.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -71.35 -28.62 64.19 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.7 mmmt -80.47 -15.73 56.05 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.662 -0.245 . . . . 0.0 111.577 -178.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.605 HG11 HD11 ' A' ' 58' ' ' ILE . 33.3 m -100.23 5.48 10.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.997 0.427 . . . . 0.0 110.896 177.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.63 7.12 82.89 Favored Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.806 -0.634 . . . . 0.0 113.077 176.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.05 18.63 69.15 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.657 -179.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -61.4 -56.35 21.21 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 121.327 0.584 . . . . 0.0 109.988 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.667 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.1 OUTLIER -117.35 152.44 19.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 177.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.847 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 138.95 -146.77 18.58 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 119.29 -1.433 . . . . 0.0 114.599 170.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 97.4 p 59.3 -64.22 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 125.431 1.492 . . . . 0.0 112.764 -178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 t -91.41 11.68 23.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 111.775 0.287 . . . . 0.0 111.775 -172.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.847 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -77.37 -3.33 39.61 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 120.824 -0.351 . . . . 0.0 111.498 179.28 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 84.56 -104.52 2.74 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.204 -0.998 . . . . 0.0 111.819 179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.8 m-80 -146.64 -175.56 4.84 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 170.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.49 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.53 -36.03 71.06 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 113.526 0.935 . . . . 0.0 113.526 -169.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 35.5 p30 -81.96 -9.53 59.54 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -118.73 9.72 12.19 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.356 0.598 . . . . 0.0 109.562 -178.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.617 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.1 OUTLIER -53.96 -65.64 0.53 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.829 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.65 -38.15 59.89 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 123.187 0.304 . . . . 0.0 111.455 -175.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -48.21 58.43 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.519 -178.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -73.57 -35.45 65.46 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.891 0.377 . . . . 0.0 111.031 -178.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -57.17 -51.46 69.22 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.195 176.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 99.1 mt-30 -64.02 -36.6 84.54 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.677 178.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.69 99.27 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.974 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.82 -33.76 72.76 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.867 0.365 . . . . 0.0 110.57 177.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.05 22.05 2.0 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.58 -0.819 . . . . 0.0 113.138 176.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.667 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 6.4 m-30 -87.87 156.5 19.34 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 177.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 5.4 m -99.02 109.83 22.53 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -101.08 127.13 54.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 CA-C-O 121.789 0.804 . . . . 0.0 110.445 -178.027 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.759 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 25.1 m-20 -122.83 -147.66 0.38 Allowed 'General case' 0 N--CA 1.438 -1.047 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 172.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.481 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 21.1 p80 -150.32 73.61 1.15 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.874 0.845 . . . . 0.0 111.137 173.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 13.2 m -149.78 89.44 4.68 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.432 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.471 ' HB2' HG11 ' A' ' 81' ' ' VAL . 14.0 Cg_endo -54.8 144.48 65.91 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.567 2.178 . . . . 0.0 112.429 179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 38.5 t -157.3 162.07 39.14 Favored 'General case' 0 N--CA 1.449 -0.519 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 -174.863 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.619 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 81.4 tttt -60.89 113.25 2.42 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.963 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.28 -9.15 53.67 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.377 179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.12 -166.69 1.41 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.605 HD11 HG11 ' A' ' 24' ' ' VAL . 3.6 mp -135.13 144.88 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.931 0.396 . . . . 0.0 111.141 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.663 HD22 HD13 ' A' ' 83' ' ' ILE . 8.6 tp -90.27 145.59 24.87 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.661 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.6 tm0? -154.97 144.26 21.14 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-O 121.57 0.7 . . . . 0.0 112.845 -176.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.497 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 12.9 t -152.74 158.81 42.84 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.284 -0.871 . . . . 0.0 108.724 172.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.2 p -89.75 -8.57 51.95 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.682 0.277 . . . . 0.0 111.392 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -76.7 132.41 39.32 Favored 'General case' 0 C--O 1.236 0.361 0 CA-C-O 121.029 0.442 . . . . 0.0 110.821 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 127.78 167.34 12.26 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.957 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -65.49 -37.3 30.44 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.54 2.16 . . . . 0.0 111.911 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.49 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 80.2 m-85 -121.29 8.41 10.27 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.091 177.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 96.35 -165.2 23.68 Favored Glycine 0 N--CA 1.45 -0.414 0 N-CA-C 111.364 -0.695 . . . . 0.0 111.364 -175.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.3 t-160 -144.16 95.87 2.79 Favored 'General case' 0 C--O 1.223 -0.315 0 CA-C-N 117.532 0.666 . . . . 0.0 110.924 178.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.579 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 34.5 m -115.42 139.83 39.92 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 C-N-CA 120.276 -0.57 . . . . 0.0 110.775 168.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.48 ' CB ' HD12 ' A' ' 83' ' ' ILE . . . -146.08 125.21 12.89 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.274 179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.417 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 17.0 t80 -70.34 130.61 42.44 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.155 0.502 . . . . 0.0 110.229 -175.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 83' ' ' ILE . 21.6 t -88.5 113.87 26.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.413 -175.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.619 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 47.0 mt-10 -81.56 -24.32 36.61 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.165 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.7 p 179.03 145.85 0.16 Allowed 'General case' 0 C--N 1.333 -0.151 0 O-C-N 123.596 0.56 . . . . 0.0 110.767 -179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.733 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -106.18 129.14 59.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 170.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -82.74 148.35 27.91 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.234 -174.491 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 9.9 p -64.79 -11.01 32.21 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.969 0.414 . . . . 0.0 111.682 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 25.4 m-20 -76.57 -16.47 59.59 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.132 178.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.86 5.38 53.66 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.634 -175.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.0 m -103.48 140.6 37.28 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 177.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.894 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 48.8 t -108.76 130.59 61.33 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-O 120.953 0.406 . . . . 0.0 111.3 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.0 m -98.18 104.39 16.42 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.017 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.663 HD13 HD22 ' A' ' 59' ' ' LEU . 39.3 pt -111.39 169.75 3.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.328 -177.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 22.3 p -141.32 121.68 14.01 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.147 176.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.868 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -128.66 110.04 11.87 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.574 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 57.7 ttm -91.29 125.04 35.93 Favored 'General case' 0 C--N 1.322 -0.614 0 O-C-N 122.196 -0.315 . . . . 0.0 111.092 -177.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.647 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 7.2 t30 74.77 -46.72 0.61 Allowed 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 123.686 0.794 . . . . 0.0 111.838 175.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.827 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 34.7 t80 66.8 -87.56 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 O-C-N 123.843 0.714 . . . . 0.0 109.608 -177.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 49.6 m -160.17 27.62 0.17 Allowed 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -146.83 -83.21 0.05 OUTLIER Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.273 -0.965 . . . . 0.0 113.144 -172.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.647 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -84.52 113.24 3.73 Favored Glycine 0 N--CA 1.449 -0.48 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.567 -175.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.444 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.5 Cg_exo -58.53 121.1 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.328 0 C-N-CA 122.902 2.401 . . . . 0.0 112.282 -179.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.3 m-85 70.83 7.66 6.29 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.268 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.2 m -65.64 92.76 0.15 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 172.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 38.7 t -67.79 86.83 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 175.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.868 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 32.0 t -75.23 119.78 19.83 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.354 -172.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.6 m -91.87 138.51 31.49 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 114.886 -1.052 . . . . 0.0 108.978 176.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.644 ' HB3' HD11 ' A' ' 83' ' ' ILE . 41.9 ttm-85 -151.32 143.45 24.0 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.113 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 27.3 m -115.47 117.48 30.5 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.147 -0.478 . . . . 0.0 109.937 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.894 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.3 mm -96.46 115.42 35.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.351 -174.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.5 m -69.86 153.55 43.14 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 173.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.32 -41.14 60.34 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 112.369 0.507 . . . . 0.0 112.369 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 47.3 t -61.24 -40.59 94.61 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.945 0.402 . . . . 0.0 110.493 178.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.551 ' HB3' HG23 ' A' ' 100' ' ' ILE . 2.8 tp10 -71.8 -35.81 70.1 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.124 0.488 . . . . 0.0 109.731 178.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.99 -28.32 70.02 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.96 178.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.34 -23.22 69.94 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.34 175.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 31.7 t30 -82.34 -39.27 23.04 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.289 0.566 . . . . 0.0 110.314 177.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 69.1 m-85 -83.42 127.68 33.89 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.428 -0.805 . . . . 0.0 112.209 -173.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 89.6 m-20 -82.32 167.72 18.29 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.107 -0.951 . . . . 0.0 109.298 175.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.759 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -148.18 138.31 22.63 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 172.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.627 HD12 ' CD2' ' A' ' 47' ' ' PHE . 34.3 pt -108.26 123.12 63.63 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.848 0 CA-C-O 121.506 0.67 . . . . 0.0 110.493 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 33.7 p80 -132.48 160.09 37.49 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.847 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.437 -1.103 0 CA-C-O 118.782 -0.627 . . . . 0.0 109.42 171.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.777 0 N-CA-C 111.914 -0.475 . . . . 0.0 111.914 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 m -80.27 94.39 6.08 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 120.961 0.41 . . . . 0.0 110.896 -178.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 p -104.47 167.41 9.76 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.109 -0.496 . . . . 0.0 109.843 175.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 66.6 mt -62.97 -62.05 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-O 120.968 0.413 . . . . 0.0 110.511 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 49.2 m -154.61 104.16 2.52 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 34.4 m170 67.16 -81.32 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.681 0.613 . . . . 0.0 110.225 -173.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 32.3 t -154.78 146.23 23.07 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -140.8 -48.41 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.978 -179.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.663 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 49.1 t-20 -140.35 147.69 40.2 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.0 mt -84.1 -6.38 59.4 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.751 -179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.47 ' HD2' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -85.32 -178.77 6.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-O 121.599 0.714 . . . . 0.0 112.062 -173.103 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 3.5 m -78.27 161.0 27.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.695 -1.139 . . . . 0.0 110.702 -175.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -67.78 103.64 1.47 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.581 -174.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.42 67.43 1.56 Allowed Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.481 -0.866 . . . . 0.0 111.949 177.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.564 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.4 mm-40 -116.44 161.71 18.68 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 176.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.461 ' O ' HG23 ' A' ' 20' ' ' VAL . 4.6 p -60.49 -46.54 89.72 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.111 0.482 . . . . 0.0 109.947 177.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.446 HG22 HG21 ' A' ' 69' ' ' VAL . 15.6 p -75.17 -28.77 60.2 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.465 -179.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.663 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 91.9 t90 -64.24 -49.48 71.75 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.421 178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.561 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 58.7 t80 -70.32 -39.03 75.01 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.489 -176.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 16' ' ' CYS . 60.7 t -56.53 -43.08 77.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-O 120.886 0.374 . . . . 0.0 110.526 175.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -67.35 -35.39 79.28 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -62.88 -47.97 81.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.823 176.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -65.44 -32.56 74.24 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.732 -0.667 . . . . 0.0 112.579 -176.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -83.46 4.61 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 120.843 0.354 . . . . 0.0 111.172 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.66 26.14 74.55 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 121.029 -0.605 . . . . 0.0 112.221 178.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 61.27 38.18 95.25 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 121.118 -0.563 . . . . 0.0 112.66 -179.068 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -93.95 -51.67 4.76 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 111.743 0.275 . . . . 0.0 111.743 -176.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.728 ' CD1' ' HZ3' ' A' ' 32' ' ' TRP . 1.6 pp -87.11 -149.54 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.846 -178.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' A' ' 28' ' ' ILE . . . -51.22 125.21 24.32 Favored Glycine 0 C--O 1.223 -0.56 0 N-CA-C 115.383 0.913 . . . . 0.0 115.383 -166.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.4 p -110.93 -14.74 13.91 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.554 0.692 . . . . 0.0 109.214 168.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 21.3 p -119.56 25.17 10.22 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.876 -179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.728 ' HZ3' ' CD1' ' A' ' 28' ' ' ILE . 0.5 OUTLIER -72.48 -8.91 57.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.718 -179.051 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.43 -121.19 5.76 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.031 -177.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.422 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 10.3 p30 -120.32 -175.02 2.91 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 176.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.522 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -65.24 -23.71 67.13 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -170.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 19.0 t-20 -85.89 -29.55 23.57 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.238 0.542 . . . . 0.0 110.691 -178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.8 t30 -92.79 2.97 56.47 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.362 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.844 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -51.4 -68.0 0.21 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.599 0.963 . . . . 0.0 113.599 -172.424 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -53.54 -40.49 65.54 Favored 'General case' 0 C--N 1.329 -0.296 0 O-C-N 123.129 0.268 . . . . 0.0 111.43 -173.665 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.83 -50.54 71.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.407 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.627 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.64 -35.92 73.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.063 0.458 . . . . 0.0 111.293 -179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.516 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -66.69 -42.41 86.52 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.593 -0.731 . . . . 0.0 111.464 -179.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.482 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 55.6 mt-30 -61.34 -38.71 87.9 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.411 178.129 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.55 -11.91 82.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.206 178.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -89.95 -14.35 34.27 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.784 0.326 . . . . 0.0 110.63 178.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 98.03 27.18 9.01 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.731 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.618 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 8.5 m-30 -88.53 158.33 18.34 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.897 0.38 . . . . 0.0 110.167 179.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 12.5 m -90.74 100.97 13.73 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.825 HG22 HG22 ' A' ' 111' ' ' ILE . 45.3 t -99.07 108.19 21.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.268 -172.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 1.051 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.1 m-20 -120.12 -144.1 0.36 Allowed 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 175.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.533 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 4.6 p80 -157.64 81.7 0.88 Allowed 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.659 0.742 . . . . 0.0 111.161 175.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 84.9 m -165.43 105.82 0.76 Allowed Pre-proline 0 C--N 1.325 -0.499 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.177 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo -55.07 152.66 29.24 Favored 'Trans proline' 0 C--O 1.235 0.35 0 C-N-CA 122.301 2.001 . . . . 0.0 112.77 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 55.0 m -160.83 149.36 16.34 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -175.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.582 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 24.6 ttmm -59.66 114.84 2.95 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 120.625 0.25 . . . . 0.0 110.6 178.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 100.56 -2.73 56.07 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.092 178.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.94 -163.59 0.9 Allowed 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 178.129 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.844 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -124.86 -176.0 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.094 0.473 . . . . 0.0 111.447 -175.446 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.632 ' H ' HG22 ' A' ' 58' ' ' ILE . 4.7 tp -144.02 122.98 12.77 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 -179.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.629 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.9 tm0? -136.08 135.7 39.57 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.481 0.658 . . . . 0.0 112.39 -172.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.755 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -127.26 140.64 52.08 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.466 175.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 5.9 m -109.5 8.92 25.4 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-O 121.502 0.668 . . . . 0.0 109.344 176.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -88.71 13.95 11.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.634 -176.035 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.13 171.86 15.02 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.715 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo -61.88 -43.46 25.37 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.874 2.383 . . . . 0.0 111.773 -176.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.522 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 82.2 m-85 -121.34 20.45 11.27 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.549 175.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 83.2 -155.52 32.89 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.652 178.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.755 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.2 t60 -164.21 102.19 0.85 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 179.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.621 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 33.2 m -116.05 131.41 68.62 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.653 0 C-N-CA 119.858 -0.737 . . . . 0.0 111.585 173.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.438 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -137.81 130.55 29.84 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.421 179.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.409 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 70.1 t80 -74.39 130.39 39.56 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 120.641 -0.424 . . . . 0.0 110.145 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 27.5 t -92.41 117.51 35.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.724 -175.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.582 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.4 mt-10 -94.05 -31.12 14.35 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.984 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 46.8 m -160.98 139.02 9.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.734 0.302 . . . . 0.0 111.492 -175.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.617 HG13 HG22 ' A' ' 81' ' ' VAL . 61.6 t -105.26 115.96 48.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 164.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 78.3 m-20 -68.53 158.35 34.04 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.378 -171.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 34.1 t -61.7 -30.59 70.85 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.444 -178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -19.78 57.85 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.676 -178.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 122.5 -22.15 7.46 Favored Glycine 0 N--CA 1.454 -0.164 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.584 179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 40.0 p -71.3 145.1 49.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.886 0.374 . . . . 0.0 110.52 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.715 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.9 t -110.15 129.75 64.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 CA-C-O 120.813 0.339 . . . . 0.0 111.073 -177.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.6 m -95.96 112.17 23.98 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 121.256 0.55 . . . . 0.0 110.12 177.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.49 HG21 HD22 ' A' ' 59' ' ' LEU . 32.6 pt -111.67 156.05 12.88 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.241 -177.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 8.4 t -126.02 96.66 4.82 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.758 178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.927 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.8 pt-20 -117.68 106.22 12.85 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.473 178.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.795 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 57.3 ttm -75.55 130.48 38.89 Favored 'General case' 0 C--N 1.32 -0.689 0 O-C-N 121.797 -0.564 . . . . 0.0 110.868 179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.4 HD22 ' HA ' ' A' ' 15' ' ' GLN . 23.4 t30 70.05 -90.59 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.934 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 50.1 t80 57.25 -65.53 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.498 0 O-C-N 123.856 0.723 . . . . 0.0 112.921 -172.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.4 t -89.49 9.27 27.14 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -167.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 103.78 11.58 32.32 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 119.77 -1.205 . . . . 0.0 113.727 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -100.29 106.7 3.19 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.327 174.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -54.09 112.09 0.89 Allowed 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.912 2.408 . . . . 0.0 112.616 -177.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 67.52 13.28 9.25 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.257 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.0 m -69.92 84.82 0.5 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.795 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -67.61 92.49 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-O 121.759 0.79 . . . . 0.0 109.277 179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.927 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 47.4 t -66.53 104.82 1.34 Allowed 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.491 -174.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 18.3 m -88.08 80.54 7.65 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 114.888 -1.051 . . . . 0.0 108.724 174.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.451 ' HB3' HD11 ' A' ' 83' ' ' ILE . 46.1 ttt180 -100.17 151.07 21.85 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.934 -171.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 m -106.41 114.33 28.39 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.235 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.715 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 45.9 mm -90.26 113.34 26.15 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.867 177.508 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 21.7 t -73.62 156.1 38.38 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 174.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -51.23 -32.04 22.73 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 120.861 0.362 . . . . 0.0 111.501 179.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 2.2 p -61.11 -34.08 74.4 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.989 -0.551 . . . . 0.0 111.595 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.0 mp0 -88.96 -34.5 16.86 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.91 0.386 . . . . 0.0 110.07 176.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -55.13 -32.16 61.86 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.334 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -57.48 -43.47 94.03 Favored Glycine 0 CA--C 1.525 0.672 0 CA-C-N 115.945 -0.571 . . . . 0.0 113.863 178.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -86.18 -14.59 43.55 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 117.586 0.693 . . . . 0.0 111.8 -175.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.525 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 30.9 m-85 -81.38 127.06 32.36 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.143 0.497 . . . . 0.0 111.837 -177.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.533 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 30.8 m-80 -88.3 169.7 11.62 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.008 177.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 1.051 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -154.58 149.83 27.09 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 174.05 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.825 HG22 HG22 ' A' ' 49' ' ' VAL . 39.7 pt -120.69 111.54 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.994 0 CA-C-O 121.585 0.707 . . . . 0.0 110.027 -175.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.1 p80 -129.27 142.09 50.94 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.473 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.472 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.8 pt . . . . . 0 C--O 1.248 0.977 0 CA-C-O 119.03 -0.51 . . . . 0.0 111.842 -176.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.593 0 N-CA-C 111.718 -0.553 . . . . 0.0 111.718 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.5 t -87.07 104.91 16.77 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 178.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.2 m -79.73 -30.52 40.92 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.084 -178.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 34.2 pt -101.6 129.17 53.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 121.323 0.582 . . . . 0.0 111.266 -178.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 m -123.07 -47.53 2.03 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.289 179.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.91 113.42 25.23 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.323 171.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.2 t -63.34 -36.61 84.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.072 0.463 . . . . 0.0 110.114 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.15 -36.95 2.29 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.51 175.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.48 HD21 ' HA ' ' A' ' 18' ' ' TRP . 36.6 t-20 -110.32 146.64 35.37 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.707 0.289 . . . . 0.0 110.282 -176.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 81.8 mt -87.99 -19.16 27.58 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.807 179.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.437 ' CB ' ' HD1' ' A' ' 18' ' ' TRP . 25.1 m-85 -71.95 -178.69 2.44 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.948 -176.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 59.3 m -70.79 -89.39 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.844 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -177.26 124.9 0.14 Allowed 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 110.476 -0.194 . . . . 0.0 110.476 -177.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.527 ' O ' ' HB2' ' A' ' 88' ' ' TYR . . . 66.79 26.76 73.09 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.808 175.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.561 ' HG2' ' CB ' ' A' ' 88' ' ' TYR . 19.6 mt-30 -96.55 157.62 15.81 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.476 ' O ' HG23 ' A' ' 20' ' ' VAL . 53.3 m -52.41 -55.18 23.49 Favored 'General case' 0 C--N 1.326 -0.435 0 O-C-N 123.362 0.414 . . . . 0.0 111.216 179.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 p -74.4 -20.59 60.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.372 0.606 . . . . 0.0 110.05 -177.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.48 ' HA ' HD21 ' A' ' 9' ' ' ASN . 84.8 t90 -72.68 -52.55 14.8 Favored 'General case' 0 N--CA 1.451 -0.398 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.625 175.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.411 ' O ' ' HG2' ' A' ' 23' ' ' LYS . 51.6 t80 -57.67 -44.1 85.48 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.381 -177.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 16' ' ' CYS . 99.4 t -58.77 -48.64 85.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.367 178.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -64.94 -34.5 78.56 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.895 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -70.35 -43.96 69.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.531 178.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.411 ' HG2' ' O ' ' A' ' 19' ' ' TYR . 30.0 mmmt -62.68 -35.93 81.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.838 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -82.14 -4.57 8.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 120.834 0.35 . . . . 0.0 111.173 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 78.43 24.83 62.3 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.896 176.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.89 6.88 60.86 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.647 -179.41 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -69.02 -30.02 68.32 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.339 0.59 . . . . 0.0 110.79 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.97 129.61 28.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.157 -179.046 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.603 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 136.35 -155.78 22.68 Favored Glycine 0 N--CA 1.444 -0.767 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.347 169.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 67.0 m 69.6 -57.94 0.53 Allowed 'General case' 0 N--CA 1.468 0.451 0 C-N-CA 123.924 0.89 . . . . 0.0 111.883 -178.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.421 ' O ' ' HB1' ' A' ' 41' ' ' ALA . 19.1 p -78.08 -1.58 33.1 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.788 0.328 . . . . 0.0 111.447 -178.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.603 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.4 OUTLIER -75.37 -6.89 52.28 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.205 179.184 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.454 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.15 -106.04 3.25 Favored Glycine 0 N--CA 1.445 -0.748 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.171 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.491 ' H ' ' HB3' ' A' ' 37' ' ' ASN . 3.3 m-80 -143.26 -171.58 3.51 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 172.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -50.76 -58.01 6.97 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 113.093 0.775 . . . . 0.0 113.093 -170.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.513 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 64.2 t30 -77.41 -6.22 52.58 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.233 0.539 . . . . 0.0 111.531 -173.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.491 ' HB3' ' H ' ' A' ' 34' ' ' ASN . 7.0 t30 -99.36 -3.44 33.91 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-O 121.374 0.607 . . . . 0.0 109.793 -178.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.689 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.7 OUTLIER -52.14 -68.88 0.13 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.079 -0.964 . . . . 0.0 113.515 -173.794 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -28.12 21.81 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -172.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.4 -57.26 3.92 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.746 0.308 . . . . 0.0 111.109 178.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.49 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -70.48 -39.22 74.34 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.761 -175.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -54.84 -50.48 68.51 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.863 178.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.417 HE21 HG22 ' A' ' 49' ' ' VAL . 92.6 mt-30 -62.97 -34.77 78.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.93 178.273 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.63 -36.09 87.27 Favored Glycine 0 C--N 1.33 0.241 0 C-N-CA 121.163 -0.542 . . . . 0.0 112.005 177.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -69.43 -27.58 65.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.925 0.393 . . . . 0.0 110.345 175.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.04 10.66 4.62 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.61 -0.805 . . . . 0.0 113.407 175.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.601 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.0 m-30 -80.45 162.24 24.5 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 117.154 0.477 . . . . 0.0 109.884 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.41 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 8.5 m -114.59 130.58 56.79 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.031 177.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.575 HG12 HG22 ' A' ' 111' ' ' ILE . 4.8 m -109.36 126.54 66.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.328 0.585 . . . . 0.0 110.879 179.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.676 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 41.8 m-20 -117.94 -3.51 11.15 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 25.8 p-80 41.66 71.92 0.19 Allowed 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 114.484 -1.235 . . . . 0.0 112.866 -171.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 38.9 m -160.16 87.9 1.89 Allowed Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.584 177.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -49.24 147.68 11.29 Favored 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 123.518 2.812 . . . . 0.0 113.637 -174.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 13.5 p -151.35 168.23 25.46 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.601 -176.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.645 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 60.7 tttm -65.39 111.95 3.3 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.428 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.9 3.04 49.21 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.864 -0.684 . . . . 0.0 112.222 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -104.31 -159.07 0.7 Allowed 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.663 0.268 . . . . 0.0 110.849 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.689 HG21 ' CH2' ' A' ' 38' ' ' TRP . 1.7 mp -138.93 172.13 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 -178.179 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.637 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.2 tp -120.84 164.18 17.03 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 178.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -151.01 124.99 9.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.19 0.519 . . . . 0.0 111.046 178.904 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 3.7 m -126.3 114.8 18.74 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.141 177.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.3 m -70.26 91.79 0.75 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.189 0.519 . . . . 0.0 110.798 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.886 ' H ' ' HA2' ' A' ' 67' ' ' GLY . 38.9 mt-10 -102.14 154.36 19.08 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.69 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.485 ' N ' ' HD2' ' A' ' 65' ' ' PRO . . . -51.72 -51.17 40.17 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 115.282 -0.872 . . . . 0.0 115.149 -178.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' A' ' 64' ' ' GLY . 18.6 Cg_endo -58.9 -60.55 0.33 Allowed 'Trans proline' 0 C--N 1.353 0.815 0 C-N-CA 122.195 1.93 . . . . 0.0 113.005 -174.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.513 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 4.6 p90 -160.79 23.57 0.14 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.722 0.296 . . . . 0.0 110.541 -178.634 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.886 ' HA2' ' H ' ' A' ' 63' ' ' GLU . . . 77.98 -158.15 46.0 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.385 -0.912 . . . . 0.0 112.354 -178.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.567 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 1.9 t60 -166.46 121.03 1.12 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 119.65 -0.214 . . . . 0.0 110.677 -176.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.652 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.6 m -126.64 133.43 68.62 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.203 170.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -133.59 130.1 37.9 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.368 -177.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.435 ' HB2' HG22 ' A' ' 20' ' ' VAL . 83.1 t80 -71.55 127.94 34.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.784 0.326 . . . . 0.0 111.098 -173.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.76 HG22 HG22 ' A' ' 83' ' ' ILE . 26.3 t -92.05 111.95 24.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.333 -177.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.645 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 45.0 mt-10 -84.63 -18.97 33.76 Favored 'General case' 0 C--N 1.321 -0.661 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.292 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 37.2 p -178.93 162.1 1.24 Allowed 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 121.057 0.456 . . . . 0.0 111.989 -178.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.564 ' HA ' ' HA ' ' A' ' 81' ' ' VAL . 4.5 p -112.61 134.23 55.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 170.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -84.69 157.01 21.23 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 120.748 0.308 . . . . 0.0 110.603 -175.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.4 m -61.86 -21.01 64.32 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.143 178.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -60.96 -21.27 63.31 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.883 175.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 103.63 -16.89 51.24 Favored Glycine 0 N--CA 1.45 -0.416 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -176.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 12.1 m -91.67 147.14 23.22 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.152 -0.524 . . . . 0.0 109.783 177.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.967 HG22 ' HB ' ' A' ' 100' ' ' ILE . 5.9 m -98.78 156.4 3.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 C-N-CA 120.724 -0.39 . . . . 0.0 111.175 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 93.7 m -107.42 108.37 19.69 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.119 178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.76 HG22 HG22 ' A' ' 72' ' ' VAL . 2.7 pp -97.03 145.17 9.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.546 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.5 m -132.93 110.12 10.06 Favored 'General case' 0 N--CA 1.444 -0.772 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.118 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.561 ' CG ' ' HB3' ' A' ' 96' ' ' SER . 14.2 pt-20 -128.04 163.75 23.9 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 176.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.745 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 16.7 tpp -109.8 116.59 31.95 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 164.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.506 ' HB3' ' HB2' ' A' ' 94' ' ' SER . 2.6 t-20 -83.43 100.61 10.82 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 120.701 -0.4 . . . . 0.0 110.33 -176.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.971 ' HA ' ' HA ' ' A' ' 92' ' ' PRO . 33.7 t80 -91.6 -46.12 8.12 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.331 170.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 66' ' ' PHE . 19.3 m -79.49 86.34 5.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.41 0.624 . . . . 0.0 110.161 177.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.79 -90.44 0.14 Allowed Glycine 0 N--CA 1.448 -0.532 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -174.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -121.96 84.54 0.37 Allowed Glycine 0 N--CA 1.448 -0.503 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 169.179 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.971 ' HA ' ' HA ' ' A' ' 88' ' ' TYR . 96.5 Cg_exo -44.14 130.02 8.26 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.517 2.811 . . . . 0.0 114.77 -167.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 74.65 11.07 3.95 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 113.697 -1.592 . . . . 0.0 112.462 -178.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.506 ' HB2' ' HB3' ' A' ' 87' ' ' ASN . 12.5 m -72.3 84.93 1.07 Allowed 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 166.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.745 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.2 p -64.56 96.3 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-O 121.845 0.831 . . . . 0.0 108.809 176.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.561 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . 29.4 t -80.9 137.19 36.15 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 114.532 -1.213 . . . . 0.0 111.244 -170.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.486 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 50.6 m -136.44 89.96 2.52 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.011 176.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.464 ' H ' HD11 ' A' ' 83' ' ' ILE . 34.0 ttt180 -97.6 151.7 19.81 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.188 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 24.4 m -94.57 102.55 14.48 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 177.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.967 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.6 mm -81.06 114.53 22.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.739 -175.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 11.7 m -59.9 148.21 35.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.771 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -55.64 -34.75 65.22 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 111.96 0.356 . . . . 0.0 111.96 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 33.2 t -63.57 -40.86 98.07 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.94 0.4 . . . . 0.0 110.238 177.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.479 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 38.7 mt-10 -77.04 -30.22 55.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.871 179.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.8 -44.12 90.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.347 176.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -79.26 37.67 2.0 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 120.964 -0.636 . . . . 0.0 111.925 176.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -145.02 -49.81 0.25 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 27.9 m-85 -67.3 125.92 27.6 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.754 179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.654 ' O ' ' HB3' ' A' ' 60' ' ' GLN . 6.4 m120 -84.46 120.99 26.94 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.974 -172.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.676 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -106.91 154.0 21.7 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 176.836 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.601 HD12 ' CD2' ' A' ' 47' ' ' PHE . 20.5 pt -110.6 118.26 56.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -176.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.41 ' HB2' ' O ' ' A' ' 48' ' ' THR . 0.2 OUTLIER -97.23 144.27 27.2 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.743 -173.583 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.2 mt . . . . . 0 C--O 1.248 1.025 0 CA-C-N 115.76 -0.654 . . . . 0.0 109.301 173.496 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.644 0 N-CA-C 111.977 -0.449 . . . . 0.0 111.977 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 20.2 m -96.03 -24.45 16.34 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.222 0.534 . . . . 0.0 110.027 179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 5.5 t -153.76 167.61 29.06 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 175.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 54.1 mt -104.44 97.53 5.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.186 0.517 . . . . 0.0 111.752 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -130.06 -39.15 1.39 Allowed 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 172.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.71 90.46 1.63 Allowed 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 172.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 23.3 t -86.92 -26.68 23.78 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.092 -176.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 91.17 18.9 44.44 Favored Glycine 0 N--CA 1.444 -0.808 0 N-CA-C 110.742 -0.943 . . . . 0.0 110.742 -175.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.601 HD22 ' N ' ' A' ' 10' ' ' LEU . 0.2 OUTLIER -134.36 127.86 32.5 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 -176.305 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.601 ' N ' HD22 ' A' ' 9' ' ' ASN . 88.0 mt -70.21 -22.55 62.91 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.679 0.622 . . . . 0.0 112.679 -175.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -86.27 -177.26 6.19 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -171.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.536 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.0 m -60.35 -91.32 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 115.54 -0.754 . . . . 0.0 112.458 -173.602 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.529 ' H ' ' HG2' ' A' ' 15' ' ' GLN . . . -175.44 111.82 0.12 Allowed 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.377 -178.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 69.16 25.35 75.5 Favored Glycine 0 N--CA 1.453 -0.208 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.466 179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.536 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 12.8 mm100 -87.3 178.89 6.72 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.778 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.5 p -61.82 -59.18 5.54 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.832 0.349 . . . . 0.0 111.402 -175.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.626 HG22 HG21 ' A' ' 69' ' ' VAL . 43.6 p -72.94 -21.58 60.86 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.074 0.464 . . . . 0.0 110.75 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . . . . . . . . . 64.6 t90 -65.55 -54.27 30.33 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.894 -0.594 . . . . 0.0 109.808 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.523 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 73.6 t80 -58.11 -40.97 82.56 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.521 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.618 HG13 HG12 ' A' ' 58' ' ' ILE . 79.7 t -57.6 -51.13 73.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.306 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.594 ' OH ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -61.89 -41.08 97.46 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.161 -176.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -61.93 -48.14 81.74 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.127 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -67.38 -32.18 72.91 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.374 -175.413 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.556 HG11 HD11 ' A' ' 58' ' ' ILE . 33.9 m -81.28 -1.55 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.719 0.295 . . . . 0.0 111.435 -178.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.2 -3.2 69.35 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.481 -0.866 . . . . 0.0 113.044 175.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.1 10.07 86.45 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.758 -0.734 . . . . 0.0 113.505 178.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -81.0 -29.25 35.24 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.556 0.694 . . . . 0.0 109.858 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.434 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -118.7 130.12 73.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.289 -174.678 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.634 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 106.5 18.47 10.92 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.417 -0.896 . . . . 0.0 114.957 166.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.594 ' HB3' ' OH ' ' A' ' 21' ' ' TYR . 9.4 p -77.92 43.65 0.43 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 117.303 0.552 . . . . 0.0 111.156 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.581 HG21 ' HB2' ' A' ' 45' ' ' ALA . 8.9 t -178.01 -7.85 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.634 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -69.65 -17.54 63.51 Favored 'General case' 0 CA--C 1.54 0.587 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -169.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 85.24 -108.79 3.23 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.154 -1.022 . . . . 0.0 112.578 -176.11 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.571 HD21 ' HA ' ' A' ' 66' ' ' PHE . 4.3 t30 -129.76 171.78 12.32 Favored 'General case' 0 N--CA 1.447 -0.612 0 N-CA-C 108.76 -0.829 . . . . 0.0 108.76 178.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.632 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -49.62 -48.48 49.07 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.522 0.934 . . . . 0.0 113.522 -171.036 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.408 ' HA ' HE22 ' A' ' 60' ' ' GLN . 29.6 p-10 -80.49 -3.09 48.71 Favored 'General case' 0 C--N 1.324 -0.516 0 O-C-N 121.955 -0.465 . . . . 0.0 111.708 -170.648 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.5 t30 -112.5 9.11 19.54 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.515 0.674 . . . . 0.0 109.211 177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.69 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -53.24 -65.31 0.58 Allowed 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.199 -0.909 . . . . 0.0 112.737 -174.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.55 -39.46 57.82 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.95 0.352 . . . . 0.0 111.95 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.23 -50.17 55.85 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.626 -177.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.627 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -76.42 -37.01 57.7 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.47 -176.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.44 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -62.5 -48.61 78.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.165 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 26.4 mt-30 -64.56 -26.4 68.4 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.778 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.73 -26.34 73.82 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.96 176.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.581 ' HB2' HG21 ' A' ' 31' ' ' THR . . . -87.88 -8.59 55.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.236 0.541 . . . . 0.0 110.64 178.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 94.89 24.95 15.86 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.767 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.635 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -76.11 158.73 31.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.987 0.423 . . . . 0.0 110.118 177.197 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.7 m -100.92 113.82 27.12 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.326 178.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.87 HG22 HG22 ' A' ' 111' ' ' ILE . 42.9 t -111.07 119.94 60.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.793 -178.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.755 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 52.8 m-20 -126.83 3.86 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.418 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.701 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 12.6 p80 40.1 75.35 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.304 -0.862 . . . . 0.0 112.598 -172.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 62.4 m -163.55 98.02 1.0 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.217 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HB2' HG11 ' A' ' 81' ' ' VAL . 17.2 Cg_endo -55.46 155.88 19.42 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.891 2.394 . . . . 0.0 113.476 -176.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 49.6 m -159.78 162.92 34.93 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 7.1 ttpm? -65.7 109.83 2.56 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.698 0.285 . . . . 0.0 110.366 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.31 -1.44 46.77 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.406 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.96 -166.16 1.34 Allowed 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 179.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.618 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -137.16 146.47 28.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 110.453 -0.203 . . . . 0.0 110.453 -179.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.604 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.7 tp -90.06 161.72 15.68 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.633 -179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.665 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 2.2 tp60 -150.85 124.59 9.12 Favored 'General case' 0 CA--C 1.517 -0.309 0 CA-C-O 121.515 0.674 . . . . 0.0 111.495 176.101 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.471 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 31.1 t -135.17 99.95 4.41 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.661 -1.154 . . . . 0.0 109.073 175.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 13.2 t -82.24 92.24 6.88 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -127.16 18.27 7.09 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.38 -173.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 172.16 -158.78 29.56 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.92 -177.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.49 -34.06 35.03 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 123.247 2.631 . . . . 0.0 112.761 -176.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.571 ' HA ' HD21 ' A' ' 34' ' ' ASN . 81.0 m-85 -110.44 -50.86 2.92 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.981 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.79 -177.3 53.38 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.479 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.665 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 75.3 m-70 -113.49 114.71 26.92 Favored 'General case' 0 CA--C 1.509 -0.613 0 O-C-N 122.762 -0.257 . . . . 0.0 111.452 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.632 HG22 ' HB2' ' A' ' 35' ' ' ALA . 24.2 m -117.72 108.96 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.892 0 CA-C-O 121.845 0.831 . . . . 0.0 108.945 157.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.548 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -117.91 128.45 54.83 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.778 -176.03 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.1 t80 -70.31 120.76 16.46 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.336 0.589 . . . . 0.0 110.279 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.662 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.2 t -78.75 108.76 12.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.159 -0.928 . . . . 0.0 110.111 -175.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -69.78 -32.89 71.61 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.901 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 17.7 p 173.35 156.94 0.11 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.509 -175.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 8.4 p -92.17 147.43 5.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 171.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 -90.07 172.16 9.03 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.066 0.46 . . . . 0.0 110.901 -176.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 10.0 p -68.12 -29.78 68.77 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.979 -177.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -81.08 -25.08 37.3 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.834 0.35 . . . . 0.0 111.068 -176.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 126.44 -18.28 6.45 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.573 -0.822 . . . . 0.0 112.124 -177.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.5 m -73.21 158.27 35.54 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 177.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 ' HB ' ' A' ' 100' ' ' ILE . 27.7 m -116.14 140.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.468 -0.493 . . . . 0.0 111.526 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 94.8 m -95.77 119.6 34.55 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.566 176.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.662 HG22 ' HA ' ' A' ' 72' ' ' VAL . 27.3 pt -130.46 154.38 40.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.365 -173.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 7.6 p -128.4 121.59 29.43 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.735 178.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.87 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 3.9 pt-20 -127.05 96.91 4.76 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.652 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.822 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.0 ttm -69.13 134.28 49.11 Favored 'General case' 0 C--N 1.321 -0.649 0 O-C-N 122.206 -0.309 . . . . 0.0 110.889 -179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.517 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.7 t30 74.53 -63.95 0.4 Allowed 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 123.967 0.907 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.778 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 31.1 t80 65.53 -73.97 0.06 Allowed 'General case' 0 N--CA 1.464 0.239 0 O-C-N 123.786 0.679 . . . . 0.0 110.361 -174.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.8 t -174.53 101.05 0.09 Allowed 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 146.05 -93.91 0.16 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.598 -0.81 . . . . 0.0 112.626 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -90.33 121.25 6.13 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.027 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.517 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 43.7 Cg_exo -58.21 128.82 30.1 Favored 'Trans proline' 0 C--O 1.235 0.37 0 C-N-CA 122.569 2.179 . . . . 0.0 112.515 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 72.09 12.89 5.91 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.317 176.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 25.6 p -73.11 89.88 1.51 Allowed 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 171.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.822 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.3 p -61.33 94.38 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-O 121.741 0.782 . . . . 0.0 109.973 178.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.87 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 30.8 t -68.7 121.04 15.65 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.287 -175.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -94.76 112.92 24.63 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.084 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.428 ' HB2' HG13 ' A' ' 83' ' ' ILE . 13.8 mmt180 -125.64 162.45 24.97 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.275 0.559 . . . . 0.0 111.136 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 52.3 m -145.34 113.71 6.65 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.545 -0.752 . . . . 0.0 109.501 177.183 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.61 ' HB ' HG22 ' A' ' 81' ' ' VAL . 39.7 mm -94.59 130.01 44.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.434 -0.348 . . . . 0.0 111.368 -174.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.4 p -68.25 141.21 55.97 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.084 172.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.96 -34.76 30.21 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.108 0.41 . . . . 0.0 112.108 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.3 t -57.0 -52.34 65.66 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.989 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -81.01 -22.48 39.37 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.647 0.26 . . . . 0.0 111.13 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.33 -34.79 78.94 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.915 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.69 -27.47 72.0 Favored Glycine 0 CA--C 1.519 0.342 0 C-N-CA 120.889 -0.672 . . . . 0.0 112.405 177.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.2 t30 -82.72 -41.67 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.102 0.477 . . . . 0.0 110.389 178.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.459 ' HE2' HD12 ' A' ' 100' ' ' ILE . 18.6 m-30 -63.57 132.94 52.81 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.421 -174.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.701 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 50.4 m-80 -79.32 163.72 24.67 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.176 -175.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.755 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.27 143.16 22.09 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 174.781 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.87 HG22 HG22 ' A' ' 49' ' ' VAL . 36.7 pt -116.54 120.65 65.61 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 C-N-CA 120.489 -0.484 . . . . 0.0 110.143 -178.093 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -125.65 146.35 49.76 Favored 'General case' 0 C--N 1.32 -0.683 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 174.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 15.7 mt . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.602 -0.714 . . . . 0.0 110.996 -173.399 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 112.19 -0.364 . . . . 0.0 112.19 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 t -73.52 -47.52 40.32 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 120.663 0.268 . . . . 0.0 110.298 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.6 m 59.33 63.02 1.65 Allowed 'General case' 0 C--O 1.235 0.322 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.477 179.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 pt -99.55 168.49 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.929 176.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.7 t -113.19 -84.34 0.59 Allowed 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 61.2 m80 -122.73 -30.99 3.77 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.4 t -124.36 149.89 46.14 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.522 175.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -85.86 49.79 4.19 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.306 176.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.581 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 52.0 t30 -124.67 144.86 49.97 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.997 0.427 . . . . 0.0 110.494 -176.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 43.5 mt -90.77 -14.27 32.32 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.542 -173.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -69.26 168.93 13.16 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.094 0.473 . . . . 0.0 111.679 -172.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.583 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 4.4 m -60.69 138.16 58.11 Favored 'General case' 0 N--CA 1.451 -0.382 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.685 -179.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.54 111.22 2.26 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.081 -177.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.57 42.88 3.8 Favored Glycine 0 N--CA 1.446 -0.689 0 C-N-CA 120.406 -0.902 . . . . 0.0 112.226 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.583 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 22.0 mm-40 -107.12 154.22 21.49 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.585 0.231 . . . . 0.0 110.693 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.952 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 3.1 p -60.07 -46.03 90.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.128 0.489 . . . . 0.0 109.94 175.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.447 HG22 HG21 ' A' ' 69' ' ' VAL . 47.5 p -72.72 -24.75 61.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.508 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.581 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 87.4 t90 -70.47 -47.71 59.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.037 177.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -62.11 -46.06 90.74 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.78 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.426 HG11 ' CH2' ' A' ' 38' ' ' TRP . 72.6 t -57.14 -46.46 84.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.969 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -61.71 -40.36 94.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.872 -177.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -63.39 -47.82 80.43 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.072 0.463 . . . . 0.0 111.228 177.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.31 -24.77 67.37 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.235 -174.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 28' ' ' ILE . 33.1 m -93.04 5.35 6.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.889 0.376 . . . . 0.0 110.987 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.21 22.76 70.14 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.931 -0.652 . . . . 0.0 112.841 176.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 62.41 36.5 93.2 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.869 -0.682 . . . . 0.0 112.264 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 7.9 tp10 -88.31 -50.35 6.39 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.887 0.375 . . . . 0.0 111.127 -176.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.62 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.3 142.37 30.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.784 -178.313 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.623 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 111.14 -137.41 14.28 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.16 -1.019 . . . . 0.0 114.303 166.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 45.9 p 68.9 -39.42 0.42 Allowed 'General case' 0 N--CA 1.474 0.726 0 C-N-CA 125.137 1.375 . . . . 0.0 110.757 -171.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.434 ' H ' ' C ' ' A' ' 29' ' ' GLY . 18.4 p -101.42 5.48 42.1 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.577 -0.283 . . . . 0.0 111.527 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.628 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -73.15 -2.64 22.38 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.114 0.483 . . . . 0.0 111.555 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.11 -117.17 4.35 Favored Glycine 0 N--CA 1.438 -1.219 0 C-N-CA 119.857 -1.163 . . . . 0.0 111.829 -179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -128.2 -174.89 3.34 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.505 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -63.66 -42.85 98.04 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.303 0.853 . . . . 0.0 113.303 -168.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.8 p30 -82.49 -2.15 52.52 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.144 -177.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.429 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.1 t30 -107.85 -1.4 20.84 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.961 -178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.806 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -53.84 -62.48 1.63 Allowed 'General case' 0 C--O 1.222 -0.355 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -173.248 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.51 -35.86 66.08 Favored 'General case' 0 C--N 1.328 -0.352 0 O-C-N 123.385 0.428 . . . . 0.0 111.093 -172.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.01 -52.96 16.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.938 179.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.628 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -63.9 -45.4 89.52 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.046 -178.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.593 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -56.01 -49.08 74.65 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.502 -178.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -67.9 -32.8 73.53 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.739 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.66 -32.09 67.44 Favored Glycine 0 C--N 1.33 0.197 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.128 177.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.15 -22.56 55.27 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.544 176.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 106.67 26.29 5.92 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.898 -0.667 . . . . 0.0 113.246 176.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.549 ' CD2' HD12 ' A' ' 111' ' ' ILE . 15.3 m-30 -79.92 157.67 26.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.873 0.368 . . . . 0.0 110.663 179.744 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 21.8 m -101.03 118.18 36.49 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.206 177.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.476 ' HB ' ' O ' ' A' ' 110' ' ' TYR . 0.8 OUTLIER -118.24 135.66 57.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-O 121.148 0.499 . . . . 0.0 111.212 -176.737 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -140.64 -41.17 0.41 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 172.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.51 ' HA ' ' CG ' ' A' ' 110' ' ' TYR . 76.0 t60 69.17 80.85 0.18 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.93 -1.487 . . . . 0.0 111.923 -178.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.444 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 87.2 m -126.83 102.98 24.47 Favored Pre-proline 0 C--N 1.308 -1.213 0 CA-C-N 113.914 -1.494 . . . . 0.0 107.492 169.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 3.9 Cg_exo -31.43 115.92 0.06 OUTLIER 'Trans proline' 0 C--N 1.356 0.948 0 C-N-CA 124.41 3.406 . . . . 0.0 113.83 -179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 73.7 m -160.57 148.37 16.13 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.778 -177.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 62.2 tttp -61.0 123.02 16.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.866 0.365 . . . . 0.0 110.396 176.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 99.76 5.47 55.21 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.649 -0.786 . . . . 0.0 111.856 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.602 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -106.4 -178.34 3.62 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 175.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.806 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -129.03 -174.4 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.051 0.453 . . . . 0.0 111.106 -178.649 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 1.2 tt -151.79 136.94 17.42 Favored 'General case' 0 N--CA 1.445 -0.676 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.403 -178.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.891 ' HG2' HD22 ' A' ' 109' ' ' ASN . 0.0 OUTLIER -138.48 141.11 39.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.663 -178.679 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.855 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 10.8 t -133.13 147.34 52.1 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 114.691 -1.14 . . . . 0.0 109.096 177.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 3.3 p -92.29 -0.67 57.38 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.215 0.531 . . . . 0.0 110.298 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.0 mp0 -90.14 94.33 9.73 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.073 -177.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 163.73 -178.28 39.27 Favored Glycine 0 N--CA 1.45 -0.389 0 N-CA-C 111.603 -0.599 . . . . 0.0 111.603 -179.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -73.83 -58.5 0.06 OUTLIER 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.579 2.186 . . . . 0.0 111.418 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 88.7 m-85 -100.81 11.08 40.29 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.659 177.345 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.71 -148.38 18.24 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 111.159 -0.777 . . . . 0.0 111.159 -176.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.855 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.6 t-160 -164.49 95.65 0.74 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.703 0.251 . . . . 0.0 110.492 179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 28.7 m -117.12 126.23 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.366 172.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.44 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -128.89 138.43 52.01 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 114.955 -1.021 . . . . 0.0 110.036 -178.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.567 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 34.5 t80 -81.68 134.61 35.48 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.091 0.472 . . . . 0.0 110.453 -178.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.442 HG22 HG22 ' A' ' 83' ' ' ILE . 39.9 t -89.17 110.18 21.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.744 -177.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.567 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 27.5 mt-10 -85.66 -32.38 22.03 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.828 -179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 70.0 m -166.97 149.43 6.27 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.581 -178.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.787 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -110.03 130.25 63.55 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 169.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 31.2 m-80 -77.25 147.14 36.49 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.6 m -66.88 -20.29 65.89 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.249 -176.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -67.73 -17.87 64.7 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.988 177.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.75 -10.27 27.76 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.91 -0.662 . . . . 0.0 111.86 -178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 6.0 p -86.26 146.28 26.59 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 177.195 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.841 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 16.5 t -112.92 137.89 44.24 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-O 120.747 0.308 . . . . 0.0 111.136 -175.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.3 m -101.86 108.03 19.39 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.201 0.524 . . . . 0.0 110.293 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.463 HD13 HD11 ' A' ' 100' ' ' ILE . 45.6 pt -112.66 150.83 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.685 -179.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 68.4 m -130.52 129.85 43.38 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.473 0.654 . . . . 0.0 110.406 177.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.661 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 14.0 pt-20 -140.86 111.18 6.73 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.454 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 1.01 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 45.0 ttm -75.25 123.97 26.24 Favored 'General case' 0 C--N 1.319 -0.736 0 O-C-N 121.609 -0.682 . . . . 0.0 110.345 -175.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.505 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 24.4 t30 75.69 -56.15 0.6 Allowed 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 124.066 0.946 . . . . 0.0 111.436 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.952 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 6.4 t80 69.45 -67.21 0.23 Allowed 'General case' 0 C--O 1.233 0.226 0 O-C-N 123.599 0.562 . . . . 0.0 110.373 -174.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.9 t -179.6 86.61 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 178.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 155.88 -72.86 0.25 Allowed Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.303 -0.951 . . . . 0.0 113.112 176.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -94.5 115.17 4.98 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.536 -175.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -56.07 116.73 3.38 Favored 'Trans proline' 0 C--O 1.235 0.326 0 C-N-CA 122.833 2.355 . . . . 0.0 112.372 -178.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.421 ' HA ' ' HG2' ' A' ' 86' ' ' MET . 69.8 m-85 71.17 14.42 6.65 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.718 178.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.5 m -73.44 82.64 1.45 Allowed 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.01 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.0 p -61.75 97.75 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 121.755 0.788 . . . . 0.0 109.539 179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.661 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 41.9 t -71.14 128.46 36.0 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 114.904 -1.044 . . . . 0.0 110.878 -172.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 16.3 m -107.94 109.28 20.74 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.015 176.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -124.37 144.16 50.19 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 17.6 m -106.61 121.25 43.94 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.825 0.345 . . . . 0.0 110.105 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.841 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.0 mm -87.01 120.56 36.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.747 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.2 t -79.0 141.35 37.55 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 168.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -45.92 -37.79 6.79 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 112.286 0.476 . . . . 0.0 112.286 179.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 5.7 m -53.39 -49.81 66.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.058 177.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -76.23 -29.76 57.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.428 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.55 -46.03 70.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.282 -177.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -65.2 -8.63 37.71 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 120.77 -0.728 . . . . 0.0 113.822 -179.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -92.58 -18.24 23.35 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -176.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' CD2' HD11 ' A' ' 59' ' ' LEU . 40.4 m-85 -97.7 175.84 6.04 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -172.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.891 HD22 ' HG2' ' A' ' 60' ' ' GLN . 0.6 OUTLIER -126.12 151.11 47.7 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.332 177.744 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.733 ' HB2' ' H ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -129.04 161.43 29.99 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 169.285 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.593 HG21 ' CB ' ' A' ' 42' ' ' ALA . 27.8 pt -134.7 126.63 48.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.042 0 CA-C-O 121.44 0.638 . . . . 0.0 111.073 -176.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 15.7 m-70 -116.19 -179.74 3.75 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.676 178.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.595 HG13 HG22 ' A' ' 28' ' ' ILE . 3.8 mp . . . . . 0 C--O 1.248 0.994 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.391 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 111.372 -0.691 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 22.1 t -125.82 -44.89 1.77 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.004 0.431 . . . . 0.0 110.333 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.9 m -94.28 25.36 3.87 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.108 0.48 . . . . 0.0 110.368 -178.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 44.1 mm -92.32 -16.25 7.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.025 -174.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 15.0 m -60.43 -60.62 3.52 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.751 -175.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -140.05 20.62 2.45 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.2 m 59.87 84.51 0.12 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.866 -173.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -65.65 -29.66 75.63 Favored Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 115.746 -0.661 . . . . 0.0 113.06 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' HB3' ' NE1' ' A' ' 18' ' ' TRP . 48.1 t-20 -157.95 149.83 21.87 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -177.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 57.4 mt -86.68 -21.42 26.69 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.692 -0.686 . . . . 0.0 110.719 -178.057 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.656 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.7 t80 -72.24 -171.5 0.77 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.828 -174.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.406 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 2.1 m -57.94 -89.67 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.911 -0.586 . . . . 0.0 112.483 -175.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.406 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . 174.94 123.18 0.02 OUTLIER 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 123.212 0.605 . . . . 0.0 109.578 -179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 87' ' ' ASN . . . 61.02 22.9 60.95 Favored Glycine 0 C--O 1.223 -0.532 0 C-N-CA 121.125 -0.56 . . . . 0.0 113.016 177.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.716 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.9 mm-40 -80.29 162.28 24.66 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.702 0.287 . . . . 0.0 111.353 -179.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.759 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 40.0 t -58.7 -47.03 85.93 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.719 174.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.423 HG22 ' CG2' ' A' ' 69' ' ' VAL . 26.8 p -75.33 -30.66 60.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.428 179.009 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.716 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 75.2 t90 -65.44 -45.02 85.45 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.964 178.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.424 ' CE2' ' HG3' ' A' ' 23' ' ' LYS . 86.7 t80 -57.33 -49.0 77.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.358 177.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.602 ' CG1' HG12 ' A' ' 58' ' ' ILE . 75.9 t -55.0 -54.61 22.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.434 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 66.9 t80 -59.09 -39.17 81.35 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.301 -176.278 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -70.46 -40.66 73.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.754 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.424 ' HG3' ' CE2' ' A' ' 19' ' ' TYR . 27.0 mmmt -69.37 -29.63 67.45 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.947 -177.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.567 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -85.05 2.04 4.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-O 120.91 0.386 . . . . 0.0 110.808 177.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.71 23.96 73.68 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 121.076 -0.583 . . . . 0.0 112.805 177.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.72 22.86 68.54 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.253 -178.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -69.5 -43.25 73.52 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.086 0.47 . . . . 0.0 110.391 -177.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -129.86 151.58 36.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.646 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 134.44 -133.11 6.64 Favored Glycine 0 N--CA 1.44 -1.053 0 C-N-CA 119.826 -1.178 . . . . 0.0 114.183 170.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.432 ' HG ' ' C ' ' A' ' 29' ' ' GLY . 77.4 p 57.9 -64.07 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 125.382 1.473 . . . . 0.0 112.557 -177.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 9.1 t -95.78 18.9 12.17 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.838 0.351 . . . . 0.0 111.393 -174.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.646 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.3 OUTLIER -81.26 -1.87 46.67 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.932 0.396 . . . . 0.0 111.243 178.796 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 81.23 -127.73 8.07 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.026 -1.083 . . . . 0.0 112.255 178.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 8.6 m120 -113.07 -177.18 3.07 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.01 -43.18 99.39 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -173.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.596 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 33.2 p-10 -84.55 6.44 23.73 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 120.924 0.392 . . . . 0.0 111.564 -177.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -116.67 4.29 13.11 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.669 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -54.92 -66.47 0.4 Allowed 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 115.054 -0.975 . . . . 0.0 112.853 -174.314 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.15 -34.88 33.11 Favored 'General case' 0 C--N 1.33 -0.247 0 O-C-N 123.381 0.425 . . . . 0.0 111.936 -173.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.15 -52.83 9.28 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.244 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 32' ' ' TRP . . . -71.87 -35.55 69.82 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.71 0.29 . . . . 0.0 111.599 -175.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -55.2 -53.14 59.83 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.35 174.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 49.7 mt-30 -66.91 -30.43 70.57 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.852 0.358 . . . . 0.0 110.84 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.66 -30.79 78.13 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.727 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.04 -21.09 31.71 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.052 0.453 . . . . 0.0 110.844 177.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 110.65 30.1 3.39 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.749 178.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.727 ' HD2' HD12 ' A' ' 111' ' ' ILE . 9.5 m-30 -91.31 156.56 17.7 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 177.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 2.8 m -99.89 95.74 7.1 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.631 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.498 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -96.49 128.31 47.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.713 -178.655 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 1.057 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 17.5 m-20 -121.22 -135.25 0.31 Allowed 'General case' 0 C--N 1.318 -0.786 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 171.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.454 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 17.1 p-80 -163.08 81.29 0.48 Allowed 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 121.504 0.669 . . . . 0.0 111.587 170.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 94.7 m -161.86 110.97 1.17 Allowed Pre-proline 0 C--N 1.324 -0.533 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.248 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.812 ' HG3' ' HB1' ' A' ' 105' ' ' ALA . 18.3 Cg_endo -55.98 152.25 37.57 Favored 'Trans proline' 0 C--O 1.233 0.27 0 C-N-CA 122.845 2.363 . . . . 0.0 113.125 -175.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 51.3 m -160.49 147.34 15.66 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -176.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.599 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 28.9 ttpp -63.14 115.75 4.77 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 177.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 103.49 -1.54 46.18 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.18 -177.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.0 -167.68 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 178.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.602 HG12 ' CG1' ' A' ' 20' ' ' VAL . 3.8 mp -137.51 139.13 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 110.306 -0.257 . . . . 0.0 110.306 -178.532 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.72 HD11 ' CD2' ' A' ' 108' ' ' TYR . 2.5 tm? -96.08 130.44 43.11 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.484 ' N ' HD13 ' A' ' 59' ' ' LEU . 0.0 OUTLIER -116.31 132.68 56.6 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.632 0.73 . . . . 0.0 111.968 -176.395 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.593 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 27.2 t -133.57 153.0 52.0 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.903 174.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.732 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 26.8 m -66.95 -68.18 0.4 Allowed 'General case' 0 C--N 1.327 -0.399 0 O-C-N 123.122 0.264 . . . . 0.0 111.291 -177.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.452 ' HG3' ' HB2' ' A' ' 68' ' ' HIS . 5.6 mm-40 59.67 -172.1 0.12 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 121.163 0.506 . . . . 0.0 111.792 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.632 ' H ' ' HD2' ' A' ' 65' ' ' PRO . . . -106.5 -66.22 0.64 Allowed Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.89 -0.672 . . . . 0.0 114.23 -174.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . 0.632 ' HD2' ' H ' ' A' ' 64' ' ' GLY . 4.9 Cg_endo -46.67 -64.33 0.26 Allowed 'Trans proline' 0 C--N 1.35 0.623 0 C-N-CA 123.574 2.849 . . . . 0.0 113.741 -169.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.407 ' HD1' ' HB2' ' A' ' 65' ' ' PRO . 17.0 p90 -147.75 12.81 1.02 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.173 0.511 . . . . 0.0 110.499 -178.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.732 ' HA2' ' O ' ' A' ' 62' ' ' SER . . . 97.47 -174.43 29.53 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.061 -177.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.593 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 2.3 t60 -144.58 110.5 5.4 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.111 179.242 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.669 HG11 ' CD2' ' A' ' 38' ' ' TRP . 20.7 m -128.36 114.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.484 0.659 . . . . 0.0 110.841 168.449 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.428 ' HB2' ' OE1' ' A' ' 85' ' ' GLU . . . -114.19 131.63 56.39 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.424 -0.807 . . . . 0.0 109.884 -178.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.547 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 51.8 t80 -71.03 125.16 26.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.308 0.575 . . . . 0.0 110.406 -175.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.444 HG22 HG22 ' A' ' 83' ' ' ILE . 19.5 t -84.04 113.74 23.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.02 -176.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.599 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 30.3 mt-10 -90.73 -18.07 25.63 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.182 -177.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 58.3 p -178.66 144.55 0.28 Allowed 'General case' 0 C--O 1.234 0.275 0 CA-C-O 121.096 0.474 . . . . 0.0 111.607 -177.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.545 HG13 HG22 ' A' ' 81' ' ' VAL . 46.1 t -101.89 124.7 55.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 167.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.7 m-20 -78.09 159.78 28.47 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.919 0.39 . . . . 0.0 111.13 -171.032 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.2 p -66.75 -20.38 65.94 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.802 -177.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -87.79 3.38 48.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.632 0.254 . . . . 0.0 111.292 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.85 2.4 72.06 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.492 178.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.446 ' HB2' ' CG2' ' A' ' 99' ' ' THR . 8.6 p -92.76 146.97 23.25 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.867 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 71.4 t -109.08 131.99 58.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 O-C-N 122.181 -0.324 . . . . 0.0 111.392 -176.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.6 m -97.65 112.98 24.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.421 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.444 HG22 HG22 ' A' ' 72' ' ' VAL . 43.9 pt -115.44 145.0 21.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.792 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.9 m -127.27 139.38 52.95 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.358 0.599 . . . . 0.0 110.516 179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.662 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 9.2 pt-20 -143.98 172.84 12.32 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.346 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.693 ' SD ' ' HA ' ' A' ' 93' ' ' PHE . 42.4 tpp -127.16 125.87 41.87 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.793 -0.363 . . . . 0.0 110.716 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 6.5 t30 66.75 -52.99 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 124.087 0.867 . . . . 0.0 112.792 177.303 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.759 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 9.8 t80 65.5 -82.31 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.14 0 C-N-CA 123.221 0.609 . . . . 0.0 109.922 -174.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 35.6 p -154.41 18.54 0.48 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.118 0.485 . . . . 0.0 110.583 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -123.61 -93.54 1.08 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.598 -0.81 . . . . 0.0 113.057 -175.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -101.84 124.79 8.32 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.653 -176.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.459 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 42.0 Cg_exo -58.14 130.58 38.66 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 123.168 2.579 . . . . 0.0 112.756 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.693 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 71.1 m-85 66.68 21.62 10.57 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.386 -0.825 . . . . 0.0 112.228 -179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.7 m -76.59 94.74 3.79 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 166.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 57.6 t -62.71 93.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 175.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.662 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 15.4 m -85.93 104.88 15.99 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.748 -170.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.1 t -93.5 128.39 39.58 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.167 177.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 25.6 ttm105 -143.0 163.21 33.39 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 26.8 m -118.03 124.62 48.58 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 120.986 0.422 . . . . 0.0 111.327 -175.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.867 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 49.0 mm -96.13 116.23 37.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.222 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -64.09 140.7 58.9 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.178 -0.465 . . . . 0.0 109.956 173.231 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -53.37 -35.25 60.09 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -177.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.0 m -63.03 -45.23 93.27 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.936 0.398 . . . . 0.0 110.902 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.618 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 1.0 OUTLIER -73.5 -33.02 64.58 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.063 0.459 . . . . 0.0 110.32 176.577 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.812 ' HB1' ' HG3' ' A' ' 53' ' ' PRO . . . -59.98 -33.26 71.71 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.29 178.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.58 -10.04 79.09 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.981 -0.628 . . . . 0.0 112.536 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -98.2 -47.05 5.61 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.593 0.235 . . . . 0.0 110.818 178.281 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.72 ' CD2' HD11 ' A' ' 59' ' ' LEU . 24.8 m-85 -66.38 135.01 53.71 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 121.17 0.509 . . . . 0.0 111.613 -172.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.454 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 17.8 m120 -78.89 163.72 25.05 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.721 -179.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 1.057 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -148.96 148.42 29.76 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 174.81 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.727 HD12 ' HD2' ' A' ' 47' ' ' PHE . 32.0 pt -110.14 125.03 67.36 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.331 -175.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.504 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.0 m-70 -96.48 174.63 6.75 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.666 175.107 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.458 HG12 ' CG2' ' A' ' 28' ' ' ILE . 9.4 mt . . . . . 0 C--O 1.25 1.12 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.676 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 24.5 t -167.1 -31.34 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.753 0.311 . . . . 0.0 110.318 -177.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.5 m -76.28 55.0 0.94 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.202 0.525 . . . . 0.0 111.708 -177.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.9 tp -97.6 3.67 9.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 122.063 0.935 . . . . 0.0 109.116 176.36 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.9 m -107.51 -159.91 0.71 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 114.76 -1.109 . . . . 0.0 109.691 -179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 30.1 m170 -72.41 -25.36 61.46 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.6 0.238 . . . . 0.0 110.799 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 30.7 p 52.78 51.4 16.03 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 123.595 0.758 . . . . 0.0 112.851 173.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 88.75 -68.67 2.8 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.703 -0.761 . . . . 0.0 113.515 172.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 52.1 t30 -142.51 149.04 38.63 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.756 0.312 . . . . 0.0 110.438 -175.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 70.6 mt -73.94 -34.75 64.42 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.546 -176.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 17.4 t80 -72.12 168.81 17.39 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.859 -0.61 . . . . 0.0 111.363 -171.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.64 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 85.4 m -58.3 142.76 46.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.032 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -73.79 144.21 45.68 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.956 -172.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.64 25.82 74.8 Favored Glycine 0 N--CA 1.452 -0.265 0 CA-C-N 115.773 -0.649 . . . . 0.0 112.464 178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.64 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 7.9 mm-40 -96.74 171.3 8.61 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -176.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.582 ' HB2' ' HA ' ' A' ' 88' ' ' TYR . 8.4 t -63.51 -52.04 62.94 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.071 -179.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.566 HG22 HG21 ' A' ' 69' ' ' VAL . 37.2 p -73.82 -26.2 60.49 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.167 0.508 . . . . 0.0 110.482 179.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.456 ' HB3' ' H ' ' A' ' 15' ' ' GLN . 75.8 t90 -70.67 -49.24 49.4 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.802 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.579 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 90.8 t80 -60.15 -42.91 95.88 Favored 'General case' 0 CA--C 1.521 -0.169 0 CA-C-O 121.077 0.465 . . . . 0.0 110.523 -179.798 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.698 HG13 HG12 ' A' ' 58' ' ' ILE . 43.0 t -54.04 -47.1 66.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.001 175.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 t80 -64.14 -42.4 96.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.904 -177.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -64.55 -41.87 96.06 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.983 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -66.21 -35.89 81.63 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 112.292 0.478 . . . . 0.0 112.292 -177.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.541 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -82.06 5.06 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.904 0.383 . . . . 0.0 111.247 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.45 16.42 79.99 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.408 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.78 32.31 77.62 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 121.049 -0.595 . . . . 0.0 112.959 -179.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -80.53 -47.62 13.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.792 0.329 . . . . 0.0 110.859 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.541 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -116.14 146.77 20.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.134 -174.872 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.581 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 110.4 -121.72 6.03 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 120.355 -0.926 . . . . 0.0 114.283 167.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 3.5 m 67.43 -66.18 0.21 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 123.774 0.83 . . . . 0.0 110.488 -173.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.7 t -93.36 18.96 8.84 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.129 -175.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.603 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -74.19 -7.85 54.1 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-O 121.283 0.563 . . . . 0.0 110.786 178.407 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.413 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.21 -115.85 4.11 Favored Glycine 0 N--CA 1.439 -1.1 0 C-N-CA 120.255 -0.974 . . . . 0.0 112.143 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 45.5 m-80 -124.28 -178.57 4.14 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 176.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.516 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -65.08 -30.73 71.71 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -170.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -86.49 -7.94 57.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.197 0.522 . . . . 0.0 111.215 -178.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 11.3 t30 -108.49 4.36 24.12 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.63 0.729 . . . . 0.0 109.043 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.7 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -56.65 -67.37 0.31 Allowed 'General case' 0 C--O 1.222 -0.375 0 CA-C-N 114.696 -1.138 . . . . 0.0 113.264 -171.786 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.11 -36.21 60.51 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 111.727 0.269 . . . . 0.0 111.727 -173.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.95 -52.7 22.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.122 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.603 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -68.4 -32.92 73.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.911 0.386 . . . . 0.0 111.151 -178.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.32 -49.63 76.82 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.489 176.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -68.66 -29.91 68.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.578 177.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.91 -32.12 80.86 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.912 -0.661 . . . . 0.0 111.698 173.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -83.04 -36.44 24.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.999 0.428 . . . . 0.0 110.248 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 122.59 28.6 1.41 Allowed Glycine 0 N--CA 1.449 -0.468 0 CA-C-N 115.789 -0.641 . . . . 0.0 113.017 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 10.4 m-30 -85.55 155.56 21.13 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-O 120.967 0.413 . . . . 0.0 110.401 179.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 2.1 m -94.43 124.35 38.41 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 175.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.591 ' HB ' ' HA ' ' A' ' 111' ' ' ILE . 0.5 OUTLIER -141.46 123.6 14.24 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 113.379 0.881 . . . . 0.0 113.379 -175.0 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.437 ' CG ' ' HE1' ' A' ' 110' ' ' TYR . 8.0 p30 -124.74 -145.35 0.33 Allowed 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 106.44 -1.689 . . . . 0.0 106.44 167.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.455 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 22.0 p-80 -138.6 77.69 1.64 Allowed 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.896 0.855 . . . . 0.0 112.893 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.4 m -154.72 109.56 2.35 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 114.952 -1.022 . . . . 0.0 109.716 169.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -55.33 159.42 10.44 Favored 'Trans proline' 0 C--N 1.351 0.697 0 C-N-CA 122.748 2.299 . . . . 0.0 112.972 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 66.6 m -163.75 148.2 10.48 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.873 -173.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -59.89 115.6 3.52 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.626 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 105.48 -4.85 40.46 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.593 179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -108.97 -171.13 1.79 Allowed 'General case' 0 C--N 1.327 -0.405 0 O-C-N 122.773 -0.251 . . . . 0.0 110.584 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.698 HG12 HG13 ' A' ' 20' ' ' VAL . 3.9 mp -130.68 137.2 56.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.954 0.407 . . . . 0.0 111.001 -177.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.615 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 7.1 tp -83.99 135.6 34.38 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.873 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.595 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 23.2 tm0? -137.06 134.48 36.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.37 0.605 . . . . 0.0 112.251 -175.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.74 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 36.1 t -119.88 144.56 47.33 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.107 174.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.4 t -81.39 -34.86 31.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.239 0.542 . . . . 0.0 109.954 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -85.76 163.11 18.38 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.722 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 129.82 -175.51 19.05 Favored Glycine 0 N--CA 1.449 -0.482 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.664 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -65.79 -44.45 7.95 Favored 'Trans proline' 0 C--N 1.343 0.258 0 C-N-CA 122.587 2.192 . . . . 0.0 111.006 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 3.0 p90 -139.93 19.23 2.47 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 114.901 -1.045 . . . . 0.0 108.418 178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.56 -169.79 21.65 Favored Glycine 0 N--CA 1.444 -0.809 0 CA-C-N 114.617 -1.174 . . . . 0.0 111.119 -172.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.74 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 3.7 t-160 -145.5 101.01 3.53 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.974 0.387 . . . . 0.0 110.401 179.313 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 31.0 m -116.46 113.53 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.025 0.916 . . . . 0.0 111.889 172.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.545 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -118.04 123.7 46.31 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.631 -1.168 . . . . 0.0 109.056 179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.401 ' HA ' HG23 ' A' ' 58' ' ' ILE . 18.5 t80 -69.71 131.1 44.04 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.422 -0.511 . . . . 0.0 109.828 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.483 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.4 t -87.2 107.25 16.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.473 -175.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -69.44 -37.13 77.24 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.33 -179.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 19.9 t 175.81 149.03 0.11 Allowed 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.982 -175.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.651 HG13 HG22 ' A' ' 81' ' ' VAL . 50.6 t -100.24 129.84 50.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 172.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -71.29 171.03 11.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.928 0.394 . . . . 0.0 111.127 -174.308 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -72.38 -26.13 61.77 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.077 -175.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -82.46 -25.84 33.2 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.274 -177.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 129.46 -23.08 4.88 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.658 -178.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -67.31 143.96 56.12 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.853 0.358 . . . . 0.0 110.221 176.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.782 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.3 t -110.22 129.43 65.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-O 121.063 0.458 . . . . 0.0 111.272 -175.787 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 20.7 m -93.61 112.2 24.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.844 176.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.74 HD11 ' HB2' ' A' ' 98' ' ' ARG . 2.9 pp -115.11 168.53 6.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.619 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.5 t -141.01 117.15 10.59 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 176.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.461 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.7 pt-20 -131.77 112.55 12.6 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.701 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.753 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.9 ttm -81.54 128.62 34.1 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 120.912 0.386 . . . . 0.0 111.597 -178.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 44.2 t30 74.63 -66.91 0.27 Allowed 'General case' 0 N--CA 1.466 0.358 0 C-N-CA 123.942 0.897 . . . . 0.0 112.315 173.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.582 ' HA ' ' HB2' ' A' ' 16' ' ' CYS . 23.5 t80 60.96 29.89 19.29 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.489 0.662 . . . . 0.0 110.161 -176.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 59.0 m 62.44 44.74 6.94 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.539 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -127.87 -57.93 0.12 Allowed Glycine 0 N--CA 1.446 -0.68 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 177.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -142.45 112.24 0.72 Allowed Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 174.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_exo -42.41 117.5 0.84 Allowed 'Trans proline' 0 C--O 1.234 0.311 0 C-N-CA 123.236 2.624 . . . . 0.0 113.699 -176.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.482 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 91.5 m-85 78.42 7.12 2.4 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 114.593 -1.185 . . . . 0.0 113.615 176.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 29.4 p -72.28 90.1 1.24 Allowed 'General case' 0 CA--C 1.512 -0.511 0 C-N-CA 119.441 -0.904 . . . . 0.0 108.825 170.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.753 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -63.01 96.96 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 CA-C-O 121.748 0.785 . . . . 0.0 109.097 177.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.461 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 16.3 m -80.2 140.63 36.22 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.284 -168.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 25.4 p -106.31 124.22 49.25 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.535 -178.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.74 ' HB2' HD11 ' A' ' 83' ' ' ILE . 4.8 mmt180 -132.66 132.39 42.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.126 175.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.6 m -98.6 96.96 8.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.802 176.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.782 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 44.7 mm -74.86 110.03 8.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.616 -176.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 41.1 t -78.15 160.91 27.74 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 173.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.446 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -53.09 -31.02 39.67 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-O 120.732 0.301 . . . . 0.0 111.5 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.1 m -58.43 -42.73 87.94 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.571 177.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.449 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.3 mp0 -86.71 -27.03 23.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.297 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.446 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -58.25 -38.05 76.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.368 -179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.96 -8.96 79.29 Favored Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.711 177.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.449 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -88.58 -36.83 16.11 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.061 0.458 . . . . 0.0 110.893 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.555 ' CE1' ' HB2' ' A' ' 61' ' ' SER . 99.3 m-85 -89.22 140.8 29.11 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.69 -174.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.473 ' HB2' ' OE1' ' A' ' 60' ' ' GLN . 83.9 m-20 -85.08 172.31 11.36 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 173.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.437 ' HE1' ' CG ' ' A' ' 50' ' ' ASN . 1.4 p90 -154.61 133.86 12.52 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.826 -0.35 . . . . 0.0 110.388 173.165 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.743 HD12 ' HD2' ' A' ' 47' ' ' PHE . 34.7 pt -100.09 126.77 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 23.1 p80 -131.39 153.09 50.03 Favored 'General case' 0 C--N 1.313 -1.0 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.726 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.841 ' H ' HD12 ' A' ' 113' ' ' ILE . 2.4 mp . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.409 -0.805 . . . . 0.0 110.214 -173.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.935 0 N-CA-C 111.936 -0.466 . . . . 0.0 111.936 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.0 p -69.42 -22.27 63.69 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 -175.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.1 p -77.45 -5.35 49.57 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.916 0.388 . . . . 0.0 110.779 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mm 54.5 75.51 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.26 179.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.4 m -121.45 -50.26 2.11 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -133.0 128.94 37.46 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.491 170.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 14.1 m -112.24 141.82 45.48 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.412 -179.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.28 -114.32 2.75 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.706 176.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.2 p30 -117.34 -158.69 0.71 Allowed 'General case' 0 C--N 1.324 -0.517 0 O-C-N 122.838 -0.213 . . . . 0.0 110.47 -178.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -81.19 -28.43 34.94 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -173.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.447 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -81.55 -171.07 3.11 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.813 0.339 . . . . 0.0 111.394 -170.453 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.402 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 9.7 m -70.56 -96.92 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.972 -172.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.402 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -179.61 121.93 0.07 Allowed 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 -177.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.5 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 66.31 50.95 47.18 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.236 -0.983 . . . . 0.0 111.217 -175.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.575 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 20.0 mm-40 -117.96 158.21 25.33 Favored 'General case' 0 C--N 1.32 -0.706 0 O-C-N 122.518 -0.401 . . . . 0.0 110.216 178.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.1 p -58.82 -40.96 85.72 Favored 'General case' 0 C--N 1.326 -0.433 0 O-C-N 123.46 0.475 . . . . 0.0 111.214 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 70.9 p -95.2 -1.27 52.06 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.316 0.579 . . . . 0.0 110.573 -177.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 81.3 t90 -87.78 -51.61 5.77 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.249 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.41 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 86.2 t80 -60.25 -42.78 96.0 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.324 -178.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.424 ' HA ' ' HB2' ' A' ' 71' ' ' TYR . 94.1 t -56.32 -53.34 41.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.484 -0.78 . . . . 0.0 111.131 177.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.511 ' CZ ' ' HB3' ' A' ' 30' ' ' SER . 33.2 t80 -65.61 -34.0 77.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.987 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -70.26 -42.35 72.29 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.399 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 23.8 mmmt -67.09 -33.1 74.75 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.154 -0.476 . . . . 0.0 112.023 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.531 HG23 ' H ' ' A' ' 26' ' ' GLY . 32.5 m -84.36 -2.91 7.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 C-N-CA 120.711 -0.395 . . . . 0.0 111.127 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.78 1.9 68.51 Favored Glycine 0 N--CA 1.454 -0.14 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.727 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.531 ' H ' HG23 ' A' ' 24' ' ' VAL . . . 90.07 1.96 75.23 Favored Glycine 0 N--CA 1.445 -0.761 0 C-N-CA 120.74 -0.743 . . . . 0.0 113.265 179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.729 ' HG3' HG22 ' A' ' 28' ' ' ILE . 13.7 pt-20 -69.32 -22.14 63.8 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 117.283 0.541 . . . . 0.0 110.753 -178.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.729 HG22 ' HG3' ' A' ' 27' ' ' GLU . 0.0 OUTLIER -129.32 135.39 61.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.398 176.741 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.41 ' H ' ' HZ ' ' A' ' 47' ' ' PHE . . . 107.97 -139.56 15.12 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.563 -0.827 . . . . 0.0 114.195 170.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.511 ' HB3' ' CZ ' ' A' ' 21' ' ' TYR . 24.2 p 73.82 -40.37 0.46 Allowed 'General case' 0 N--CA 1.474 0.764 0 C-N-CA 125.312 1.445 . . . . 0.0 111.791 -177.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 30.9 p -100.54 11.41 39.53 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.898 0.38 . . . . 0.0 111.147 -179.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.564 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -84.56 -0.42 53.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.889 -174.783 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.687 ' HA3' HD21 ' A' ' 37' ' ' ASN . . . 71.22 -117.04 6.54 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.606 -178.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.522 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 15.6 m120 -124.64 176.82 6.3 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 177.245 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -59.46 -26.98 65.69 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -169.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.428 ' HB3' ' N ' ' A' ' 67' ' ' GLY . 12.0 p-10 -79.34 -39.96 31.42 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 111.764 0.283 . . . . 0.0 111.764 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.687 HD21 ' HA3' ' A' ' 33' ' ' GLY . 3.9 p-10 -95.08 11.78 30.91 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.996 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.732 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.3 OUTLIER -50.12 -64.7 0.73 Allowed 'General case' 0 C--O 1.218 -0.588 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.556 -178.021 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -49.62 -42.55 45.2 Favored 'General case' 0 C--N 1.331 -0.224 0 O-C-N 123.425 0.453 . . . . 0.0 111.39 -174.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.98 -45.8 69.74 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.453 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.564 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -72.44 -39.32 67.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.046 0.45 . . . . 0.0 111.005 -178.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.534 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -57.69 -48.42 79.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.355 176.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.5 mt-30 -65.47 -27.8 68.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 178.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.47 -35.75 90.53 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.652 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -76.04 -26.55 56.7 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.948 0.404 . . . . 0.0 110.372 176.099 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.13 6.68 6.23 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.919 -0.658 . . . . 0.0 113.121 177.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.62 ' CD2' HD12 ' A' ' 111' ' ' ILE . 2.7 m-30 -71.09 154.19 41.96 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.893 0.378 . . . . 0.0 110.547 -178.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.492 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 19.4 m -111.95 117.33 32.41 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 175.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 1.012 HG12 HG22 ' A' ' 111' ' ' ILE . 5.2 m -93.43 175.41 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -169.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.448 ' ND2' ' C ' ' A' ' 50' ' ' ASN . 0.0 OUTLIER 95.7 -11.9 0.09 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 114.208 -1.36 . . . . 0.0 113.583 165.495 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.642 ' O ' ' HB ' ' A' ' 52' ' ' THR . 54.8 t-80 -54.21 -9.2 0.25 Allowed 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -164.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.642 ' HB ' ' O ' ' A' ' 51' ' ' HIS . 0.9 OUTLIER 72.61 137.22 0.05 OUTLIER Pre-proline 0 CA--C 1.54 0.576 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -172.764 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.707 ' HG3' HD12 ' A' ' 59' ' ' LEU . 67.9 Cg_exo -51.59 148.25 21.41 Favored 'Trans proline' 0 N--CA 1.476 0.473 0 C-N-CA 123.39 2.727 . . . . 0.0 114.262 -172.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB3' ' HE2' ' A' ' 110' ' ' TYR . 14.0 t -165.05 164.08 20.5 Favored 'General case' 0 N--CA 1.453 -0.292 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 53.4 tttp -58.06 128.58 37.83 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -176.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 79.07 43.67 10.57 Favored Glycine 0 N--CA 1.449 -0.451 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.261 177.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -148.71 -162.68 1.61 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.653 0.263 . . . . 0.0 110.617 -176.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.732 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.9 OUTLIER -138.78 156.69 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 121.197 0.522 . . . . 0.0 110.869 179.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.707 HD12 ' HG3' ' A' ' 53' ' ' PRO . 4.6 tp -91.09 162.45 14.68 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.336 175.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.462 ' HB3' ' HB2' ' A' ' 109' ' ' ASN . 21.2 tm0? -163.72 137.63 5.71 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.383 0.611 . . . . 0.0 111.179 175.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.794 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 13.7 t -156.18 138.23 14.54 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.623 -1.172 . . . . 0.0 108.83 174.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.4 m -95.81 8.15 44.34 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.318 0.58 . . . . 0.0 110.139 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -80.8 56.67 2.77 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.107 -177.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -176.93 168.08 39.78 Favored Glycine 0 N--CA 1.447 -0.626 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.99 -179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.23 -40.58 31.86 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.829 2.352 . . . . 0.0 112.145 -178.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 89.2 m-85 -118.75 16.43 13.57 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.912 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.428 ' N ' ' HB3' ' A' ' 36' ' ' ASN . . . 78.4 -168.59 53.93 Favored Glycine 0 C--O 1.227 -0.333 0 C-N-CA 120.989 -0.624 . . . . 0.0 113.241 178.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.794 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 57.0 m-70 -143.64 84.51 1.8 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 119.127 -0.463 . . . . 0.0 110.604 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.686 HG11 ' CD2' ' A' ' 38' ' ' TRP . 13.2 m -117.21 129.76 73.21 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.572 0 C-N-CA 119.294 -0.963 . . . . 0.0 111.306 172.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.607 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -139.81 135.76 33.34 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.591 -1.186 . . . . 0.0 108.424 176.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.446 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 38.1 t80 -70.69 124.34 24.05 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-O 121.278 0.561 . . . . 0.0 110.228 -174.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 83' ' ' ILE . 44.6 t -86.24 116.13 28.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.573 -176.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.446 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 6.0 mm-40 -77.25 -46.05 24.42 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.139 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 58.2 m -170.32 151.7 3.88 Favored 'General case' 0 C--O 1.232 0.183 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.828 -176.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.588 HG23 HG22 ' A' ' 81' ' ' VAL . 6.1 p -97.08 131.09 44.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 169.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -80.22 161.08 25.37 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.745 0.307 . . . . 0.0 110.63 -173.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 19.5 t -73.87 -11.84 60.49 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.407 0.622 . . . . 0.0 109.439 179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.92 -21.34 64.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.777 177.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 105.81 -4.87 39.51 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.477 -176.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.548 ' HB2' HG22 ' A' ' 99' ' ' THR . 11.7 p -105.73 152.16 23.52 Favored 'General case' 0 N--CA 1.447 -0.599 0 CA-C-O 120.901 0.381 . . . . 0.0 110.504 179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.588 HG22 HG23 ' A' ' 75' ' ' VAL . 46.8 t -106.42 135.92 43.0 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.343 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 85.7 m -100.27 109.95 22.18 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.236 176.72 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 HG22 ' A' ' 72' ' ' VAL . 40.9 pt -105.39 153.87 6.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.403 178.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.0 t -122.33 120.13 33.12 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 176.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.497 ' HB3' ' CB ' ' A' ' 70' ' ' ALA . 7.8 pt-20 -133.78 117.22 16.64 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.699 -178.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.58 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.3 ttm -82.7 115.8 21.79 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.563 178.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.445 ' HA ' ' OG ' ' A' ' 94' ' ' SER . 21.3 t30 74.18 -72.4 0.11 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 124.119 0.887 . . . . 0.0 111.7 176.074 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.721 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 17.6 t80 51.37 67.9 0.88 Allowed 'General case' 0 CA--C 1.537 0.477 0 CA-C-O 121.35 0.595 . . . . 0.0 111.141 -175.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 t 57.33 33.24 23.02 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.892 173.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -136.87 -109.53 0.95 Allowed Glycine 0 N--CA 1.445 -0.73 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.341 -178.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 92' ' ' PRO . . . -90.83 135.18 12.71 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.225 -179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 91' ' ' GLY . 53.6 Cg_exo -52.6 119.95 6.74 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.122 2.548 . . . . 0.0 112.775 -178.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 61.43 26.5 16.26 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.302 175.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.445 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 13.1 p -74.17 82.81 1.82 Allowed 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 119.71 -0.796 . . . . 0.0 109.321 170.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.9 p -64.78 84.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 122.344 1.069 . . . . 0.0 108.791 172.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.7 m -92.16 166.26 12.73 Favored 'General case' 0 N--CA 1.44 -0.952 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.724 -170.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 83' ' ' ILE . 49.5 m -139.64 105.75 5.23 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.846 -178.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.512 ' HB3' HD11 ' A' ' 83' ' ' ILE . 37.2 ttm105 -97.48 146.48 25.19 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.402 179.114 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.548 HG22 ' HB2' ' A' ' 80' ' ' SER . 11.9 m -108.87 108.14 18.81 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.791 0.329 . . . . 0.0 110.173 -177.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.488 HD11 HD13 ' A' ' 83' ' ' ILE . 3.8 mp -90.11 114.01 27.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.729 -176.752 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 49.5 m -68.23 156.63 37.23 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 174.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.41 -38.11 58.23 Favored 'General case' 0 C--O 1.235 0.316 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -174.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . 0.401 ' HB3' ' OE2' ' A' ' 104' ' ' GLU . 9.4 t -58.3 -39.23 78.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.843 0.354 . . . . 0.0 110.651 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.483 ' HB2' HG23 ' A' ' 100' ' ' ILE . 4.5 mp0 -86.53 -22.99 26.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.938 0.399 . . . . 0.0 110.318 178.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -62.44 -33.98 75.89 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.168 178.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -83.45 25.49 5.01 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.991 -0.623 . . . . 0.0 112.361 175.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -123.26 -18.14 6.38 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.136 0.493 . . . . 0.0 110.547 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD2' HD11 ' A' ' 59' ' ' LEU . 56.9 m-85 -101.67 142.71 32.59 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.135 0.493 . . . . 0.0 111.678 -174.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.462 ' HB2' ' HB3' ' A' ' 60' ' ' GLN . 16.3 m120 -92.93 115.96 28.6 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.621 -175.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 51' ' ' HIS . 0.1 OUTLIER -86.42 119.42 26.67 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 173.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 1.012 HG22 HG12 ' A' ' 49' ' ' VAL . 29.8 pt -92.32 111.39 24.24 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 CA-C-O 121.571 0.7 . . . . 0.0 110.535 -178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.492 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 29.8 m-70 -64.73 170.88 3.75 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 114.806 -1.088 . . . . 0.0 111.041 178.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.8 mt . . . . . 0 C--O 1.245 0.865 0 CA-C-O 118.744 -0.646 . . . . 0.0 109.554 178.562 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.882 0 N-CA-C 111.782 -0.527 . . . . 0.0 111.782 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 29.5 t 55.7 -100.33 0.11 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 123.076 0.55 . . . . 0.0 111.359 -178.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.1 m -95.37 -18.52 20.69 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.117 0.484 . . . . 0.0 110.611 -178.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.2 mm -73.96 92.75 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.444 0.64 . . . . 0.0 110.497 -177.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m -150.2 -48.46 0.13 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.175 175.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -76.84 10.0 2.52 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.255 172.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.7 m -105.09 30.2 5.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.729 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -64.1 134.44 39.94 Favored Glycine 0 N--CA 1.448 -0.561 0 CA-C-N 115.456 -0.793 . . . . 0.0 113.219 -175.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.562 HD21 ' HB2' ' A' ' 22' ' ' ASP . 85.1 m-20 -85.34 -171.31 3.55 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.811 0.339 . . . . 0.0 110.128 179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 32.6 mt -78.39 12.99 1.69 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.262 0.553 . . . . 0.0 110.25 174.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.401 ' H ' ' C ' ' A' ' 9' ' ' ASN . 0.7 OUTLIER -122.08 -168.61 1.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.351 -173.152 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.98 -151.43 0.17 Allowed 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.991 -178.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -119.03 97.21 5.57 Favored 'General case' 0 N--CA 1.442 -0.829 0 CA-C-O 120.975 0.417 . . . . 0.0 109.98 176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.7 57.0 1.28 Allowed Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.375 -0.917 . . . . 0.0 112.163 -178.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.683 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.4 mm-40 -109.5 157.02 19.39 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 173.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.892 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.9 p -59.71 -46.14 89.99 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.286 0.565 . . . . 0.0 110.104 177.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.495 HG22 HG21 ' A' ' 69' ' ' VAL . 1.7 p -80.9 -19.61 43.97 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.745 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.683 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 82.2 t90 -69.16 -49.91 52.49 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.811 177.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.541 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 67.8 t80 -57.35 -42.1 81.34 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.2 0.524 . . . . 0.0 109.795 179.396 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.869 HG13 HG12 ' A' ' 58' ' ' ILE . 78.4 t -56.23 -55.46 18.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.848 175.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 29.3 t80 -61.02 -36.53 79.76 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.282 -175.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.562 ' HB2' HD21 ' A' ' 9' ' ' ASN . 19.1 t70 -70.11 -42.35 72.79 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.868 0.366 . . . . 0.0 110.912 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 31.8 mmmt -74.0 -25.01 59.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.101 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.456 HG21 HD13 ' A' ' 28' ' ' ILE . 34.5 m -88.19 10.75 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-O 120.97 0.414 . . . . 0.0 110.797 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.29 -8.42 71.2 Favored Glycine 0 N--CA 1.452 -0.24 0 CA-C-N 115.98 -0.555 . . . . 0.0 113.077 175.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.62 18.51 75.47 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.196 -177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 19.3 tp10 -93.08 -19.84 21.12 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.134 0.492 . . . . 0.0 110.502 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.456 HD13 HG21 ' A' ' 24' ' ' VAL . 0.0 OUTLIER -124.77 128.69 73.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.189 -178.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.753 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 93.2 46.79 3.22 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.879 -0.677 . . . . 0.0 114.326 166.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 32.1 p -83.76 -17.83 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.325 0.583 . . . . 0.0 109.956 178.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 2.1 m -132.99 36.34 3.48 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.041 -175.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.753 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -86.38 -7.02 58.79 Favored 'General case' 0 N--CA 1.463 0.189 0 O-C-N 121.925 -0.484 . . . . 0.0 111.144 178.73 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 83.72 -107.08 2.91 Favored Glycine 0 N--CA 1.441 -0.995 0 C-N-CA 120.043 -1.075 . . . . 0.0 112.013 -179.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -138.52 -179.61 5.91 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 171.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HA ' ' CD1' ' A' ' 38' ' ' TRP . . . -53.98 -36.21 62.66 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -172.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.442 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 24.2 t-20 -63.41 -38.02 89.54 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.04 0.447 . . . . 0.0 111.859 -177.073 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -99.22 11.07 40.13 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.387 -172.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.718 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -54.81 -62.68 1.5 Allowed 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 -172.245 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.563 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -59.04 -32.14 69.48 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.866 0.365 . . . . 0.0 111.297 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -77.01 -52.15 9.85 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.274 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.596 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -64.97 -32.95 74.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.351 -177.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.436 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.11 -42.3 98.27 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.661 176.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 74.5 mt-30 -68.29 -35.78 78.38 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.028 0.442 . . . . 0.0 110.12 178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -68.03 -23.87 74.49 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.941 -0.647 . . . . 0.0 112.023 176.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.86 -17.31 29.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.072 0.463 . . . . 0.0 110.474 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.12 38.23 4.64 Favored Glycine 0 N--CA 1.45 -0.426 0 CA-C-N 115.92 -0.582 . . . . 0.0 113.137 176.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.553 ' HD2' HD12 ' A' ' 111' ' ' ILE . 12.0 m-30 -95.74 151.12 19.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.127 0.464 . . . . 0.0 110.093 176.322 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 16.5 m -86.76 93.71 9.33 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 174.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.452 ' HB ' HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -94.07 135.19 29.19 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.414 0.626 . . . . 0.0 110.108 -177.882 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.437 ' OD1' ' HE1' ' A' ' 110' ' ' TYR . 7.8 p30 -148.8 -146.36 0.2 Allowed 'General case' 0 N--CA 1.439 -1.008 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 173.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.9 p80 -151.26 79.63 1.3 Allowed 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.662 0.744 . . . . 0.0 112.135 -178.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.402 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 25.5 m -152.68 93.92 3.21 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.473 172.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.423 ' CG ' HG21 ' A' ' 81' ' ' VAL . 19.6 Cg_endo -56.79 154.61 31.01 Favored 'Trans proline' 0 C--N 1.348 0.547 0 C-N-CA 123.31 2.673 . . . . 0.0 113.7 -176.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.3 t 177.83 164.9 0.66 Allowed 'General case' 0 N--CA 1.457 -0.093 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -175.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -60.53 132.74 54.84 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.714 0.292 . . . . 0.0 110.486 179.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 91.54 10.87 61.43 Favored Glycine 0 N--CA 1.448 -0.523 0 C-N-CA 120.691 -0.766 . . . . 0.0 111.895 -178.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.554 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -116.46 178.57 4.28 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.869 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -139.13 127.83 28.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 178.385 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' HG ' HG13 ' A' ' 100' ' ' ILE . 2.5 tm? -86.4 125.05 33.4 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.489 -174.006 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 3.4 tp60 -113.11 134.79 54.38 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.608 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 29.5 t -132.69 143.26 49.51 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 168.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.9 m -79.74 2.74 21.72 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -175.294 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.414 ' O ' ' HB2' ' A' ' 68' ' ' HIS . 43.6 mt-10 -108.52 140.3 42.06 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.847 0.356 . . . . 0.0 111.389 -178.158 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 152.93 -144.1 11.04 Favored Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -78.46 -52.17 0.06 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.639 0 C-N-CA 122.49 2.127 . . . . 0.0 109.665 174.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.442 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 33.3 m-85 -112.12 -60.14 1.9 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 168.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -149.32 -148.5 4.76 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 174.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.608 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 5.9 t60 -150.08 90.83 1.71 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 117.351 0.575 . . . . 0.0 110.54 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.718 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.2 m -116.01 110.99 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 CA-C-O 121.982 0.896 . . . . 0.0 111.194 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.736 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -109.15 128.71 55.24 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.507 177.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 4.3 t80 -69.95 126.58 30.1 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.167 0.508 . . . . 0.0 109.787 -176.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.774 ' HA ' HG22 ' A' ' 83' ' ' ILE . 24.2 t -79.17 118.0 25.81 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.553 -0.748 . . . . 0.0 110.748 -174.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -82.68 -43.3 17.06 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.717 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 72.6 m -169.96 139.35 1.86 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.577 -177.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.663 HG23 HG22 ' A' ' 81' ' ' VAL . 6.9 p -93.65 123.27 45.69 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 168.47 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -80.57 159.96 25.29 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 120.675 0.274 . . . . 0.0 110.988 -172.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 12.4 m -61.34 -21.04 63.64 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.833 176.14 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -66.26 -15.18 62.99 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.038 175.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 92.28 -20.17 45.31 Favored Glycine 0 N--CA 1.447 -0.583 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -173.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.497 ' HA ' ' O ' ' A' ' 100' ' ' ILE . 14.9 m -76.31 140.55 41.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.083 -0.559 . . . . 0.0 109.969 177.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.708 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 39.5 t -107.93 126.72 64.42 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.86 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.717 -171.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 96.3 m -89.8 114.84 26.63 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.39 177.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.774 HG22 ' HA ' ' A' ' 72' ' ' VAL . 30.7 pt -130.48 152.87 38.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.612 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 51.0 m -135.94 137.51 41.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.089 0.471 . . . . 0.0 111.128 179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.576 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.1 pt-20 -138.1 112.07 8.43 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.376 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.672 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -70.5 135.79 48.88 Favored 'General case' 0 C--N 1.326 -0.417 0 O-C-N 122.158 -0.339 . . . . 0.0 111.603 -179.514 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.708 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 41.9 t30 68.95 -64.0 0.34 Allowed 'General case' 0 C--N 1.327 -0.378 0 O-C-N 124.255 0.972 . . . . 0.0 112.147 176.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.892 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 27.6 t80 59.14 32.24 21.95 Favored 'General case' 0 CA--C 1.536 0.44 0 CA-C-O 121.778 0.799 . . . . 0.0 109.78 -176.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.3 m 57.89 67.58 0.94 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.758 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.53 -67.55 0.05 OUTLIER Glycine 0 N--CA 1.449 -0.481 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -114.4 110.11 2.31 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.855 -0.688 . . . . 0.0 111.474 178.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_exo -50.78 115.17 1.83 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.963 2.442 . . . . 0.0 113.091 -177.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 92.6 m-85 69.09 10.47 7.9 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 114.781 -1.099 . . . . 0.0 112.562 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 m -71.2 94.42 1.16 Allowed 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 172.087 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.672 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.6 p -60.76 99.55 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.701 176.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.576 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 40.6 m -77.59 92.14 4.05 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.5 0.667 . . . . 0.0 109.865 -178.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.1 m -74.62 112.97 11.35 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.518 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.584 ' HB2' HG13 ' A' ' 83' ' ' ILE . 2.4 mmp_? -113.57 163.96 14.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.035 0.445 . . . . 0.0 110.575 -177.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 39.5 m -136.11 111.02 8.8 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.836 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.708 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 51.3 mm -85.24 128.52 38.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.028 -177.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.9 m -79.92 136.47 36.66 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.405 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.83 -40.92 31.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -175.002 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 13.7 p -56.14 -41.88 76.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.892 0.377 . . . . 0.0 111.657 -178.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 9.8 tt0 -95.59 -12.24 25.99 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.936 0.398 . . . . 0.0 109.943 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.463 ' HB2' HG22 ' A' ' 100' ' ' ILE . . . -64.15 -34.8 78.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.14 0.495 . . . . 0.0 109.999 174.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -69.59 -11.26 65.11 Favored Glycine 0 CA--C 1.521 0.436 0 CA-C-N 115.472 -0.786 . . . . 0.0 112.34 175.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.566 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 3.3 t30 -84.05 -50.72 7.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.679 0.276 . . . . 0.0 111.262 179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 59' ' ' LEU . 42.2 m-85 -70.22 143.2 52.26 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.479 -171.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -87.55 159.35 18.63 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.984 175.216 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.554 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 8.3 p90 -146.21 152.92 39.99 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 172.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.553 HD12 ' HD2' ' A' ' 47' ' ' PHE . 33.7 pt -118.96 138.38 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.706 0 C-N-CA 120.725 -0.39 . . . . 0.0 110.228 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 25.3 p80 -150.83 149.14 29.34 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.195 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.407 ' H ' HG12 ' A' ' 113' ' ' ILE . 9.0 pt . . . . . 0 C--O 1.248 0.981 0 CA-C-O 118.879 -0.581 . . . . 0.0 110.172 176.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.881 0 N-CA-C 112.104 -0.399 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 19.4 m -87.38 5.54 38.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.128 0.49 . . . . 0.0 110.818 -178.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -66.89 -21.6 66.0 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.074 177.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.3 pt -126.09 143.85 38.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.324 177.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 41.8 t -132.55 -72.63 0.52 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.93 0.395 . . . . 0.0 110.277 178.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 26.7 m170 -107.63 10.51 29.05 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.519 ' HB3' HD21 ' A' ' 10' ' ' LEU . 4.4 m -64.89 -42.64 94.62 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 114.883 -1.053 . . . . 0.0 111.382 -176.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 67.98 -122.93 17.27 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.426 -176.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 35.4 t-20 -90.82 132.8 35.66 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 176.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.533 HD12 ' HB2' ' A' ' 30' ' ' SER . 94.8 mt -97.37 -10.98 24.53 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.38 -171.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.661 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.9 t80 -92.05 -160.5 0.74 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.261 -0.575 . . . . 0.0 110.872 -173.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.548 ' HB ' ' HG3' ' A' ' 15' ' ' GLN . 2.5 m -77.29 -97.44 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 111.962 0.356 . . . . 0.0 111.962 -170.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.43 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.63 111.62 0.15 Allowed 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.955 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.474 ' O ' ' HB2' ' A' ' 87' ' ' ASN . . . 67.96 40.72 88.82 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.182 -178.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.548 ' HG3' ' HB ' ' A' ' 12' ' ' THR . 10.8 mm100 -107.29 170.95 7.65 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.983 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 4.4 p -57.9 -60.34 3.86 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 111.968 0.359 . . . . 0.0 111.968 -179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.495 HG21 ' HA ' ' A' ' 34' ' ' ASN . 25.4 p -81.72 7.02 13.54 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.112 0.482 . . . . 0.0 111.171 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.661 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 84.5 t90 -97.3 -52.0 3.97 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.778 178.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 87.5 t80 -65.32 -43.06 92.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.307 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.522 ' CG1' HD13 ' A' ' 58' ' ' ILE . 77.7 t -57.89 -37.79 62.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.656 176.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -70.85 -35.69 72.53 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.769 -177.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -70.56 -39.45 73.94 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.83 0.347 . . . . 0.0 110.848 177.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.4 mmmt -66.79 -16.15 64.07 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 112.174 0.435 . . . . 0.0 112.174 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.576 HG21 HD13 ' A' ' 28' ' ' ILE . 32.3 m -103.74 9.33 9.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.994 0.426 . . . . 0.0 110.742 176.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.94 8.93 74.82 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.856 -0.611 . . . . 0.0 113.221 175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.69 7.97 88.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.496 -177.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -68.52 -40.14 80.93 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.443 0.639 . . . . 0.0 110.43 177.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.904 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.0 OUTLIER -121.58 135.15 62.64 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.946 -175.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.58 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 124.56 -137.87 10.84 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.222 -0.99 . . . . 0.0 114.174 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.533 ' HB2' HD12 ' A' ' 10' ' ' LEU . 84.6 p 65.98 -58.62 0.33 Allowed 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 125.407 1.483 . . . . 0.0 112.453 -179.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.5 t -94.12 14.02 21.29 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.737 0.303 . . . . 0.0 111.518 -176.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.621 ' HZ3' HD11 ' A' ' 28' ' ' ILE . 0.3 OUTLIER -81.8 -2.94 52.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.013 0.435 . . . . 0.0 111.139 179.495 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.452 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 80.79 -115.54 4.05 Favored Glycine 0 N--CA 1.443 -0.837 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.776 -178.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.495 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.8 m-80 -132.97 -171.65 2.73 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.206 -0.665 . . . . 0.0 109.206 174.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.492 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -62.16 -23.85 66.83 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 -168.324 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 46.4 t-20 -85.29 -41.29 15.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.349 0.595 . . . . 0.0 110.33 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.93 -1.46 56.7 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.456 -173.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.599 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -46.35 -67.12 0.31 Allowed 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -175.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.79 -31.51 62.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.543 -0.299 . . . . 0.0 111.606 -172.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.9 -50.01 14.31 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.799 0.333 . . . . 0.0 110.883 178.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.518 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -67.75 -37.16 81.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.901 0.381 . . . . 0.0 111.343 -177.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.71 -49.54 77.09 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.394 177.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -65.95 -36.41 83.26 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.553 178.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.21 -32.24 81.88 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.06 176.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -79.57 -33.89 41.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.844 0.354 . . . . 0.0 110.783 177.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.86 31.58 0.8 Allowed Glycine 0 CA--C 1.519 0.336 0 C-N-CA 120.808 -0.71 . . . . 0.0 113.397 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.434 ' CD2' HD12 ' A' ' 111' ' ' ILE . 1.2 m-30 -92.76 165.83 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 176.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.531 ' O ' ' HB2' ' A' ' 112' ' ' HIS . 6.2 m -112.47 117.93 33.74 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 173.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.509 ' CG1' HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -112.06 138.22 41.77 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.509 0.671 . . . . 0.0 111.102 -177.6 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.65 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.2 m-80 -129.06 -142.03 0.25 Allowed 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 105.256 -2.127 . . . . 0.0 105.256 167.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 17.3 p-80 -153.01 86.91 1.25 Allowed 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 121.619 0.723 . . . . 0.0 111.139 171.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.428 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 88.2 m -160.3 97.44 1.46 Allowed Pre-proline 0 C--N 1.323 -0.578 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.623 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 12.5 Cg_endo -54.33 146.85 48.97 Favored 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.549 2.166 . . . . 0.0 113.031 -179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 11.1 p -161.41 152.51 18.47 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.904 -175.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 74' ' ' SER . 7.7 ttpm? -57.11 111.08 0.95 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.897 0.379 . . . . 0.0 111.358 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.64 -17.54 30.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.846 -0.692 . . . . 0.0 112.585 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -85.96 -174.53 5.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.715 0.293 . . . . 0.0 110.658 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.599 HG21 ' CH2' ' A' ' 38' ' ' TRP . 37.9 mt -133.61 132.76 57.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.995 0.426 . . . . 0.0 111.273 -178.732 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.513 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 5.9 tp -75.62 141.07 42.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.154 -0.93 . . . . 0.0 110.209 -178.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.572 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.0 tm0? -148.47 144.31 27.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.564 0.697 . . . . 0.0 111.333 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 34.1 t -147.41 127.17 13.44 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.179 -0.918 . . . . 0.0 108.684 173.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.4 m -83.25 -6.14 59.37 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.243 0.544 . . . . 0.0 110.187 -179.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -86.61 113.88 22.86 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.266 178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 148.74 -177.19 27.14 Favored Glycine 0 N--CA 1.445 -0.731 0 N-CA-C 111.323 -0.711 . . . . 0.0 111.323 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -66.37 -64.35 0.05 OUTLIER 'Trans proline' 0 N--CA 1.463 -0.288 0 C-N-CA 122.293 1.995 . . . . 0.0 111.769 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.492 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 97.2 m-85 -108.14 17.7 21.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.309 178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 92.93 -148.3 18.98 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.735 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.572 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 3.0 t-160 -168.99 96.16 0.35 Allowed 'General case' 0 C--O 1.224 -0.284 0 CA-C-N 117.034 0.417 . . . . 0.0 110.539 178.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.554 HG11 ' CE2' ' A' ' 38' ' ' TRP . 30.1 m -115.69 137.67 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.509 0 C-N-CA 120.031 -0.668 . . . . 0.0 111.142 173.303 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.555 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -145.96 123.39 11.68 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.668 -177.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.469 ' HA ' HG23 ' A' ' 58' ' ' ILE . 62.6 t80 -70.23 127.09 31.61 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.113 -176.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 41.1 t -88.08 114.93 27.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.736 -175.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 74' ' ' SER . 47.3 mm-40 -79.12 -33.94 43.84 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.715 179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 55' ' ' LYS . 10.8 t 174.64 163.51 0.22 Allowed 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.92 0.39 . . . . 0.0 110.763 179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.556 HG13 HG22 ' A' ' 81' ' ' VAL . 62.0 t -107.85 127.29 64.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 173.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 m-80 -81.3 162.45 23.46 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.62 -174.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 20.0 m -70.72 -9.71 57.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.122 0.487 . . . . 0.0 110.901 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.81 -7.88 59.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.785 178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.71 -7.06 81.84 Favored Glycine 0 N--CA 1.45 -0.377 0 N-CA-C 111.121 -0.791 . . . . 0.0 111.121 -174.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.575 ' HB3' HG22 ' A' ' 99' ' ' THR . 19.5 m -91.51 143.7 26.32 Favored 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.598 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 60.2 t -105.9 134.67 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.52 -0.309 . . . . 0.0 111.308 -175.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.9 m -96.77 120.52 37.25 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.301 177.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.641 HD13 HD11 ' A' ' 100' ' ' ILE . 37.3 pt -123.86 164.14 22.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.796 -179.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 11.0 t -132.11 95.81 3.76 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.275 173.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 4.6 pt-20 -108.52 92.41 4.05 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.405 178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.777 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.0 ttm -70.2 129.03 38.27 Favored 'General case' 0 C--N 1.318 -0.796 0 O-C-N 122.006 -0.434 . . . . 0.0 110.592 178.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 14' ' ' GLY . 43.3 t-20 76.53 -79.96 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.234 0 O-C-N 124.039 0.837 . . . . 0.0 111.101 175.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.983 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 21.0 t80 50.09 83.03 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.443 0 O-C-N 123.589 0.555 . . . . 0.0 112.217 -172.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.2 m 55.04 29.26 12.07 Favored 'General case' 0 CA--C 1.536 0.424 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.819 172.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -140.26 -114.05 1.11 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.438 -0.886 . . . . 0.0 112.512 -178.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.25 129.56 9.94 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.415 -176.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.6 129.76 30.88 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 123.061 2.507 . . . . 0.0 112.777 177.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.476 ' HA ' ' SD ' ' A' ' 86' ' ' MET . 97.8 m-85 70.15 7.26 6.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.925 -1.034 . . . . 0.0 113.189 177.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.4 m -71.8 83.08 0.9 Allowed 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 169.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.777 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -63.34 94.18 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.649 0 CA-C-O 121.61 0.719 . . . . 0.0 109.707 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.882 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 33.1 t -69.62 103.65 2.16 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.224 -173.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -85.22 102.4 13.29 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.234 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.575 ' HB2' HD11 ' A' ' 83' ' ' ILE . 48.0 mtp180 -119.87 163.6 17.29 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.234 -177.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 80' ' ' SER . 25.8 m -135.07 115.36 13.37 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.461 -0.791 . . . . 0.0 109.889 176.636 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.641 HD11 HD13 ' A' ' 83' ' ' ILE . 3.5 mp -88.02 113.16 24.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.996 -176.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -72.01 153.46 41.76 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 170.181 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.87 -33.54 10.85 Favored 'General case' 0 C--O 1.237 0.434 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -176.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.1 m -54.73 -55.89 25.09 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.974 178.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 40.8 mp0 -72.26 -29.64 64.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.917 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -57.12 -31.85 65.72 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.987 0.422 . . . . 0.0 110.584 179.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -60.51 -31.8 75.8 Favored Glycine 0 CA--C 1.525 0.696 0 CA-C-N 115.593 -0.73 . . . . 0.0 114.003 178.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -98.84 7.51 45.96 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.854 0.827 . . . . 0.0 111.934 -175.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 18.9 m-85 -104.8 121.97 44.76 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 120.979 0.419 . . . . 0.0 111.778 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.522 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 88.3 m-20 -84.19 172.81 11.57 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.539 178.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.65 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -154.7 155.25 34.25 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 173.496 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.509 HG22 ' CG1' ' A' ' 49' ' ' VAL . 26.7 pt -115.96 118.57 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.463 0 CA-C-O 121.69 0.757 . . . . 0.0 111.588 -176.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.531 ' HB2' ' O ' ' A' ' 48' ' ' THR . 3.5 m-70 -91.27 130.68 37.11 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.94 -179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.904 HD11 ' HB ' ' A' ' 28' ' ' ILE . 17.7 mm . . . . . 0 C--O 1.252 1.197 0 CA-C-O 118.062 -0.97 . . . . 0.0 109.717 173.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.788 0 N-CA-C 111.68 -0.568 . . . . 0.0 111.68 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.4 m -142.45 -177.04 5.08 Favored 'General case' 0 C--N 1.323 -0.579 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -178.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.2 p -79.37 85.61 5.17 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.012 0.434 . . . . 0.0 110.548 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.6 mm -71.87 -66.39 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.364 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.6 t -147.22 -38.83 0.2 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.07 0.462 . . . . 0.0 110.067 177.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 t-80 -141.78 80.74 1.73 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.06 176.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.9 m -103.45 -80.42 0.52 Allowed 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 175.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.78 -94.8 0.21 Allowed Glycine 0 C--N 1.333 0.414 0 CA-C-N 115.959 -0.564 . . . . 0.0 113.757 173.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.595 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 59.6 t30 -75.09 159.89 31.13 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.219 0.533 . . . . 0.0 111.474 -171.585 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 72.8 mt -102.56 -4.91 24.56 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.743 -0.662 . . . . 0.0 111.39 -175.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.542 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.2 t80 -75.76 -168.83 0.94 Allowed 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.644 -174.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.451 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 3.9 m -68.04 -95.7 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.808 0.299 . . . . 0.0 111.808 -173.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.451 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -174.47 123.38 0.29 Allowed 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -178.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.499 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 64.09 23.31 67.73 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.433 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.688 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 17.5 mm-40 -83.18 159.88 21.93 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.519 0.199 . . . . 0.0 110.508 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 1.036 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.4 p -55.63 -49.05 73.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.78 176.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 30.7 p -85.87 3.63 40.89 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.247 0.546 . . . . 0.0 111.226 -178.297 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.688 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 85.6 t90 -94.08 -52.62 4.31 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.754 177.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.412 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 77.7 t80 -62.14 -38.96 90.97 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.422 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.776 HG13 HG12 ' A' ' 58' ' ' ILE . 55.4 t -57.69 -51.38 70.86 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.257 178.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -64.45 -31.14 72.23 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.679 -176.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 25.4 t70 -68.9 -47.68 65.19 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.661 177.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.536 ' HE2' ' OE2' ' A' ' 73' ' ' GLU . 31.6 mmmt -67.51 -26.98 66.61 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.272 -176.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -86.3 5.51 3.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.993 0.425 . . . . 0.0 111.392 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.91 -7.48 66.17 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.927 -0.654 . . . . 0.0 113.116 173.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.71 9.84 62.31 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.955 178.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 12.1 tp10 -77.57 -45.84 24.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.398 0.618 . . . . 0.0 110.195 176.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' HD13 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -111.07 129.47 66.29 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.974 -175.309 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.511 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 125.97 -147.43 16.67 Favored Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.064 -1.065 . . . . 0.0 114.63 167.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 83.1 p 65.92 -52.19 0.39 Allowed 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.412 1.485 . . . . 0.0 112.543 -178.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.3 t -79.49 -0.27 32.5 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.888 0.375 . . . . 0.0 111.355 -177.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.684 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -76.95 -9.94 59.03 Favored 'General case' 0 CA--C 1.538 0.512 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -175.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.52 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 83.63 -124.04 6.42 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.342 -0.932 . . . . 0.0 112.103 -176.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -115.05 -177.34 3.1 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 171.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.681 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -58.72 -36.03 73.62 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -170.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 10.6 p-10 -83.1 -10.46 58.68 Favored 'General case' 0 C--N 1.325 -0.467 0 O-C-N 121.554 -0.716 . . . . 0.0 111.594 -174.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -105.85 6.45 31.59 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.551 0.691 . . . . 0.0 109.408 179.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.591 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -53.78 -70.31 0.1 Allowed 'General case' 0 C--O 1.223 -0.336 0 N-CA-C 113.828 1.047 . . . . 0.0 113.828 -172.753 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -53.15 -39.56 63.64 Favored 'General case' 0 C--N 1.331 -0.235 0 O-C-N 123.248 0.343 . . . . 0.0 111.294 -172.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.34 -54.65 41.06 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.168 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.684 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -70.31 -34.58 72.9 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.274 -177.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -65.92 -51.07 61.83 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.36 -179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -66.34 -29.7 69.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.943 0.402 . . . . 0.0 110.225 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.39 -27.85 73.14 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.61 174.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -84.24 -14.35 50.18 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.864 0.364 . . . . 0.0 110.786 178.066 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 103.88 24.83 7.48 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.696 -0.764 . . . . 0.0 113.387 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.665 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.1 m-30 -86.87 153.7 21.43 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 175.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.537 ' HB ' ' CE1' ' A' ' 112' ' ' HIS . 2.9 m -103.11 137.8 40.79 Favored 'General case' 0 C--N 1.319 -0.755 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 177.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.534 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -128.84 144.07 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 121.663 0.744 . . . . 0.0 112.207 -177.944 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 9.2 p30 -150.87 -150.32 0.34 Allowed 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 166.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.6 m170 -127.23 72.98 1.4 Allowed 'General case' 0 C--N 1.314 -0.961 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.5 -179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 3.7 m -146.45 89.68 5.8 Favored Pre-proline 0 C--N 1.324 -0.518 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.02 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.35 147.22 82.66 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 121.827 1.685 . . . . 0.0 112.304 174.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 23.2 t -169.91 170.35 7.75 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.494 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 78.4 tttt -56.91 119.17 5.79 Favored 'General case' 0 C--N 1.326 -0.421 0 O-C-N 123.156 0.285 . . . . 0.0 111.084 -176.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 109.79 -16.19 31.09 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.946 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.43 ' HB1' ' HD2' ' A' ' 110' ' ' TYR . . . -93.95 -179.58 5.02 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 120.68 0.276 . . . . 0.0 110.556 -179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 20' ' ' VAL . 4.2 mp -138.89 141.23 37.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 177.591 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -72.5 158.42 35.76 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.689 -179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.512 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.6 tp60 -156.5 134.22 10.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.466 0.65 . . . . 0.0 111.695 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.538 ' HB2' ' CD1' ' A' ' 108' ' ' TYR . 31.4 t -155.62 129.91 8.89 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 114.905 -1.043 . . . . 0.0 109.034 171.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -85.27 10.65 11.9 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.187 0.518 . . . . 0.0 110.598 178.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -87.97 75.9 8.71 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.635 178.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 175.21 -171.03 44.2 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.753 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -76.44 -47.1 0.16 Allowed 'Trans proline' 0 N--CA 1.463 -0.304 0 C-N-CA 122.553 2.169 . . . . 0.0 112.334 -178.262 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.681 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.0 m-85 -125.37 26.33 6.86 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.396 -179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 82.98 -169.74 48.73 Favored Glycine 0 C--O 1.229 -0.198 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.391 -177.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.512 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 74.7 m-70 -146.21 91.73 2.1 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 119.434 -0.317 . . . . 0.0 110.673 179.133 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.591 HG11 ' CD2' ' A' ' 38' ' ' TRP . 24.2 m -115.72 114.41 46.2 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-O 122.052 0.929 . . . . 0.0 111.334 173.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.738 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -124.69 126.59 45.95 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.7 -1.136 . . . . 0.0 109.391 179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.674 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 53.6 t80 -70.46 126.39 29.5 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.011 0.434 . . . . 0.0 110.676 -174.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.647 ' HA ' HG22 ' A' ' 83' ' ' ILE . 5.2 t -83.14 111.66 19.7 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.982 -177.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.674 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 16.2 mt-10 -91.79 -18.43 23.87 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.167 -176.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.494 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 56.5 p -174.02 163.7 4.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.12 0.486 . . . . 0.0 110.945 -178.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.644 HG23 HG12 ' A' ' 81' ' ' VAL . 7.6 p -118.71 137.25 53.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -90.28 156.12 18.5 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -177.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -74.18 -1.1 18.96 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.858 0.361 . . . . 0.0 111.826 -178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -80.57 -14.42 58.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.477 176.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 102.91 -4.3 49.4 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -176.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 9.4 p -103.1 147.26 27.21 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 ' HB ' ' A' ' 100' ' ' ILE . 19.6 m -103.15 152.29 6.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.994 0.426 . . . . 0.0 111.01 -179.333 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 92.7 m -106.26 115.26 29.9 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.114 178.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.738 HD12 ' HB3' ' A' ' 70' ' ' ALA . 23.6 pt -117.52 142.52 31.34 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.85 -176.428 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 49.6 m -116.05 107.4 14.89 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.363 0.601 . . . . 0.0 110.559 179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.759 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.9 pt-20 -110.18 111.1 22.22 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.336 177.074 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.644 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.4 ttm -76.11 111.9 12.0 Favored 'General case' 0 C--N 1.32 -0.679 0 O-C-N 122.072 -0.392 . . . . 0.0 110.437 178.608 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.597 ' HB2' ' H ' ' A' ' 93' ' ' PHE . 28.7 t30 72.86 -58.78 0.59 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.23 -0.896 . . . . 0.0 112.037 179.095 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 1.036 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 5.3 t80 67.66 -77.01 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.256 0 O-C-N 123.596 0.56 . . . . 0.0 110.195 -173.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 75.1 m -164.19 59.72 0.15 Allowed 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 122.84 0.456 . . . . 0.0 110.052 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -174.46 -92.98 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.547 0 C-N-CA 120.489 -0.862 . . . . 0.0 112.697 -178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -81.22 113.0 3.55 Favored Glycine 0 N--CA 1.449 -0.477 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.146 -178.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -54.72 118.02 4.63 Favored 'Trans proline' 0 C--O 1.234 0.294 0 C-N-CA 123.072 2.514 . . . . 0.0 112.755 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.597 ' H ' ' HB2' ' A' ' 87' ' ' ASN . 56.5 m-85 70.83 9.36 6.8 Favored 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 115.081 -0.963 . . . . 0.0 112.308 177.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -69.01 87.99 0.39 Allowed 'General case' 0 CA--C 1.51 -0.566 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.493 173.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.644 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -60.95 93.29 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.745 0 CA-C-O 121.87 0.843 . . . . 0.0 109.095 175.1 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.759 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 44.0 m -82.71 120.51 25.67 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 115.272 -0.877 . . . . 0.0 111.165 -170.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.2 m -87.72 100.09 12.58 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.482 177.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.633 ' HB2' ' CG1' ' A' ' 83' ' ' ILE . 31.3 mmt180 -97.79 163.69 12.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.284 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 30.3 m -129.23 109.22 10.96 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.936 177.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.811 ' HB ' HG22 ' A' ' 81' ' ' VAL . 44.9 mm -98.86 109.58 24.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.413 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 14.5 m -72.81 157.62 37.13 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 176.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.77 -38.57 61.21 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-O 120.943 0.402 . . . . 0.0 111.523 178.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 11.6 p -58.33 -35.27 71.65 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.912 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.432 ' HB3' ' HE2' ' A' ' 108' ' ' TYR . 30.2 mt-10 -82.52 -36.64 26.2 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.719 177.301 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -53.31 -30.7 40.35 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.066 0.46 . . . . 0.0 110.678 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.13 -23.68 64.3 Favored Glycine 0 CA--C 1.529 0.909 0 CA-C-N 115.584 -0.735 . . . . 0.0 114.213 177.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -103.14 -0.75 30.14 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 118.245 1.022 . . . . 0.0 111.452 -179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.538 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 50.1 m-85 -106.44 134.29 49.81 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.058 0.456 . . . . 0.0 111.344 -177.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 34.8 m-20 -88.71 162.39 16.29 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 175.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.43 ' HD2' ' HB1' ' A' ' 57' ' ' ALA . 5.4 p90 -152.27 142.04 21.95 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 171.036 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.665 HD12 ' CD2' ' A' ' 47' ' ' PHE . 27.3 pt -104.89 112.29 37.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 CA-C-O 121.56 0.695 . . . . 0.0 110.578 -175.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.537 ' CE1' ' HB ' ' A' ' 48' ' ' THR . 29.6 p80 -115.45 138.31 51.14 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.618 -179.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.4 HD11 HG22 ' A' ' 28' ' ' ILE . 26.3 mt . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.362 -0.828 . . . . 0.0 110.446 -175.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.74 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.3 t -94.9 105.92 17.88 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 176.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.7 m -78.43 99.3 6.35 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.19 -175.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 17.7 pt -110.35 61.78 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 121.787 0.804 . . . . 0.0 109.579 174.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 4.0 p -87.12 45.77 1.3 Allowed 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.57 -175.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 m80 68.4 -72.29 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.515 -175.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 41.2 m -152.31 14.72 0.6 Allowed 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.277 0.56 . . . . 0.0 109.814 175.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.01 -80.62 0.34 Allowed Glycine 0 N--CA 1.444 -0.813 0 CA-C-N 115.69 -0.687 . . . . 0.0 111.592 -177.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.575 HD22 ' HA ' ' A' ' 18' ' ' TRP . 46.8 t30 -173.81 167.3 4.41 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 -179.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 89.6 mt -83.77 -15.08 49.83 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.859 0.361 . . . . 0.0 111.026 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.523 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 10.4 t80 -79.15 -166.52 0.94 Allowed 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.43 -176.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 4.0 m -67.12 -97.04 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -173.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.401 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -175.26 125.42 0.25 Allowed 'General case' 0 N--CA 1.455 -0.185 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 -178.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 60.06 35.83 88.62 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.33 179.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.486 ' H ' ' HB3' ' A' ' 18' ' ' TRP . 17.7 mm-40 -101.94 165.12 11.35 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 120.355 0.121 . . . . 0.0 110.81 -179.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 1.045 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 5.4 p -60.5 -45.25 94.47 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.093 0.473 . . . . 0.0 110.281 178.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.488 HG21 ' HA ' ' A' ' 34' ' ' ASN . 35.4 p -85.36 2.31 44.81 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.67 0.748 . . . . 0.0 110.455 -177.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.575 ' HA ' HD22 ' A' ' 9' ' ' ASN . 84.5 t90 -99.07 -52.17 3.62 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.913 178.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 81.2 t80 -61.45 -40.47 94.62 Favored 'General case' 0 C--O 1.231 0.118 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.402 179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.899 HG13 HG12 ' A' ' 58' ' ' ILE . 23.2 t -55.08 -43.87 71.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.189 176.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.653 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 48.5 t80 -72.76 -35.74 67.52 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.113 -174.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -69.8 -37.66 76.38 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 121.011 -0.276 . . . . 0.0 110.733 179.063 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -63.05 -38.21 90.27 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.486 -0.325 . . . . 0.0 111.752 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.585 HG21 HG13 ' A' ' 28' ' ' ILE . 34.4 m -80.25 -9.37 12.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 121.052 0.453 . . . . 0.0 110.439 177.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.62 31.65 49.28 Favored Glycine 0 N--CA 1.453 -0.221 0 CA-C-N 115.748 -0.66 . . . . 0.0 112.88 172.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.653 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 71.02 58.97 5.33 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.451 -0.88 . . . . 0.0 111.799 -177.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -124.04 -51.21 1.79 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.816 0.341 . . . . 0.0 111.187 -175.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.721 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.6 pp -115.15 136.56 51.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.211 0.529 . . . . 0.0 112.208 -176.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.837 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 81.38 -123.96 6.25 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 115.54 -0.754 . . . . 0.0 114.574 165.466 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.555 ' HB3' ' CE1' ' A' ' 21' ' ' TYR . 54.6 p 68.32 -39.38 0.4 Allowed 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.196 1.399 . . . . 0.0 110.592 -167.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . 0.454 ' H ' ' C ' ' A' ' 29' ' ' GLY . 32.7 p -92.01 13.07 19.79 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.233 0.539 . . . . 0.0 110.477 177.75 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.837 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -74.5 -16.9 60.83 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.459 -178.054 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.567 ' O ' ' HB3' ' A' ' 37' ' ' ASN . . . 55.43 75.75 0.23 Allowed Glycine 0 CA--C 1.518 0.268 0 CA-C-N 115.637 -0.711 . . . . 0.0 114.562 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.488 ' HA ' HG21 ' A' ' 17' ' ' THR . 15.7 m120 64.63 167.51 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 113.405 0.891 . . . . 0.0 113.405 176.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.59 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -70.36 -39.43 74.63 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.752 1.019 . . . . 0.0 113.752 -167.703 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 38.5 p30 -79.71 -1.75 39.88 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 122.096 -0.377 . . . . 0.0 111.724 -175.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 33' ' ' GLY . 10.6 t30 -117.46 5.91 12.54 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.758 -0.83 . . . . 0.0 108.758 176.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.593 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.0 OUTLIER -53.73 -65.16 0.61 Allowed 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 114.736 -1.12 . . . . 0.0 112.315 -172.635 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -55.49 -40.68 72.01 Favored 'General case' 0 C--N 1.331 -0.225 0 O-C-N 123.27 0.356 . . . . 0.0 111.39 -174.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -60.78 -54.78 40.97 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.166 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.695 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.12 -36.04 77.06 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.066 0.46 . . . . 0.0 111.382 -178.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.476 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -64.63 -47.96 76.62 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.601 -179.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -64.85 -27.68 69.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.771 -179.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.54 -25.61 69.73 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.962 175.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.03 -7.21 59.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.889 0.376 . . . . 0.0 110.727 178.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.84 46.06 2.54 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.132 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.674 ' HD2' ' HB ' ' A' ' 111' ' ' ILE . 5.6 m-30 -109.22 159.56 16.83 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.74 0.305 . . . . 0.0 110.191 178.183 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.8 m -111.42 118.39 35.66 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.916 176.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.712 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -107.88 130.24 60.64 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 CA-C-O 121.337 0.589 . . . . 0.0 110.481 179.145 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.712 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 31.9 m-20 -122.73 6.33 9.42 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.842 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 12.1 p80 37.9 70.56 0.19 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.495 -1.229 . . . . 0.0 112.574 -172.58 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 55.3 m -161.09 102.11 1.26 Allowed Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.181 177.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.481 ' HG2' HG11 ' A' ' 81' ' ' VAL . 17.8 Cg_endo -56.01 151.94 39.37 Favored 'Trans proline' 0 CA--C 1.531 0.361 0 C-N-CA 122.955 2.436 . . . . 0.0 113.417 -176.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 30.3 t -164.0 160.31 21.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.18 -176.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.549 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 3.4 ttmp? -62.05 127.92 33.68 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.56 0.219 . . . . 0.0 110.573 -179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.24 12.36 65.54 Favored Glycine 0 N--CA 1.449 -0.481 0 C-N-CA 120.475 -0.869 . . . . 0.0 112.147 178.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -125.48 -172.59 2.63 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.899 HG12 HG13 ' A' ' 20' ' ' VAL . 4.4 mp -133.72 140.32 46.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.882 0.372 . . . . 0.0 111.424 -175.512 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.613 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 6.4 tp -82.76 142.94 31.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.488 178.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.586 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 26.4 tm0? -145.56 142.84 29.51 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.325 0.583 . . . . 0.0 111.673 -177.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 48.0 t -153.2 165.18 36.49 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.847 179.353 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 12.1 m -116.66 15.95 15.44 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.993 176.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -80.02 21.8 0.55 Allowed 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.898 -177.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -144.58 162.89 27.98 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.161 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.96 -35.12 94.4 Favored 'Trans proline' 0 C--N 1.345 0.386 0 C-N-CA 123.222 2.615 . . . . 0.0 112.085 -178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.454 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 91.0 m-85 -108.1 1.24 22.16 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.082 174.667 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 100.09 -146.58 17.81 Favored Glycine 0 N--CA 1.45 -0.43 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.672 -176.652 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 14.3 t-160 -162.45 96.06 0.94 Allowed 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.721 0.261 . . . . 0.0 110.76 174.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.613 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 27.5 m -115.27 130.54 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.684 0 CA-C-O 121.692 0.758 . . . . 0.0 111.35 170.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.557 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -140.24 124.69 17.93 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 114.324 -1.307 . . . . 0.0 108.929 -179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.428 ' HE2' ' OE1' ' A' ' 73' ' ' GLU . 37.5 t80 -70.3 131.84 44.77 Favored 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.572 -174.061 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.89 116.47 30.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.41 -176.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.444 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 9.6 mm-40 -83.55 -28.86 28.29 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.987 -177.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.549 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 22.0 t -177.42 152.71 0.86 Allowed 'General case' 0 N--CA 1.454 -0.237 0 CA-C-O 120.797 0.332 . . . . 0.0 110.73 -178.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 6.2 p -106.95 132.44 54.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 171.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -74.47 148.33 41.13 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.257 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.3 p -63.73 -22.9 67.14 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.628 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -77.5 -16.97 58.42 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.536 179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.83 -28.33 4.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.249 -0.977 . . . . 0.0 113.228 177.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 32.6 p -73.09 152.19 41.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.757 0.313 . . . . 0.0 110.938 -178.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.868 HG23 ' HB ' ' A' ' 100' ' ' ILE . 0.6 OUTLIER -114.71 137.42 48.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 121.226 0.536 . . . . 0.0 111.97 -179.754 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -102.74 122.16 43.91 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.249 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.596 HD13 HD11 ' A' ' 100' ' ' ILE . 46.0 pt -122.95 162.33 23.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 121.126 0.489 . . . . 0.0 111.552 -176.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 48.8 m -135.78 109.4 8.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.263 174.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 7.5 pt-20 -116.34 111.9 20.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.542 178.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.677 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 51.1 ttm -76.82 113.68 14.75 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.593 179.432 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.443 ' HB3' ' O ' ' A' ' 86' ' ' MET . 5.6 t30 75.05 -57.33 0.61 Allowed 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 123.7 0.8 . . . . 0.0 112.062 177.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 1.045 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.4 t80 64.4 -79.83 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.522 0.514 . . . . 0.0 110.039 -171.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.6 m -163.11 86.27 0.53 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 176.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 164.2 -80.56 0.12 Allowed Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.148 -1.025 . . . . 0.0 113.064 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -97.81 113.01 4.6 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.242 -177.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -55.27 120.43 8.18 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 123.04 2.494 . . . . 0.0 112.57 -178.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.5 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 49.4 m-85 69.64 10.04 7.44 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.506 177.595 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 73.2 m -69.44 88.12 0.47 Allowed 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 170.886 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.677 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.1 p -64.98 91.09 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 CA-C-O 121.836 0.827 . . . . 0.0 109.198 176.768 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.788 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.5 t -76.99 121.99 24.28 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.903 -171.811 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 68.0 m -97.46 115.2 27.32 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.0 176.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.51 ' HE ' ' CD ' ' A' ' 85' ' ' GLU . 34.6 mtt-85 -120.22 163.76 17.28 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.343 178.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 21.7 m -131.88 108.14 9.2 Favored 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.868 ' HB ' HG23 ' A' ' 81' ' ' VAL . 3.5 mp -90.29 127.63 42.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -176.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.455 ' O ' HG22 ' A' ' 100' ' ' ILE . 35.9 t -70.57 147.72 48.95 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 171.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -48.08 -31.05 5.03 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 112.155 0.428 . . . . 0.0 112.155 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 28.4 t -54.72 -58.04 9.11 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.012 176.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 2.6 mp0 -78.47 -19.41 53.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.711 0.291 . . . . 0.0 110.602 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.484 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -62.86 -35.23 79.31 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.42 178.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.31 -20.86 71.77 Favored Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.957 -0.639 . . . . 0.0 112.54 175.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.42 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 6.5 t30 -76.49 -38.32 55.45 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 121.25 0.548 . . . . 0.0 110.808 179.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.512 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 59.6 m-85 -78.88 133.95 36.94 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.801 -174.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.842 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 40.4 m-80 -86.85 167.45 14.34 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.712 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.2 OUTLIER -153.43 137.72 16.6 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 176.514 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.712 HG22 HG12 ' A' ' 49' ' ' VAL . 33.7 pt -111.29 111.69 37.29 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-O 121.49 0.662 . . . . 0.0 111.08 -173.046 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 p80 -127.5 146.93 50.34 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.577 176.543 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.493 ' H ' HG12 ' A' ' 113' ' ' ILE . 2.3 pt . . . . . 0 C--O 1.245 0.833 0 O-C-N 123.614 0.571 . . . . 0.0 111.522 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.818 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 57.3 m -108.37 -48.74 3.29 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.905 0.353 . . . . 0.0 110.922 -179.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 48.3 t -162.05 118.11 2.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.962 -178.257 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 61.0 mt -108.95 98.17 6.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.21 0.529 . . . . 0.0 110.453 177.736 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 26.6 m -152.68 -59.48 0.14 Allowed 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 176.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 14.1 p80 -164.73 33.19 0.07 Allowed 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 167.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 8.6 m -78.14 41.85 0.38 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.983 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 163.03 -160.75 33.29 Favored Glycine 0 N--CA 1.44 -1.073 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -178.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 42.0 t-20 -168.81 161.75 11.14 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.492 HD12 ' HB3' ' A' ' 30' ' ' SER . 86.3 mt -73.67 -15.84 61.23 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.44 0.638 . . . . 0.0 109.378 173.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.44 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.5 OUTLIER -84.78 -173.13 4.56 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.899 -1.046 . . . . 0.0 111.227 179.467 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 19.2 m -77.49 -94.98 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.704 -174.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -176.79 120.8 0.13 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.793 -177.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.523 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 73.09 25.65 72.93 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.853 -0.689 . . . . 0.0 112.735 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -95.88 164.86 12.55 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.967 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 20.8 p -60.04 -58.92 6.44 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.896 0.379 . . . . 0.0 110.724 -177.748 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.405 HG22 ' HE1' ' A' ' 38' ' ' TRP . 5.8 p -76.76 3.24 12.23 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.427 0.632 . . . . 0.0 111.325 -178.543 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.44 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 85.4 t90 -94.98 -51.59 4.6 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.196 174.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 84.6 t80 -63.21 -45.65 90.68 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.864 -178.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 16' ' ' CYS . 92.0 t -54.06 -41.58 51.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.818 176.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HD1' ' HA3' ' A' ' 29' ' ' GLY . 63.9 t80 -68.03 -42.51 80.48 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.263 -175.607 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -70.33 -35.53 73.67 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.778 0.323 . . . . 0.0 110.814 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt -64.32 -33.58 76.16 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.82 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.629 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -87.28 3.94 4.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.016 0.436 . . . . 0.0 110.688 177.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.72 26.02 72.99 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.902 -0.59 . . . . 0.0 113.024 177.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.3 22.0 78.18 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.482 -178.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -67.21 -47.27 71.36 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.328 0.585 . . . . 0.0 109.801 176.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.629 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -133.99 145.96 32.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.357 179.192 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.723 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 141.29 -170.22 24.74 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 119.262 -1.447 . . . . 0.0 114.588 169.026 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.492 ' HB3' HD12 ' A' ' 10' ' ' LEU . 22.8 m 72.25 -49.97 0.69 Allowed 'General case' 0 N--CA 1.466 0.326 0 C-N-CA 124.095 0.958 . . . . 0.0 111.455 -178.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 12.9 p -80.32 -12.34 59.61 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.723 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -75.14 -5.65 45.45 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -175.44 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 78.64 -126.72 7.7 Favored Glycine 0 N--CA 1.447 -0.632 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.279 -177.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.409 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 62.9 m-20 -109.68 -178.19 3.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.309 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -64.92 -23.86 67.35 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 112.534 0.568 . . . . 0.0 112.534 -174.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.475 ' HB2' ' C ' ' A' ' 66' ' ' PHE . 63.8 t30 -87.29 -18.29 30.53 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.172 0.511 . . . . 0.0 110.981 -178.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -108.08 7.5 27.72 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.166 0.507 . . . . 0.0 109.909 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.648 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.1 OUTLIER -52.68 -72.62 0.05 Allowed 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.268 -0.878 . . . . 0.0 113.019 -172.403 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.438 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -52.25 -38.17 57.37 Favored 'General case' 0 C--N 1.329 -0.318 0 O-C-N 123.323 0.389 . . . . 0.0 111.37 -175.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -62.95 -56.41 17.43 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.278 179.127 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -69.26 -36.34 77.04 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.968 0.413 . . . . 0.0 111.209 -178.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.68 -47.6 76.47 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.684 175.755 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.438 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 48.7 mt-30 -62.89 -33.57 75.58 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.685 178.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.44 -34.88 89.13 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.539 176.075 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -78.97 -8.54 58.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.143 0.497 . . . . 0.0 110.574 175.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.39 15.84 36.64 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.97 -0.633 . . . . 0.0 113.413 175.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.656 ' HD2' HD12 ' A' ' 111' ' ' ILE . 6.2 m-30 -76.12 152.11 36.84 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 117.207 0.504 . . . . 0.0 109.853 179.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.4 m -97.53 109.14 21.95 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.546 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -102.17 127.97 55.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-O 121.556 0.693 . . . . 0.0 110.822 -177.614 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.904 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 10.5 m-20 -124.49 -140.09 0.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 105.49 -2.041 . . . . 0.0 105.49 172.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.661 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 1.1 p-80 -159.9 88.58 0.84 Allowed 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.725 0.774 . . . . 0.0 111.768 168.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.437 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 28.1 m -157.32 92.51 2.3 Favored Pre-proline 0 C--N 1.324 -0.537 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.573 178.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.494 ' HB2' HG11 ' A' ' 81' ' ' VAL . 11.2 Cg_endo -53.88 140.6 68.25 Favored 'Trans proline' 0 CA--C 1.531 0.333 0 C-N-CA 122.813 2.342 . . . . 0.0 113.079 -178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.2 t -157.53 158.81 36.36 Favored 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 -176.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.563 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 25.0 ttmm -60.83 116.41 4.42 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.829 0.347 . . . . 0.0 110.691 -177.176 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 102.61 -4.29 50.39 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.095 178.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.18 -165.53 1.21 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 120.625 0.25 . . . . 0.0 110.348 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.73 HG22 ' H ' ' A' ' 59' ' ' LEU . 1.6 mp -133.1 173.95 14.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -177.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.73 ' H ' HG22 ' A' ' 58' ' ' ILE . 2.4 tp -137.82 107.34 6.17 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 122.03 0.132 . . . . 0.0 111.164 -172.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.638 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 38.4 tt0 -105.12 139.74 39.34 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.713 0.292 . . . . 0.0 110.795 178.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.2 t -96.31 -31.82 12.71 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.658 179.113 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.1 m 68.66 8.92 7.03 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.846 -0.615 . . . . 0.0 111.461 -177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 79.3 mm-40 -121.39 150.94 40.76 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 106.71 168.72 22.57 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.086 -179.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -60.77 -50.62 6.18 Favored 'Trans proline' 0 C--N 1.343 0.255 0 C-N-CA 122.907 2.405 . . . . 0.0 112.324 -178.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.523 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 69.2 m-85 -109.98 16.89 21.62 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.478 177.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.436 ' N ' ' HB2' ' A' ' 36' ' ' ASN . . . 74.29 -138.28 24.07 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.232 179.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.638 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 28.1 t-80 -178.67 108.99 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 119.377 -0.344 . . . . 0.0 110.317 -178.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.64 HG11 ' CD2' ' A' ' 38' ' ' TRP . 27.8 m -122.08 119.46 58.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.613 0.72 . . . . 0.0 111.316 170.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.525 ' HB1' HD13 ' A' ' 83' ' ' ILE . . . -114.83 126.83 55.27 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.669 178.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.556 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 82.1 t80 -71.1 123.72 22.77 Favored 'General case' 0 C--N 1.318 -0.772 0 C-N-CA 120.693 -0.403 . . . . 0.0 110.204 -178.531 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.666 ' HA ' HG22 ' A' ' 83' ' ' ILE . 21.3 t -85.33 119.15 33.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.55 -175.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.563 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 10.3 mt-10 -102.0 -22.02 14.37 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.54 -0.464 . . . . 0.0 111.15 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 50.4 m -160.43 143.14 13.21 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.742 0.306 . . . . 0.0 111.462 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.683 HG23 HG22 ' A' ' 81' ' ' VAL . 7.4 p -114.22 118.72 59.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 165.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -76.16 160.78 29.4 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.763 -0.653 . . . . 0.0 111.07 -169.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 t -67.33 -23.79 65.66 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.992 -174.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -84.88 -6.22 59.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.115 -178.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 111.01 -25.08 14.86 Favored Glycine 0 N--CA 1.448 -0.5 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.765 178.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.505 ' HB3' HG22 ' A' ' 99' ' ' THR . 55.1 m -66.92 144.93 55.95 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.813 0.339 . . . . 0.0 110.912 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.738 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 53.8 t -112.51 127.24 69.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-O 120.869 0.366 . . . . 0.0 111.32 -177.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 99.3 m -97.4 114.55 26.39 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.165 178.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.666 HG22 ' HA ' ' A' ' 72' ' ' VAL . 2.9 pp -116.74 165.16 12.4 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.291 -178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 50.3 m -130.04 96.92 4.31 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.823 175.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.949 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 9.5 pt-20 -108.15 103.04 12.15 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.646 178.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.69 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 52.7 ttm -78.79 111.69 15.18 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.384 -178.049 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.532 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 34.8 t30 72.96 -63.0 0.45 Allowed 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 115.427 -0.806 . . . . 0.0 113.1 172.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.967 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 28.6 t80 70.54 -72.01 0.12 Allowed 'General case' 0 N--CA 1.466 0.335 0 O-C-N 123.33 0.394 . . . . 0.0 110.024 -169.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 52.3 p -174.33 77.19 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 175.339 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -173.36 -80.43 0.05 OUTLIER Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.177 -177.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -104.31 106.04 2.69 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.773 -0.727 . . . . 0.0 111.48 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 77.5 Cg_exo -51.32 123.48 12.13 Favored 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.953 2.435 . . . . 0.0 112.899 -177.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.436 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 96.0 m-85 71.78 5.62 5.41 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.784 177.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -70.04 91.02 0.66 Allowed 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.69 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.6 p -67.72 92.41 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 CA-C-O 121.636 0.731 . . . . 0.0 109.53 178.71 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.949 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 35.8 t -68.26 115.68 7.99 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.335 -173.739 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.0 m -92.42 98.49 11.51 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.081 178.798 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.599 ' HB3' HD11 ' A' ' 83' ' ' ILE . 52.9 ttt180 -115.12 152.0 33.35 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.057 -177.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.505 HG22 ' HB3' ' A' ' 80' ' ' SER . 26.4 m -122.8 106.44 10.91 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 109.87 -178.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.738 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 3.8 mp -79.79 128.41 38.6 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.944 -175.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 13.0 t -78.54 146.79 34.1 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 170.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -46.74 -35.21 5.89 Favored 'General case' 0 N--CA 1.467 0.414 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -178.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.2 p -58.71 -45.08 90.34 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.759 0.314 . . . . 0.0 111.234 -179.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.409 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.4 mp0 -78.89 -31.57 45.49 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.895 0.379 . . . . 0.0 110.126 178.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -58.55 -25.81 62.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.467 177.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -64.77 -32.42 84.16 Favored Glycine 0 CA--C 1.523 0.587 0 CA-C-N 115.589 -0.732 . . . . 0.0 113.491 177.064 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -99.11 -11.5 21.37 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 117.555 0.677 . . . . 0.0 111.0 -177.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.452 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 11.9 m-85 -80.58 111.33 16.9 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.03 0.443 . . . . 0.0 111.439 -178.13 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.661 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 88.2 m-20 -78.4 163.18 25.87 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.625 -177.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.904 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -149.43 159.32 44.39 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 173.579 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.656 HD12 ' HD2' ' A' ' 47' ' ' PHE . 17.5 pt -120.17 126.11 74.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 121.253 0.549 . . . . 0.0 111.529 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.1 m-70 -103.36 148.19 26.18 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.631 -178.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.402 HD11 HG22 ' A' ' 28' ' ' ILE . 25.2 mm . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.162 -0.923 . . . . 0.0 109.751 172.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.596 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.3 p 48.49 46.81 20.68 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.279 0.631 . . . . 0.0 111.61 -178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 50.9 m -82.76 111.47 18.71 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.051 0.453 . . . . 0.0 110.555 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 13.2 tt -114.56 142.06 28.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.894 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 30.5 t -87.56 94.92 9.86 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 65.07 -81.42 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.657 -176.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 66.9 m -162.63 176.18 10.62 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -71.5 -34.1 63.63 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.068 175.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -105.48 -173.89 2.41 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 176.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.532 HD12 ' HB2' ' A' ' 30' ' ' SER . 85.1 mt -89.92 -23.72 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 -172.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.79 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 2.3 t80 -78.08 174.56 11.0 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.479 -168.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 24.3 m -55.95 -90.11 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.558 0.743 . . . . 0.0 112.602 -177.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 179.35 128.17 0.07 Allowed 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.633 -177.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 75.38 -14.22 5.46 Favored Glycine 0 C--O 1.218 -0.854 0 N-CA-C 114.57 0.588 . . . . 0.0 114.57 172.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 19.6 mm-40 -64.63 159.25 22.34 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 117.48 0.64 . . . . 0.0 111.544 -172.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.723 ' SG ' ' HA ' ' A' ' 88' ' ' TYR . 73.7 m -57.55 -45.38 85.19 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 121.143 0.497 . . . . 0.0 109.671 173.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.476 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 1.0 OUTLIER -70.26 -30.13 67.1 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.205 -178.25 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.79 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 92.4 t90 -69.61 -50.84 40.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.788 175.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 29.8 t80 -63.01 -43.98 97.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.168 -178.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 16' ' ' CYS . 52.4 t -59.08 -45.29 92.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.544 -0.298 . . . . 0.0 110.762 177.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 41.1 t80 -62.32 -36.93 83.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.947 -177.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -69.56 -45.68 68.18 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.808 0.337 . . . . 0.0 110.758 177.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' CE2' ' A' ' 71' ' ' TYR . 26.0 mmmt -63.92 -36.25 83.32 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.917 -177.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -78.31 -6.11 8.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.882 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.04 16.62 69.27 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.803 174.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 74.03 25.8 70.4 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.525 -178.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -76.84 -53.41 7.94 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.273 0.558 . . . . 0.0 110.785 178.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.789 HD12 ' HZ3' ' A' ' 32' ' ' TRP . 2.0 pp -111.89 142.76 23.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.395 -171.637 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.786 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 99.57 -92.36 1.14 Allowed Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.697 -0.683 . . . . 0.0 114.281 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.532 ' HB2' HD12 ' A' ' 10' ' ' LEU . 88.5 p 61.89 -56.0 0.13 Allowed 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.218 1.407 . . . . 0.0 112.689 -174.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 15.4 t -119.06 28.43 8.26 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.415 0.626 . . . . 0.0 110.348 -175.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.789 ' HZ3' HD12 ' A' ' 28' ' ' ILE . 0.4 OUTLIER -68.41 -5.05 16.91 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.995 -179.101 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.431 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 87.09 -123.16 6.44 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 119.615 -1.278 . . . . 0.0 111.767 -177.096 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -118.07 179.16 4.18 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 174.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.639 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -60.8 -37.82 83.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 112.055 0.391 . . . . 0.0 112.055 -174.74 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -72.91 -16.83 61.55 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 120.817 0.342 . . . . 0.0 111.737 -177.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -101.5 -0.59 34.84 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.19 0.519 . . . . 0.0 109.724 179.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.706 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.2 OUTLIER -52.05 -60.51 3.11 Favored 'General case' 0 CA--C 1.516 -0.341 0 CA-C-N 115.254 -0.884 . . . . 0.0 113.181 -172.197 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -57.4 -37.55 72.9 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.993 0.183 . . . . 0.0 111.35 -173.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.9 -48.12 59.83 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.742 0.306 . . . . 0.0 111.094 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.38 -43.63 80.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.932 0.396 . . . . 0.0 111.169 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -58.84 -50.04 75.46 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.342 -178.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -64.8 -36.48 84.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.452 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.04 -32.35 83.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.969 -0.634 . . . . 0.0 111.849 176.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -77.49 -17.91 57.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.811 0.339 . . . . 0.0 110.767 176.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.43 24.31 7.17 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.793 -0.718 . . . . 0.0 113.028 176.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.718 ' HZ ' ' H ' ' A' ' 29' ' ' GLY . 10.0 m-30 -82.37 158.88 23.18 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 117.062 0.431 . . . . 0.0 110.113 178.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 97.37 8.03 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 173.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -104.92 132.88 50.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-O 121.695 0.759 . . . . 0.0 110.469 -177.02 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.594 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 4.5 m-80 -124.37 -138.1 0.29 Allowed 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 170.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 109' ' ' ASN . 10.1 p80 -153.37 83.85 1.19 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.601 0.715 . . . . 0.0 111.407 170.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 86.4 m -162.11 99.19 1.16 Allowed Pre-proline 0 C--N 1.323 -0.575 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.168 178.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.407 ' HG2' HG21 ' A' ' 81' ' ' VAL . 18.3 Cg_endo -57.95 153.25 45.72 Favored 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.496 2.131 . . . . 0.0 112.954 -178.455 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 10.7 p -157.42 161.73 38.97 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.481 -175.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -64.66 112.15 3.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.677 0.275 . . . . 0.0 110.526 -175.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 104.27 -1.97 43.56 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.603 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -101.34 -159.5 0.74 Allowed 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 120.604 0.24 . . . . 0.0 110.638 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 59' ' ' LEU . 2.0 mp -135.68 174.25 12.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.409 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 -177.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.706 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -115.55 167.32 11.0 Favored 'General case' 0 C--N 1.326 -0.448 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.551 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.5 tp60 -167.01 129.8 1.77 Allowed 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.295 0.569 . . . . 0.0 111.811 178.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.771 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 14.4 t -111.7 -24.09 10.26 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.817 177.857 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 41.5 m 72.09 -27.75 0.18 Allowed 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 123.461 0.704 . . . . 0.0 111.337 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.456 ' H ' ' C ' ' A' ' 61' ' ' SER . 5.4 mm-40 -82.5 152.76 25.92 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 176.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 118.21 162.73 12.4 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.249 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 16.9 Cg_endo -58.25 -54.52 3.0 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 123.029 2.486 . . . . 0.0 112.132 -179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -99.03 -6.25 28.86 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.779 175.023 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 103.35 -157.8 17.57 Favored Glycine 0 N--CA 1.449 -0.488 0 N-CA-C 111.186 -0.765 . . . . 0.0 111.186 -172.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.771 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 34.6 m80 -150.26 84.48 1.38 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 117.204 0.502 . . . . 0.0 111.255 178.255 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.699 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.7 m -116.79 110.21 30.59 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 CA-C-O 122.087 0.946 . . . . 0.0 110.939 172.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.432 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -111.31 133.13 53.86 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.684 -1.143 . . . . 0.0 109.286 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.439 ' HB2' HG22 ' A' ' 20' ' ' VAL . 29.7 t80 -70.99 128.02 34.56 Favored 'General case' 0 C--N 1.315 -0.921 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 -177.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 21.8 t -82.06 108.72 15.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.414 -176.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.437 ' OE1' ' HE2' ' A' ' 71' ' ' TYR . 8.2 mm-40 -71.08 -30.48 66.62 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.245 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 23.0 t 175.1 160.14 0.21 Allowed 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.391 -176.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.585 HG23 HG22 ' A' ' 81' ' ' VAL . 6.2 p -113.75 121.29 65.63 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 39.9 m-80 -73.96 157.07 36.88 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.89 -172.589 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 2.9 p -66.95 -13.49 61.86 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.892 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -86.8 -1.94 58.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.943 0.402 . . . . 0.0 111.0 178.196 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 96.58 -18.41 57.54 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.894 -179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 13.7 m -73.74 141.56 46.33 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.941 0.401 . . . . 0.0 110.285 178.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.69 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 94.3 t -108.97 128.54 64.75 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.075 -175.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 51.7 m -92.61 112.95 25.09 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.086 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.57 HD13 HD22 ' A' ' 59' ' ' LEU . 39.0 pt -114.46 152.18 16.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 -178.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 17.7 t -132.27 113.55 13.37 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.121 179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.432 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 16.2 pt-20 -131.31 130.98 43.44 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.815 176.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.899 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 20.9 tpp -91.36 136.5 33.06 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.564 -176.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.43 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 7.5 t30 69.06 -65.48 0.29 Allowed 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 123.583 0.753 . . . . 0.0 112.504 172.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.723 ' HA ' ' SG ' ' A' ' 16' ' ' CYS . 26.2 t80 65.09 -83.0 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 O-C-N 123.489 0.493 . . . . 0.0 110.776 -172.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 53.9 m -158.35 89.01 0.96 Allowed 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 116.152 -0.476 . . . . 0.0 109.797 -179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 153.23 -97.2 0.17 Allowed Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.15 -1.024 . . . . 0.0 112.761 179.129 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -76.09 115.44 4.48 Favored Glycine 0 N--CA 1.447 -0.593 0 C-N-CA 121.179 -0.534 . . . . 0.0 112.319 -177.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.43 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 34.3 Cg_exo -60.85 119.07 6.04 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.861 2.374 . . . . 0.0 112.066 -178.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.507 ' HA ' ' HG3' ' A' ' 86' ' ' MET . 96.5 m-85 66.01 17.98 10.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.376 -0.829 . . . . 0.0 111.985 -177.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.5 m -78.14 83.93 4.4 Favored 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 169.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.899 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 1.7 p -56.43 106.59 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.322 175.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 16.2 m -81.76 103.19 11.27 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.652 -171.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 7.5 m -68.83 113.57 6.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.474 178.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.409 ' HD3' ' OE2' ' A' ' 85' ' ' GLU . 67.1 mtp180 -126.31 158.71 35.1 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 120.912 0.387 . . . . 0.0 110.617 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 18.0 m -132.17 118.62 19.8 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.702 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.69 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 48.3 mm -96.12 119.89 44.78 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.243 -176.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 39.8 t -74.4 150.17 40.14 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 172.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -52.54 -34.81 51.75 Favored 'General case' 0 C--O 1.234 0.263 0 N-CA-C 111.714 0.264 . . . . 0.0 111.714 -179.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 39.2 m -57.37 -42.76 82.75 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.094 179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -83.48 -31.88 26.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.948 0.404 . . . . 0.0 110.498 178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -59.31 -23.65 62.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.781 177.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.48 -30.55 76.75 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.71 -0.677 . . . . 0.0 113.612 176.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -101.96 -6.62 23.24 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 117.849 0.825 . . . . 0.0 111.771 -176.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.44 ' HA ' ' O ' ' A' ' 60' ' ' GLN . 26.8 m-85 -84.76 119.25 25.07 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.992 0.425 . . . . 0.0 111.62 -177.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' HIS . 3.6 m-20 -78.29 167.05 21.96 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.871 179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.594 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -153.86 151.76 29.87 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 175.274 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.706 HG12 ' CZ3' ' A' ' 38' ' ' TRP . 34.8 pt -121.1 118.87 57.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 CA-C-O 121.606 0.717 . . . . 0.0 110.501 -175.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 29.7 p80 -137.3 150.53 47.85 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.341 178.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.877 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 C--O 1.251 1.17 0 CA-C-O 118.406 -0.807 . . . . 0.0 109.766 175.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.803 0 N-CA-C 112.153 -0.379 . . . . 0.0 112.153 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.9 t -149.71 161.86 41.38 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 -179.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.2 t -122.32 84.43 2.26 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.222 0.534 . . . . 0.0 110.192 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 65.5 mt -97.38 111.65 27.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.803 177.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.1 p -139.33 -58.61 0.59 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.204 0.526 . . . . 0.0 109.692 -177.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.7 t-80 -126.45 86.84 2.57 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.05 172.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 35.5 m -134.38 94.78 3.27 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.976 179.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -73.57 170.22 52.77 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.884 -0.598 . . . . 0.0 113.417 -174.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.567 ' ND2' ' HB3' ' A' ' 21' ' ' TYR . 54.2 t-20 -79.91 145.45 32.66 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.156 -179.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 49.1 mt -69.63 -22.71 63.46 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.689 178.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.541 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.2 OUTLIER -67.43 -175.93 0.54 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.122 -174.903 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 7.5 m -65.9 -90.31 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.237 -173.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.414 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.68 124.44 0.13 Allowed 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.069 -177.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.52 -5.49 10.62 Favored Glycine 0 C--O 1.223 -0.589 0 C-N-CA 121.446 -0.407 . . . . 0.0 113.801 175.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.43 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 14.7 mm-40 -63.86 159.64 19.23 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 117.122 0.461 . . . . 0.0 111.473 -174.148 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.506 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 9.9 p -58.31 -49.64 76.44 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.139 178.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.2 p -79.41 -1.17 35.97 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.431 0.634 . . . . 0.0 110.928 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.541 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 82.8 t90 -93.89 -50.15 5.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.42 175.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -65.18 -43.13 92.69 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.506 -179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.86 HG13 HG12 ' A' ' 58' ' ' ILE . 38.6 t -52.98 -51.36 38.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 115.89 -0.595 . . . . 0.0 111.211 175.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.567 ' HB3' ' ND2' ' A' ' 9' ' ' ASN . 55.0 t80 -67.55 -31.27 71.24 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.809 -176.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -67.59 -46.1 73.59 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.363 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.5 mmmt -67.2 -32.2 73.11 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.967 -177.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.4 HG22 ' HA ' ' A' ' 21' ' ' TYR . 34.7 m -82.83 -3.94 7.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.93 0.395 . . . . 0.0 110.841 178.112 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.05 16.8 76.81 Favored Glycine 0 C--N 1.33 0.224 0 CA-C-N 115.989 -0.55 . . . . 0.0 113.165 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.5 5.87 89.62 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.578 -0.82 . . . . 0.0 112.591 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -62.37 -37.89 87.46 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.531 0.682 . . . . 0.0 109.915 177.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.794 ' HB ' HD11 ' A' ' 113' ' ' ILE . 0.1 OUTLIER -136.15 138.07 47.65 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.48 -179.69 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 127.06 -152.63 18.71 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 119.942 -1.123 . . . . 0.0 114.373 168.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.4 p 71.21 -44.73 0.6 Allowed 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.216 1.406 . . . . 0.0 112.079 179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 17.2 p -94.97 11.3 32.38 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.801 0.297 . . . . 0.0 111.801 -177.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.56 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.6 OUTLIER -86.4 -6.42 58.93 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 111.923 0.342 . . . . 0.0 111.923 -178.001 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 82.64 -125.19 6.84 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.116 -178.128 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -111.87 179.65 3.95 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -56.8 -46.54 81.53 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -173.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.533 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 60.6 t30 -69.26 -19.36 63.93 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.163 0.506 . . . . 0.0 111.591 -176.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.441 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 13.4 t30 -101.29 6.58 42.89 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.257 0.551 . . . . 0.0 110.133 -177.395 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.607 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.4 OUTLIER -54.87 -66.44 0.4 Allowed 'General case' 0 CA--C 1.515 -0.378 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.922 -175.082 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.5 -24.9 61.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.854 0.359 . . . . 0.0 111.176 -172.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -76.38 -56.06 4.98 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.084 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.498 ' HB3' ' HA ' ' A' ' 32' ' ' TRP . . . -72.11 -36.03 69.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.645 -176.046 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -57.21 -38.35 73.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.879 0.371 . . . . 0.0 110.514 177.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.507 ' NE2' HG13 ' A' ' 49' ' ' VAL . 16.2 mm-40 -62.8 -46.22 88.99 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.426 177.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.17 -31.86 72.23 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.22 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -71.62 -16.71 62.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.025 0.44 . . . . 0.0 110.909 177.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 96.34 36.51 5.12 Favored Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.959 176.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.679 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.6 m-30 -103.99 149.89 24.74 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 175.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 7.5 m -90.7 113.02 25.01 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 175.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.73 HG12 HG22 ' A' ' 111' ' ' ILE . 0.9 OUTLIER -98.16 124.48 51.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.148 -179.869 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 1.039 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 7.6 m-20 -124.37 -143.77 0.32 Allowed 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 172.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 2.1 p-80 -158.79 88.01 0.89 Allowed 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.552 0.691 . . . . 0.0 111.776 171.237 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.431 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 76.2 m -160.77 95.08 1.46 Allowed Pre-proline 0 C--N 1.325 -0.457 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.522 177.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.457 ' CG ' ' HB1' ' A' ' 105' ' ' ALA . 11.3 Cg_endo -52.66 142.15 51.19 Favored 'Trans proline' 0 C--N 1.345 0.374 0 C-N-CA 123.12 2.547 . . . . 0.0 113.078 -178.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 75.0 m -162.14 154.17 19.04 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 -175.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 74' ' ' SER . 20.6 pttm -63.67 138.98 58.72 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.078 0.466 . . . . 0.0 109.936 -178.175 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 88.48 -15.4 56.89 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.127 -177.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -98.28 -178.05 3.91 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.86 HG12 HG13 ' A' ' 20' ' ' VAL . 4.1 mp -135.37 147.49 28.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-O 120.66 0.267 . . . . 0.0 110.693 -176.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.497 ' O ' ' HA ' ' A' ' 69' ' ' VAL . 8.7 tp -89.59 164.58 14.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.689 -178.263 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.55 ' HB3' ' O ' ' A' ' 109' ' ' ASN . 4.4 tp60 -151.55 139.04 19.52 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.955 0.407 . . . . 0.0 111.082 178.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.467 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 31.7 t -157.24 135.82 11.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.386 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 9.9 m -97.28 93.17 6.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.806 -0.442 . . . . 0.0 109.806 177.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.3 mt-10 -99.48 -0.7 40.2 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -176.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 124.87 -72.16 0.44 Allowed Glycine 0 CA--C 1.523 0.565 0 C-N-CA 120.175 -1.012 . . . . 0.0 114.589 177.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -49.69 -66.79 0.12 Allowed 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.343 2.696 . . . . 0.0 113.784 -169.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.471 ' C ' ' HB2' ' A' ' 36' ' ' ASN . 2.1 p90 -154.04 14.53 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.702 -176.21 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.533 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 97.32 173.9 34.13 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.848 -0.691 . . . . 0.0 112.049 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.663 ' HA ' ' HE1' ' A' ' 88' ' ' TYR . 3.5 t-160 -141.56 94.0 2.63 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -175.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.607 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.4 m -116.12 118.54 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 CA-C-O 121.862 0.839 . . . . 0.0 110.869 175.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 85' ' ' GLU . . . -120.75 125.95 48.92 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 114.806 -1.088 . . . . 0.0 109.772 -178.545 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.482 ' HB2' HG22 ' A' ' 20' ' ' VAL . 56.8 t80 -70.56 125.27 26.35 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.49 HG22 HG22 ' A' ' 83' ' ' ILE . 17.4 t -84.12 120.42 34.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.629 -174.445 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -88.62 -26.38 21.94 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.976 -178.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 55' ' ' LYS . 22.6 p -179.34 155.66 0.71 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.545 -0.298 . . . . 0.0 111.145 -177.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.447 HG23 HG22 ' A' ' 81' ' ' VAL . 4.7 p -110.94 121.89 64.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 170.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -75.77 157.58 33.3 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.906 -172.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 23.2 t -75.17 -7.23 53.24 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.332 0.587 . . . . 0.0 109.738 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -85.69 -1.57 57.31 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.413 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 84.44 5.4 87.01 Favored Glycine 0 C--N 1.331 0.283 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.811 -178.018 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 8.6 p -98.53 146.19 26.04 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.818 ' HB ' ' HB ' ' A' ' 100' ' ' ILE . 67.9 t -109.82 126.76 67.0 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-O 121.068 0.461 . . . . 0.0 111.134 -177.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 88.8 m -92.82 106.97 18.85 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.169 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.592 HD11 ' HB2' ' A' ' 98' ' ' ARG . 26.9 pt -110.96 150.36 13.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.726 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.3 t -125.02 98.84 5.86 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.818 -178.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.488 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 10.6 pt-20 -112.93 107.21 15.69 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.657 -0.702 . . . . 0.0 110.278 177.19 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 1.058 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 48.9 ttm -80.09 132.13 35.89 Favored 'General case' 0 C--N 1.32 -0.692 0 O-C-N 122.146 -0.347 . . . . 0.0 110.456 -177.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.76 ' OD1' ' HA ' ' A' ' 92' ' ' PRO . 5.6 t30 70.63 -63.16 0.42 Allowed 'General case' 0 N--CA 1.471 0.607 0 O-C-N 124.114 0.884 . . . . 0.0 111.802 175.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.663 ' HE1' ' HA ' ' A' ' 68' ' ' HIS . 39.5 t80 64.98 -83.59 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.139 0 O-C-N 123.93 0.769 . . . . 0.0 109.671 -175.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.4 m -169.01 36.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.766 0.826 . . . . 0.0 108.977 175.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -124.73 -88.29 0.77 Allowed Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.602 -176.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -98.36 126.64 8.96 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 120.558 -0.83 . . . . 0.0 111.069 175.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.76 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 72.0 Cg_exo -52.01 113.33 1.13 Allowed 'Trans proline' 0 C--O 1.235 0.349 0 C-N-CA 122.694 2.262 . . . . 0.0 112.438 178.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 82.9 m-85 68.48 10.56 7.94 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.036 -0.984 . . . . 0.0 112.354 -178.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.1 m -72.33 89.43 1.22 Allowed 'General case' 0 CA--C 1.51 -0.585 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 172.699 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 1.058 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.1 p -62.02 98.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.666 177.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.488 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 48.1 m -75.04 111.06 9.87 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.712 -0.677 . . . . 0.0 111.039 -173.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.4 m -82.95 91.98 7.24 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.359 177.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.592 ' HB2' HD11 ' A' ' 83' ' ' ILE . 34.7 mmt180 -91.63 163.49 14.09 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 50.7 m -133.4 105.83 7.16 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.118 0.485 . . . . 0.0 110.077 179.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.818 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 42.6 mm -83.38 129.45 37.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.281 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 t -82.3 142.08 32.37 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.536 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -54.61 -29.09 50.84 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -175.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.2 m -58.95 -42.04 88.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.289 179.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -88.48 -21.17 24.33 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.705 0.288 . . . . 0.0 110.332 176.833 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -60.82 -35.72 77.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.012 178.716 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -67.27 -17.72 68.57 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.605 176.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -87.59 -35.96 17.8 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.456 . . . . 0.0 110.669 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.42 ' CD2' HD21 ' A' ' 59' ' ' LEU . 26.2 m-85 -74.65 118.25 17.4 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.778 -173.381 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.56 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 63.6 m-80 -78.35 148.32 33.79 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.086 179.245 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 1.039 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.1 OUTLIER -136.43 151.43 49.49 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.934 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.73 HG22 HG12 ' A' ' 49' ' ' VAL . 20.8 pt -108.81 134.52 50.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.189 0.518 . . . . 0.0 111.339 -174.297 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -116.6 148.29 41.06 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.837 -175.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.794 HD11 ' HB ' ' A' ' 28' ' ' ILE . 36.8 mm . . . . . 0 C--O 1.247 0.932 0 CA-C-O 118.544 -0.741 . . . . 0.0 109.585 171.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 112.13 -0.388 . . . . 0.0 112.13 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 m -72.34 115.42 11.56 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 178.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 22.6 t -102.35 91.13 4.13 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.006 0.431 . . . . 0.0 110.282 -179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 51.2 mm -111.45 -42.14 4.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.8 178.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.4 t 72.31 152.75 0.12 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.313 179.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 m80 62.7 17.26 9.63 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.936 175.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 47.4 m 61.21 20.17 10.74 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.118 -177.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.11 -148.25 18.05 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.836 -0.697 . . . . 0.0 111.604 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.68 HD22 ' HA ' ' A' ' 18' ' ' TRP . 58.1 t30 -128.12 6.23 5.92 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.475 0.655 . . . . 0.0 110.939 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 31.6 mt 62.69 1.31 0.77 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 115.242 -0.89 . . . . 0.0 112.599 179.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.564 ' HD1' ' HG3' ' A' ' 15' ' ' GLN . 0.2 OUTLIER -102.06 174.42 5.94 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-O 121.349 0.595 . . . . 0.0 111.643 -172.571 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.658 ' HB ' ' HG2' ' A' ' 15' ' ' GLN . 2.0 m -75.16 146.33 41.38 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 114.843 -1.072 . . . . 0.0 110.429 -176.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -54.43 111.54 0.81 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.895 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 76.06 44.43 18.67 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.934 -0.651 . . . . 0.0 113.085 176.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.658 ' HG2' ' HB ' ' A' ' 12' ' ' THR . 18.3 mm-40 -90.08 160.34 16.36 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.637 0.218 . . . . 0.0 110.675 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.741 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 6.0 p -56.47 -52.2 65.58 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.023 0.44 . . . . 0.0 110.866 176.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.406 ' O ' ' HZ2' ' A' ' 32' ' ' TRP . 18.1 p -73.61 -21.22 60.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.484 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.68 ' HA ' HD22 ' A' ' 9' ' ' ASN . 87.4 t90 -74.01 -48.42 30.31 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.368 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.591 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 53.8 t80 -63.9 -37.86 88.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.325 -175.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.429 ' CG1' HD12 ' A' ' 58' ' ' ILE . 72.1 t -57.76 -42.41 81.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.972 177.797 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.432 ' CZ ' ' HA2' ' A' ' 26' ' ' GLY . 33.2 t80 -69.95 -36.36 75.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.196 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -63.77 -46.58 84.6 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.586 175.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -64.38 -35.19 80.1 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.923 -0.58 . . . . 0.0 112.16 -178.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.422 HG21 HD13 ' A' ' 28' ' ' ILE . 32.9 m -83.34 -5.32 9.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 120.569 -0.452 . . . . 0.0 110.914 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 67.5 39.32 91.12 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.493 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' CZ ' ' A' ' 21' ' ' TYR . . . 67.66 18.0 69.65 Favored Glycine 0 CA--C 1.518 0.259 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.874 179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 34.2 tt0 -65.81 -48.94 70.03 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.524 0.202 . . . . 0.0 111.293 -177.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -131.81 144.77 36.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.328 178.724 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.492 ' HA3' ' CZ3' ' A' ' 32' ' ' TRP . . . 116.95 -137.98 13.93 Favored Glycine 0 N--CA 1.445 -0.704 0 C-N-CA 119.957 -1.116 . . . . 0.0 114.967 165.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 96.8 p 63.98 -43.2 0.26 Allowed 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.663 1.585 . . . . 0.0 112.196 -173.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 10.6 t -91.8 12.16 22.36 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.876 0.37 . . . . 0.0 110.905 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.597 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -85.05 -6.09 59.33 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.871 0.367 . . . . 0.0 111.469 -178.215 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 79.73 -115.81 4.16 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.932 -1.128 . . . . 0.0 111.836 -176.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -126.85 170.56 12.08 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HB1' HG13 ' A' ' 69' ' ' VAL . . . -50.57 -49.09 57.09 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 113.016 0.747 . . . . 0.0 113.016 -171.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.449 ' N ' ' HA3' ' A' ' 67' ' ' GLY . 27.3 t-20 -52.91 -34.09 53.51 Favored 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 122.92 0.488 . . . . 0.0 112.246 -179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.421 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.6 t30 -101.12 7.78 43.09 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.964 0.412 . . . . 0.0 110.797 -173.894 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.807 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.4 OUTLIER -51.81 -62.86 1.37 Allowed 'General case' 0 C--O 1.222 -0.367 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -175.465 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -54.22 -37.29 64.43 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 111.638 0.236 . . . . 0.0 111.638 -174.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.56 -53.43 18.99 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.828 0.347 . . . . 0.0 111.305 178.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.597 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -66.43 -41.91 88.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.344 -177.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.95 79.59 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.609 179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.498 ' HG3' HG21 ' A' ' 49' ' ' VAL . 76.3 mt-30 -61.5 -45.4 94.38 Favored 'General case' 0 C--O 1.232 0.154 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.828 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.15 -35.09 91.02 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.913 -0.66 . . . . 0.0 112.39 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -74.83 -14.13 60.65 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.636 0.255 . . . . 0.0 111.335 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 105.3 13.46 24.65 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.643 -0.789 . . . . 0.0 113.045 175.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.654 ' HD2' HD12 ' A' ' 111' ' ' ILE . 4.4 m-30 -76.99 153.01 34.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.032 0.444 . . . . 0.0 109.957 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 27.9 m -88.95 103.16 15.78 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 174.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.831 HG22 HG22 ' A' ' 111' ' ' ILE . 59.5 t -98.6 115.37 38.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-O 121.063 0.459 . . . . 0.0 111.086 -175.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 31.0 m-20 -123.71 -150.8 0.46 Allowed 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 175.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.437 ' HB3' ' OD1' ' A' ' 109' ' ' ASN . 0.5 OUTLIER -154.2 73.74 0.94 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-O 122.075 0.94 . . . . 0.0 111.401 175.711 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 74.1 m -157.57 95.82 2.04 Favored Pre-proline 0 C--N 1.318 -0.777 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.318 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.591 ' HG2' HG21 ' A' ' 81' ' ' VAL . 36.3 Cg_endo -64.46 149.11 90.59 Favored 'Trans proline' 0 CA--C 1.53 0.311 0 C-N-CA 122.391 2.061 . . . . 0.0 113.262 -178.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.525 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 23.2 t -167.62 172.12 9.65 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -53.14 115.28 1.8 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.782 0.325 . . . . 0.0 111.268 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 98.61 -2.87 58.99 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.341 177.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.571 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -92.13 -171.84 2.95 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 177.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.807 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.3 OUTLIER -133.08 -171.99 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.4 179.873 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.621 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.3 tp -132.75 166.87 21.23 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.468 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 4.9 tp60 -159.62 134.71 8.1 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.149 0.499 . . . . 0.0 112.097 179.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.64 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 33.2 t -134.23 138.97 45.46 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 171.096 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -71.81 -19.94 61.92 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 120.734 0.302 . . . . 0.0 111.771 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -102.56 -176.45 3.11 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.088 0.47 . . . . 0.0 111.937 -174.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 116.1 -161.66 12.86 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 -176.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.35 -29.21 6.37 Favored 'Trans proline' 0 N--CA 1.462 -0.331 0 C-N-CA 122.194 1.929 . . . . 0.0 111.199 177.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.1 p90 -168.06 33.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.776 -1.102 . . . . 0.0 109.476 177.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.449 ' HA3' ' N ' ' A' ' 36' ' ' ASN . . . 108.02 177.58 22.17 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.332 178.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.64 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 6.3 t-160 -145.28 96.03 2.77 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 110.636 -0.135 . . . . 0.0 110.636 -179.802 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.66 HG11 ' CD2' ' A' ' 38' ' ' TRP . 34.9 m -118.37 122.74 70.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.519 0.676 . . . . 0.0 111.12 174.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.489 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -123.42 132.42 53.95 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.07 -178.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -73.35 132.36 42.96 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 121.075 0.464 . . . . 0.0 110.612 -177.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 35.4 t -89.82 123.38 41.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.07 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -94.62 -30.75 14.18 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.73 177.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 35.8 p -176.49 147.38 0.66 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.833 0.349 . . . . 0.0 111.502 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.548 HG23 HG22 ' A' ' 81' ' ' VAL . 7.3 p -95.71 133.05 38.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 169.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 46.0 m-20 -86.01 170.83 11.91 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 120.93 0.395 . . . . 0.0 110.731 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.2 p -73.21 -10.2 59.51 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.039 -178.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -88.44 -0.28 57.03 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.932 0.396 . . . . 0.0 110.712 178.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.53 -20.68 36.68 Favored Glycine 0 N--CA 1.45 -0.419 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -175.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.532 ' HB3' HG22 ' A' ' 99' ' ' THR . 15.6 m -70.91 145.82 49.93 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.327 177.847 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.591 HG21 ' HG2' ' A' ' 53' ' ' PRO . 60.4 t -111.18 129.72 65.96 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 120.935 0.398 . . . . 0.0 111.4 -175.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 90.6 m -89.45 114.07 25.51 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.053 178.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.476 HD13 HD22 ' A' ' 59' ' ' LEU . 36.3 pt -120.75 150.25 23.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.517 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 31.2 t -133.23 102.44 5.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.615 0.722 . . . . 0.0 110.138 176.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.827 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 17.0 pt-20 -107.56 161.52 14.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 172.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.626 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.2 ttm -120.83 139.18 53.52 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.501 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 0.0 OUTLIER 72.79 -69.56 0.19 Allowed 'General case' 0 C--N 1.325 -0.489 0 O-C-N 123.507 0.505 . . . . 0.0 111.114 -179.558 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.741 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.0 t80 60.62 -71.33 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 O-C-N 123.497 0.498 . . . . 0.0 111.55 -173.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.6 m -152.42 144.4 23.75 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.485 -177.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.82 -76.09 0.47 Allowed Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.765 174.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -126.9 163.16 20.89 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.199 -177.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.501 ' HA ' ' HB2' ' A' ' 87' ' ' ASN . 3.0 Cg_exo -81.81 143.98 13.51 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.025 2.484 . . . . 0.0 112.147 176.832 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.599 ' HA ' ' CG ' ' A' ' 86' ' ' MET . 94.1 m-85 72.93 2.2 4.29 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 175.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.424 ' OG ' ' HA ' ' A' ' 87' ' ' ASN . 2.9 p -70.14 89.12 0.62 Allowed 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.502 173.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 2.7 t -61.02 102.05 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -177.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.827 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 28.5 t -75.16 87.44 2.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-O 121.672 0.748 . . . . 0.0 109.875 -177.238 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.8 m -78.58 104.47 9.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.429 178.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 75.2 mtt180 -123.33 157.87 32.29 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.164 0.507 . . . . 0.0 110.853 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.532 HG22 ' HB3' ' A' ' 80' ' ' SER . 20.0 m -124.21 109.34 13.29 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.256 174.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.481 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 47.7 mm -74.88 128.87 37.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.377 -173.768 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 m -71.61 138.16 48.5 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 174.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.45 -35.51 29.15 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 9.6 m -53.75 -45.15 70.48 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.235 178.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -92.77 -15.19 26.89 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.481 -0.327 . . . . 0.0 111.092 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -64.63 -35.35 80.72 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.995 0.426 . . . . 0.0 110.302 177.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -74.56 -11.54 82.77 Favored Glycine 0 CA--C 1.519 0.316 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.514 176.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 4.6 t30 -93.05 -51.88 4.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.863 0.363 . . . . 0.0 110.629 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 20.9 m-85 -59.79 130.68 47.96 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.601 -0.727 . . . . 0.0 112.063 -173.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.437 ' OD1' ' HB3' ' A' ' 51' ' ' HIS . 87.3 m-20 -78.62 159.57 28.0 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.569 -179.176 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.713 ' CE1' ' HB2' ' A' ' 50' ' ' ASN . 3.7 p90 -149.95 158.62 44.34 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 174.377 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.831 HG22 HG22 ' A' ' 49' ' ' VAL . 36.5 pt -126.61 131.72 70.94 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.213 -174.117 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 16.5 p80 -140.44 137.54 34.01 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 176.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 8.8 pt . . . . . 0 C--O 1.25 1.112 0 CA-C-O 118.559 -0.734 . . . . 0.0 111.396 -176.776 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.4 m -70.7 -24.79 62.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.028 0.442 . . . . 0.0 110.626 -179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.1 t -143.93 99.68 3.44 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.65 176.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 7.5 tt -151.0 -42.11 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.872 179.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.2 m -95.08 -131.66 0.16 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.262 173.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -66.99 116.91 8.35 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 176.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.555 ' O ' ' HA3' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -58.31 131.47 50.75 Favored 'General case' 0 C--N 1.327 -0.41 0 O-C-N 123.215 0.322 . . . . 0.0 111.269 -177.888 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -56.58 -71.18 0.78 Allowed Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.994 -174.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.488 ' HA ' ' CD2' ' A' ' 21' ' ' TYR . 2.0 t30 -158.79 129.67 6.17 Favored 'General case' 0 C--N 1.323 -0.56 0 C-N-CA 120.967 -0.293 . . . . 0.0 110.512 176.498 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.8 mt -103.04 -40.93 6.28 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -173.111 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.8 t80 -69.91 -179.28 1.81 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.237 0.458 . . . . 0.0 112.237 -167.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.408 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 1.3 m -49.56 -98.17 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.686 1.194 . . . . 0.0 113.579 -172.272 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.408 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -177.56 128.75 0.15 Allowed 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 116.088 -0.506 . . . . 0.0 109.789 -177.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 72.96 -6.71 11.84 Favored Glycine 0 C--O 1.224 -0.505 0 C-N-CA 121.272 -0.489 . . . . 0.0 113.458 177.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.524 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 16.4 mm-40 -66.14 162.18 20.28 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.844 0.322 . . . . 0.0 111.202 -176.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.428 ' O ' HG23 ' A' ' 20' ' ' VAL . 3.5 p -64.81 -46.53 81.62 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.969 0.414 . . . . 0.0 110.092 178.2 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.453 HG22 HG21 ' A' ' 69' ' ' VAL . 44.4 p -71.54 -21.33 61.91 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.116 178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.524 ' HB2' ' HB2' ' A' ' 15' ' ' GLN . 84.3 t90 -75.94 -50.38 15.13 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.262 178.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.457 ' HB2' ' HB2' ' A' ' 86' ' ' MET . 83.0 t80 -60.81 -41.04 94.93 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-O 121.017 0.436 . . . . 0.0 110.432 179.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.707 HG13 HG12 ' A' ' 58' ' ' ILE . 46.2 t -56.13 -47.66 80.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.779 177.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.488 ' CD2' ' HA ' ' A' ' 9' ' ' ASN . 26.7 t80 -66.43 -36.63 83.29 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.237 -174.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -68.98 -38.05 79.11 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.955 0.407 . . . . 0.0 111.254 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 30.0 mmmt -72.46 -32.12 65.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.67 -178.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.598 HG21 HD13 ' A' ' 28' ' ' ILE . 34.3 m -84.18 2.94 3.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 120.789 0.328 . . . . 0.0 111.4 179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.34 26.6 73.95 Favored Glycine 0 N--CA 1.452 -0.284 0 CA-C-N 116.084 -0.507 . . . . 0.0 112.833 176.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.555 ' HA3' ' O ' ' A' ' 7' ' ' SER . . . 64.81 33.9 88.47 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 121.038 -0.601 . . . . 0.0 112.839 -179.16 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -83.49 -64.17 1.22 Allowed 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.691 0.281 . . . . 0.0 111.683 -177.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.644 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -98.91 152.34 4.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-O 121.314 0.578 . . . . 0.0 112.168 -169.61 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.841 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 85.55 -79.67 1.87 Allowed Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.27 -0.877 . . . . 0.0 113.611 168.28 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 21.5 p 58.18 -49.8 0.05 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 125.354 1.462 . . . . 0.0 113.476 -174.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 14.9 t -121.54 27.05 8.46 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.095 0.474 . . . . 0.0 110.3 -177.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.841 ' CE3' ' HA3' ' A' ' 29' ' ' GLY . 0.7 OUTLIER -65.89 -16.38 63.8 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.293 -178.086 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.428 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 89.34 -110.75 3.75 Favored Glycine 0 N--CA 1.441 -1.027 0 C-N-CA 119.902 -1.142 . . . . 0.0 112.564 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -124.44 179.08 5.07 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 120.851 0.358 . . . . 0.0 110.117 179.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.699 ' HB2' HG22 ' A' ' 69' ' ' VAL . . . -69.35 -43.8 72.89 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 29.6 p30 -70.26 -5.35 27.05 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.904 0.383 . . . . 0.0 111.557 -176.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -118.89 4.45 11.47 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.591 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.651 ' CD2' HG11 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -52.83 -63.97 0.97 Allowed 'General case' 0 CA--C 1.509 -0.616 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.161 -174.018 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.505 ' HB1' HG21 ' A' ' 49' ' ' VAL . . . -46.04 -45.61 16.15 Favored 'General case' 0 C--N 1.326 -0.424 0 O-C-N 123.704 0.627 . . . . 0.0 111.69 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.08 -39.67 82.86 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.5 -0.318 . . . . 0.0 111.663 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.65 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -75.72 -39.01 58.05 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 121.321 0.581 . . . . 0.0 110.346 178.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.462 ' HB1' ' CD2' ' A' ' 47' ' ' PHE . . . -58.7 -46.24 87.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.586 177.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.409 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 98.3 mt-30 -67.67 -29.26 68.5 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.524 177.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.7 -31.54 81.24 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.43 174.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -80.17 -37.08 34.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.965 0.412 . . . . 0.0 110.155 173.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.7 25.98 1.34 Allowed Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.979 176.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.675 ' CD2' HD12 ' A' ' 111' ' ' ILE . 7.3 m-30 -85.57 158.19 20.2 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.914 0.388 . . . . 0.0 110.478 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . 0.844 ' HB ' ' HB2' ' A' ' 112' ' ' HIS . 23.0 m -100.75 100.9 11.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.036 177.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.863 HG12 HG22 ' A' ' 111' ' ' ILE . 1.0 OUTLIER -92.77 126.94 45.17 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.71 -174.67 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 173.83 -38.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.176 177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.658 ' O ' ' HB3' ' A' ' 110' ' ' TYR . 6.5 t-80 -62.45 129.78 42.19 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-O 122.441 1.115 . . . . 0.0 113.309 -154.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 4.7 m -44.79 126.77 5.17 Favored Pre-proline 0 C--N 1.305 -1.355 0 CA-C-N 113.294 -1.775 . . . . 0.0 109.432 159.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.55 ' HB2' HG11 ' A' ' 81' ' ' VAL . 9.6 Cg_endo -50.89 154.57 6.89 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 123.534 2.823 . . . . 0.0 114.508 -171.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 42.1 m -160.1 171.16 19.77 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -175.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.578 ' CB ' ' HA ' ' A' ' 74' ' ' SER . 55.0 pttt -69.64 150.75 46.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.232 0.539 . . . . 0.0 111.121 -176.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 67.61 33.18 80.27 Favored Glycine 0 N--CA 1.45 -0.409 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.442 178.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -142.43 -165.86 2.13 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.345 -0.242 . . . . 0.0 110.345 -178.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.707 HG12 HG13 ' A' ' 20' ' ' VAL . 2.9 mp -136.96 152.61 28.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.178 -178.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.707 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.2 tm? -116.24 125.2 51.9 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.043 -177.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.626 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 27.5 tt0 -111.77 134.94 53.0 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 112.918 0.71 . . . . 0.0 112.918 -178.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 1.001 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 38.0 t -112.32 145.7 39.55 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 114.933 -1.03 . . . . 0.0 108.879 169.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 p -79.95 -24.53 40.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.351 -177.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -92.8 158.82 15.68 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.926 -177.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 119.51 153.07 9.21 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.565 -179.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -51.37 -50.61 13.37 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.18 2.587 . . . . 0.0 111.817 -179.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 92.2 m-85 -110.72 5.17 20.64 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.395 175.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 86.45 -172.91 45.44 Favored Glycine 0 N--CA 1.447 -0.6 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.518 -174.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 1.001 ' HB2' ' HB3' ' A' ' 61' ' ' SER . 79.1 m80 -125.62 109.27 12.44 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.834 0.317 . . . . 0.0 110.943 178.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.699 HG22 ' HB2' ' A' ' 35' ' ' ALA . 13.3 m -119.96 108.92 24.5 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-O 121.922 0.868 . . . . 0.0 110.323 162.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.719 ' HA ' ' HB3' ' A' ' 85' ' ' GLU . . . -108.92 126.14 52.76 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 114.421 -1.263 . . . . 0.0 108.893 178.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -70.17 127.56 33.24 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.452 HG22 HG22 ' A' ' 83' ' ' ILE . 11.7 t -88.78 119.6 36.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.346 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -76.3 -37.3 57.66 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.114 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.578 ' HA ' ' CB ' ' A' ' 55' ' ' LYS . 14.2 t 177.0 164.81 0.51 Allowed 'General case' 0 C--O 1.234 0.254 0 O-C-N 123.581 0.551 . . . . 0.0 110.727 -174.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 10.2 p -100.84 142.36 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 173.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 47.1 m-80 -88.41 173.83 8.48 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.928 0.394 . . . . 0.0 110.907 -176.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.6 m -69.29 -12.23 61.49 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.786 -177.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -100.72 -3.28 30.47 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 120.682 0.277 . . . . 0.0 111.339 -175.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 100.43 -17.42 56.79 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.005 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.443 ' HB2' HG22 ' A' ' 99' ' ' THR . 2.7 p -78.04 145.99 35.56 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 176.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.638 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.5 m -109.03 142.78 20.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.125 0.488 . . . . 0.0 111.645 -176.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 86.9 m -94.6 117.31 29.92 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.771 177.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.452 HG22 HG22 ' A' ' 72' ' ' VAL . 38.0 pt -120.18 160.51 20.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.775 -176.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 69.8 m -143.88 115.54 8.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.202 0.525 . . . . 0.0 110.544 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.719 ' HB3' ' HA ' ' A' ' 70' ' ' ALA . 14.2 pt-20 -123.32 114.65 20.48 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.654 174.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.577 ' SD ' ' HB ' ' A' ' 95' ' ' VAL . 0.0 OUTLIER -74.27 140.77 45.2 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.466 -0.333 . . . . 0.0 111.365 178.78 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.595 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 8.5 t30 64.04 -69.33 0.08 Allowed 'General case' 0 C--N 1.326 -0.452 0 O-C-N 124.288 0.992 . . . . 0.0 112.349 179.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.425 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 11.7 t80 62.92 -73.33 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.235 0 O-C-N 123.565 0.541 . . . . 0.0 110.387 -171.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 38.9 t -172.97 86.69 0.06 Allowed 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 165.82 -61.43 0.23 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.005 -1.093 . . . . 0.0 113.17 -178.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -138.07 126.95 3.68 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.244 -177.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -56.41 121.22 9.64 Favored 'Trans proline' 0 C--O 1.233 0.259 0 C-N-CA 122.84 2.36 . . . . 0.0 112.64 -179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 72.23 9.31 5.91 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 115.217 -0.901 . . . . 0.0 112.104 177.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.2 m -70.83 88.24 0.73 Allowed 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 173.237 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.577 ' HB ' ' SD ' ' A' ' 86' ' ' MET . 2.7 p -58.32 109.61 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.077 177.216 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.6 t -67.0 108.37 2.58 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 1.7 p -84.84 93.96 8.62 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.886 -179.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.5 ttt180 -134.62 142.27 46.85 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.798 -171.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.443 HG22 ' HB2' ' A' ' 80' ' ' SER . 16.1 m -119.75 115.4 23.83 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.119 -0.491 . . . . 0.0 109.794 177.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.638 ' HB ' HG22 ' A' ' 81' ' ' VAL . 38.3 mm -83.98 121.82 36.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.468 -177.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 22.7 t -70.28 150.75 46.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 174.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -50.22 -42.59 51.88 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -177.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 4.1 p -60.74 -50.22 74.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.88 0.371 . . . . 0.0 111.32 -178.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.505 ' HG2' ' CE2' ' A' ' 108' ' ' TYR . 27.6 tt0 -65.61 -38.66 90.09 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.815 177.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.499 ' HA ' ' HD2' ' A' ' 108' ' ' TYR . . . -59.21 -27.7 65.98 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.035 178.357 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -62.53 -24.01 65.49 Favored Glycine 0 CA--C 1.523 0.556 0 CA-C-N 115.668 -0.696 . . . . 0.0 114.558 -178.039 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -94.44 -15.81 23.94 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 118.577 1.188 . . . . 0.0 111.919 -177.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.707 ' CD2' HD11 ' A' ' 59' ' ' LEU . 35.1 m-85 -81.56 168.89 17.73 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 120.818 0.342 . . . . 0.0 111.765 -173.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -119.63 116.89 26.93 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.129 0.49 . . . . 0.0 112.01 -175.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.658 ' HB3' ' O ' ' A' ' 51' ' ' HIS . 0.0 OUTLIER -96.39 124.98 40.57 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 168.016 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.863 HG22 HG12 ' A' ' 49' ' ' VAL . 26.3 pt -92.93 109.55 21.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-O 121.499 0.666 . . . . 0.0 110.594 -175.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . 0.844 ' HB2' ' HB ' ' A' ' 48' ' ' THR . 0.3 OUTLIER -71.16 143.75 50.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.066 -177.785 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 47.1 mt . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.599 176.256 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.779 0 N-CA-C 112.06 -0.416 . . . . 0.0 112.06 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.5 t -167.97 133.49 1.9 Allowed 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.5 0.191 . . . . 0.0 110.654 178.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 17.1 m 66.83 -174.58 0.19 Allowed 'General case' 0 C--O 1.233 0.23 0 O-C-N 123.862 0.727 . . . . 0.0 112.332 172.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -103.64 35.43 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.89 0.853 . . . . 0.0 108.9 179.318 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.9 m -63.85 -49.7 71.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.295 -178.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m-70 -79.87 -69.11 0.61 Allowed 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 171.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 36.9 t -177.41 158.58 1.44 Allowed 'General case' 0 N--CA 1.449 -0.512 0 CA-C-N 115.241 -0.89 . . . . 0.0 109.411 174.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.84 6.81 58.81 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 175.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 37.3 t-20 -112.19 138.38 48.95 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -178.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 84.5 mt -96.3 -8.29 33.11 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -176.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.692 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 1.9 t80 -87.14 -166.86 1.69 Allowed 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.048 -173.496 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 2.8 m -69.31 -97.58 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.293 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.916 -173.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.82 124.93 0.36 Allowed 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.066 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 63.21 19.5 61.84 Favored Glycine 0 C--O 1.224 -0.477 0 C-N-CA 121.268 -0.492 . . . . 0.0 113.144 176.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.538 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 21.0 mm-40 -82.14 162.43 22.47 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.745 0.272 . . . . 0.0 110.446 -179.72 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 1.01 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.8 p -60.61 -45.94 92.14 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.395 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.549 HG22 HG21 ' A' ' 69' ' ' VAL . 15.2 p -74.72 -31.67 61.92 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.337 0.589 . . . . 0.0 110.184 179.54 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.692 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 87.0 t90 -65.23 -48.59 72.76 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.407 -179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.606 ' CZ ' ' HD3' ' A' ' 23' ' ' LYS . 64.1 t80 -61.89 -44.9 95.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.69 -179.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 16' ' ' CYS . 87.9 t -56.63 -46.65 82.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.919 177.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.0 t80 -65.06 -33.8 76.9 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.741 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -70.58 -43.5 69.29 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.679 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.606 ' HD3' ' CZ ' ' A' ' 19' ' ' TYR . 27.1 mmmt -61.56 -40.26 94.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.571 -178.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.462 HG21 HD13 ' A' ' 28' ' ' ILE . 33.9 m -78.91 0.26 3.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.818 0.342 . . . . 0.0 111.187 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.07 31.04 64.56 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 121.276 -0.488 . . . . 0.0 112.599 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 59.54 40.65 96.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 121.131 -0.557 . . . . 0.0 112.168 -179.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -98.13 -30.25 12.77 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.517 0.198 . . . . 0.0 111.5 -175.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.462 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -132.66 141.56 44.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 C-N-CA 120.686 -0.406 . . . . 0.0 111.393 -177.18 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.555 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 63.99 72.83 0.63 Allowed Glycine 0 C--O 1.226 -0.36 0 CA-C-N 115.612 -0.722 . . . . 0.0 114.796 166.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -95.35 -5.63 42.95 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 169.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 31.1 p -121.69 12.0 10.58 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.097 -0.956 . . . . 0.0 111.627 -176.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.656 ' HA ' ' CB ' ' A' ' 41' ' ' ALA . 0.5 OUTLIER -71.14 -13.65 62.02 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-O 120.946 0.403 . . . . 0.0 111.255 -175.804 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.474 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 84.92 -115.05 4.04 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.52 -0.847 . . . . 0.0 112.317 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.517 ' HA ' HG21 ' A' ' 17' ' ' THR . 2.1 p-10 -129.4 177.44 7.18 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 178.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -52.19 -30.44 27.06 Favored 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 113.883 1.068 . . . . 0.0 113.883 -170.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.65 ' HB2' ' O ' ' A' ' 66' ' ' PHE . 23.9 t-20 -78.43 -31.42 48.12 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.426 0.632 . . . . 0.0 111.212 -176.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.477 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 9.0 t30 -100.8 9.58 42.19 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.226 -170.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.896 ' HH2' HG21 ' A' ' 58' ' ' ILE . 0.2 OUTLIER -56.57 -71.29 0.1 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.42 -0.809 . . . . 0.0 113.087 -173.639 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -51.41 -39.84 58.08 Favored 'General case' 0 C--N 1.331 -0.215 0 O-C-N 123.376 0.422 . . . . 0.0 111.239 -173.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -65.29 -54.57 27.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.583 -0.281 . . . . 0.0 111.425 179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.656 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -65.89 -38.28 88.32 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.926 0.393 . . . . 0.0 111.104 -178.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.17 -43.68 98.49 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.769 178.008 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -66.73 -36.91 83.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.5 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.1 -37.51 95.05 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.106 176.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -73.68 -32.76 64.12 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.211 0.529 . . . . 0.0 110.424 176.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 116.51 46.0 0.54 Allowed Glycine 0 N--CA 1.446 -0.642 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.003 176.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.573 ' CD2' HD12 ' A' ' 111' ' ' ILE . 5.3 m-30 -103.85 138.74 40.02 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 175.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 8.6 m -81.97 108.83 15.79 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 173.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.678 HG12 HG22 ' A' ' 111' ' ' ILE . 0.7 OUTLIER -97.61 134.21 36.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.723 0.773 . . . . 0.0 111.136 -178.728 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.93 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 18.8 m-20 -123.53 -141.4 0.31 Allowed 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 168.049 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.699 ' HB3' ' HA ' ' A' ' 109' ' ' ASN . 0.4 OUTLIER -161.45 86.01 0.66 Allowed 'General case' 0 C--N 1.315 -0.897 0 CA-C-O 121.392 0.615 . . . . 0.0 111.601 170.716 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 93.9 m -163.11 105.13 1.01 Allowed Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 115.039 -0.982 . . . . 0.0 109.621 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.66 ' HB2' HG11 ' A' ' 81' ' ' VAL . 16.4 Cg_endo -55.84 143.35 81.71 Favored 'Trans proline' 0 C--N 1.343 0.273 0 C-N-CA 122.525 2.15 . . . . 0.0 112.15 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 46.2 m -153.65 155.96 37.01 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . . . . . . . . . 3.2 ttmp? -63.69 102.67 0.47 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.521 -178.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 112.08 -0.27 26.95 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.445 -179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -107.27 -162.33 0.83 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.919 0.39 . . . . 0.0 110.725 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.896 HG21 ' HH2' ' A' ' 38' ' ' TRP . 2.1 mt -130.58 175.17 11.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.309 -174.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.65 ' H ' HG22 ' A' ' 58' ' ' ILE . 7.8 tp -131.88 142.9 49.82 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -178.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.707 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 25.9 tm0? -153.08 138.74 17.83 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-O 121.748 0.785 . . . . 0.0 112.405 -177.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.591 ' HB3' ' HB2' ' A' ' 68' ' ' HIS . 32.6 t -145.01 140.8 28.41 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.264 172.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.0 m -85.63 -13.36 48.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.652 0.263 . . . . 0.0 111.706 -176.807 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -76.45 164.64 25.79 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.589 0.233 . . . . 0.0 110.491 179.645 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 110.88 -145.3 17.45 Favored Glycine 0 N--CA 1.452 -0.291 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -81.23 -74.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.645 2.23 . . . . 0.0 109.743 175.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.65 ' O ' ' HB2' ' A' ' 36' ' ' ASN . 73.1 m-85 -86.68 -66.34 0.92 Allowed 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 164.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -175.36 -155.61 13.02 Favored Glycine 0 N--CA 1.438 -1.176 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.707 ' O ' ' HA ' ' A' ' 60' ' ' GLN . 78.4 m80 -137.28 93.88 2.87 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 119.383 -0.341 . . . . 0.0 110.465 179.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.565 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 32.7 m -115.56 120.56 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.724 0 CA-C-O 121.701 0.762 . . . . 0.0 110.628 172.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -134.65 135.65 42.26 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.365 -177.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.795 ' HE2' ' HG2' ' A' ' 73' ' ' GLU . 21.7 t80 -76.79 129.86 36.86 Favored 'General case' 0 C--N 1.314 -0.967 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.457 ' HA ' HG22 ' A' ' 83' ' ' ILE . 39.1 t -92.52 112.49 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.439 -176.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.795 ' HG2' ' HE2' ' A' ' 71' ' ' TYR . 31.2 mt-10 -85.33 -25.95 26.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.813 -177.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 26.3 t -174.24 144.15 0.93 Allowed 'General case' 0 N--CA 1.454 -0.24 0 CA-C-O 120.814 0.34 . . . . 0.0 110.999 -179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.747 HG23 HG22 ' A' ' 81' ' ' VAL . 4.0 p -109.9 124.02 66.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 169.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 42.4 m-80 -82.84 153.31 25.22 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.663 -172.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 3.4 p -67.09 -15.97 64.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.4 0.619 . . . . 0.0 110.569 178.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -63.81 -25.65 68.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.809 173.78 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 107.29 -22.59 28.79 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -174.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.513 ' HB3' ' CG2' ' A' ' 99' ' ' THR . 43.6 m -75.22 139.95 42.93 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.926 0.393 . . . . 0.0 110.056 175.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.747 HG22 HG23 ' A' ' 75' ' ' VAL . 38.2 t -108.67 130.93 60.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.786 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.918 -176.527 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 91.1 m -96.5 111.46 23.57 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.4 -178.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.695 HD13 HD11 ' A' ' 100' ' ' ILE . 44.4 pt -123.65 161.06 26.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.943 -178.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 70.2 m -135.13 115.54 13.53 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.579 0.704 . . . . 0.0 110.786 176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.646 ' HG3' ' HB2' ' A' ' 96' ' ' SER . 7.7 pt-20 -124.63 117.03 23.38 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.968 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.905 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 55.8 ttm -83.57 124.14 30.47 Favored 'General case' 0 C--N 1.324 -0.526 0 O-C-N 121.945 -0.472 . . . . 0.0 111.204 -177.763 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.412 ' O ' ' HB3' ' A' ' 88' ' ' TYR . 7.9 t30 71.16 -58.38 0.57 Allowed 'General case' 0 N--CA 1.466 0.368 0 O-C-N 124.011 0.819 . . . . 0.0 111.551 177.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 1.01 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 14.2 t80 66.64 -69.91 0.12 Allowed 'General case' 0 CA--C 1.53 0.209 0 O-C-N 123.727 0.642 . . . . 0.0 110.431 -177.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.2 t -172.86 89.2 0.08 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 176.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 159.55 -92.76 0.12 Allowed Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.701 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -88.37 115.05 4.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.894 -0.67 . . . . 0.0 112.614 -176.129 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -55.89 119.88 7.34 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.977 2.451 . . . . 0.0 112.642 -176.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 69.11 4.54 4.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.643 178.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 74.1 m -72.31 91.04 1.3 Allowed 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 173.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.905 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 3.2 p -61.64 102.98 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.88 179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.646 ' HB2' ' HG3' ' A' ' 85' ' ' GLU . 18.3 m -69.11 113.46 6.49 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.891 -174.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -76.7 116.32 17.27 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.917 174.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -131.62 163.26 28.48 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.106 0.479 . . . . 0.0 111.111 -178.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 81' ' ' VAL . 27.7 m -152.14 114.09 4.43 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 178.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.695 HD11 HD13 ' A' ' 83' ' ' ILE . 1.2 mp -92.72 134.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 C-N-CA 120.561 -0.455 . . . . 0.0 110.249 -176.25 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 20.4 p -74.02 151.15 40.31 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 170.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -48.75 -41.8 33.41 Favored 'General case' 0 N--CA 1.468 0.441 0 N-CA-C 112.608 0.596 . . . . 0.0 112.608 -174.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 38.5 m -58.89 -51.76 68.64 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.617 0.246 . . . . 0.0 111.389 -178.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 107' ' ' ASN . 30.1 tt0 -77.36 -22.93 51.0 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 120.925 0.393 . . . . 0.0 110.506 -179.112 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.435 ' HB1' ' CG ' ' A' ' 53' ' ' PRO . . . -62.09 -41.33 98.09 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.611 179.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -68.61 -7.32 53.65 Favored Glycine 0 CA--C 1.523 0.556 0 C-N-CA 120.978 -0.629 . . . . 0.0 113.084 178.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.501 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 5.5 t30 -82.36 -18.7 41.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.181 0.515 . . . . 0.0 110.612 178.595 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.501 ' CD1' ' HB2' ' A' ' 61' ' ' SER . 86.2 m-85 -95.99 133.66 39.94 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.269 -177.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.699 ' HA ' ' HB3' ' A' ' 51' ' ' HIS . 61.3 m-80 -86.66 160.77 18.77 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.307 177.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.93 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.0 OUTLIER -143.5 163.66 32.51 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 174.054 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.678 HG22 HG12 ' A' ' 49' ' ' VAL . 13.0 pt -124.33 117.16 49.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 CA-C-O 121.317 0.579 . . . . 0.0 111.146 -171.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 11.8 m-70 -94.23 142.34 27.52 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.307 -0.861 . . . . 0.0 111.603 -178.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.44 HD13 HG22 ' A' ' 28' ' ' ILE . 3.5 pt . . . . . 0 C--O 1.246 0.872 0 CA-C-O 118.459 -0.781 . . . . 0.0 110.062 173.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 112.067 -0.413 . . . . 0.0 112.067 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 23.2 p -85.0 0.24 52.1 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.709 0.29 . . . . 0.0 111.512 -178.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 19.5 m -77.61 80.38 4.09 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-O 121.227 0.537 . . . . 0.0 111.526 -177.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 27.4 pt -128.49 147.56 33.0 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.318 174.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.8 t -157.38 122.29 4.46 Favored 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.42 -176.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 50.2 m80 67.21 15.35 10.0 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.56 -0.745 . . . . 0.0 111.288 177.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 48.0 t -98.98 127.57 44.93 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -81.72 -10.6 84.03 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.611 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.653 ' ND2' ' HA ' ' A' ' 18' ' ' TRP . 38.8 t30 -116.09 153.77 31.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.966 0.412 . . . . 0.0 110.365 -178.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 73.7 mt -71.41 -20.04 62.18 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.674 -177.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.51 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -77.1 -168.95 1.2 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.844 -176.338 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.421 ' HB ' ' H ' ' A' ' 13' ' ' ALA . 5.3 m -68.2 -92.73 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 CA-C-O 120.864 0.364 . . . . 0.0 111.894 -175.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.421 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -176.17 128.31 0.22 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.905 -178.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.442 ' HA2' ' SD ' ' A' ' 86' ' ' MET . . . 58.26 29.47 63.02 Favored Glycine 0 C--O 1.226 -0.357 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.844 178.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.551 ' HB2' ' HB2' ' A' ' 18' ' ' TRP . 22.3 mm-40 -92.84 166.58 12.35 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.842 0.353 . . . . 0.0 111.432 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.698 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 1.3 p -59.03 -39.76 82.93 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.276 179.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.588 HG22 HG21 ' A' ' 69' ' ' VAL . 37.5 p -96.99 2.15 51.15 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.538 0.685 . . . . 0.0 110.322 -179.084 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.653 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 80.3 t90 -92.25 -48.64 6.58 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.514 -0.766 . . . . 0.0 109.71 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 86' ' ' MET . 78.0 t80 -58.9 -39.54 81.77 Favored 'General case' 0 N--CA 1.461 0.096 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.636 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.569 HG13 HG12 ' A' ' 58' ' ' ILE . 83.4 t -58.17 -55.15 23.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.672 179.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.42 ' CE2' ' HA2' ' A' ' 26' ' ' GLY . 38.0 t80 -65.89 -29.28 69.7 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.753 0.311 . . . . 0.0 110.767 -176.107 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -69.54 -48.49 60.21 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.847 0.356 . . . . 0.0 110.507 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.4 ' HE3' ' HB3' ' A' ' 23' ' ' LYS . 28.6 mmmt -65.12 -30.59 71.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.243 -177.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 28' ' ' ILE . 33.3 m -83.79 8.11 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.969 0.414 . . . . 0.0 111.012 179.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.21 21.81 79.41 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.938 -0.574 . . . . 0.0 112.957 175.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.42 ' HA2' ' CE2' ' A' ' 21' ' ' TYR . . . 67.99 51.47 33.94 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.102 -177.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.41 ' H ' HG23 ' A' ' 24' ' ' VAL . 11.4 tp10 -103.88 -77.86 0.57 Allowed 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.741 0.305 . . . . 0.0 111.477 -178.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.678 ' HB ' ' CZ ' ' A' ' 47' ' ' PHE . 0.2 OUTLIER -93.02 136.64 24.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 C-N-CA 120.499 -0.481 . . . . 0.0 112.134 -169.892 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.639 ' HA3' ' CE3' ' A' ' 32' ' ' TRP . . . 77.78 65.85 1.85 Allowed Glycine 0 N--CA 1.45 -0.382 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 166.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 4.4 p -80.9 -12.43 59.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.438 0.637 . . . . 0.0 110.136 171.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.6 m -136.24 32.3 2.87 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.527 -176.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.645 ' HA ' ' HB1' ' A' ' 41' ' ' ALA . 0.4 OUTLIER -78.34 -10.72 59.79 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.91 0.386 . . . . 0.0 111.639 -177.376 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.522 ' N ' ' HD1' ' A' ' 32' ' ' TRP . . . 82.05 -119.56 4.9 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.606 -0.807 . . . . 0.0 111.99 -177.387 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' HG21 ' A' ' 17' ' ' THR . 0.2 OUTLIER -128.09 -176.77 3.89 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.52 0.2 . . . . 0.0 110.567 173.599 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.522 ' O ' ' HB2' ' A' ' 38' ' ' TRP . . . -55.6 -47.68 76.11 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 114.527 1.306 . . . . 0.0 114.527 -165.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 37.3 p30 -72.05 -11.5 60.79 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.02 0.438 . . . . 0.0 111.682 -176.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.414 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 10.4 t30 -104.69 -3.52 23.58 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.3 0.572 . . . . 0.0 109.528 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.576 ' CZ3' HG12 ' A' ' 111' ' ' ILE . 0.3 OUTLIER -53.01 -66.73 0.33 Allowed 'General case' 0 C--O 1.219 -0.54 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.727 -173.357 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -52.9 -34.27 54.16 Favored 'General case' 0 C--N 1.331 -0.238 0 O-C-N 123.144 0.278 . . . . 0.0 111.601 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.58 -52.4 21.79 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.922 179.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.645 ' HB1' ' HA ' ' A' ' 32' ' ' TRP . . . -67.97 -37.66 81.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.403 0.621 . . . . 0.0 110.914 -179.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.471 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -61.49 -54.08 47.98 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.432 -179.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . . . . . . . . . 48.9 mt-30 -67.19 -26.07 66.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.501 -179.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.93 -19.55 78.34 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.848 -0.691 . . . . 0.0 111.641 174.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -95.81 0.23 51.99 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.109 0.481 . . . . 0.0 110.307 175.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 97.15 12.71 48.25 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.725 -0.75 . . . . 0.0 113.563 175.361 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.678 ' CZ ' ' HB ' ' A' ' 28' ' ' ILE . 3.2 m-30 -80.68 148.37 30.22 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 117.373 0.587 . . . . 0.0 109.953 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.6 m -104.01 130.15 51.66 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 178.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' ILE . 3.0 m -110.58 125.54 67.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.699 ' HB2' ' HE1' ' A' ' 110' ' ' TYR . 43.1 m-20 -124.57 6.44 8.24 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.642 -178.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 109' ' ' ASN . 45.7 p-80 38.61 74.77 0.08 Allowed 'General case' 0 CA--C 1.533 0.322 0 CA-C-N 114.366 -1.288 . . . . 0.0 112.851 -172.201 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.413 ' HA ' ' HD2' ' A' ' 53' ' ' PRO . 57.3 m -158.76 94.32 1.87 Allowed Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.434 -179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 52' ' ' THR . 19.5 Cg_endo -56.9 152.74 41.38 Favored 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.648 2.232 . . . . 0.0 112.989 -177.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.0 m -157.73 159.9 37.34 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 -176.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.597 ' HG3' ' O ' ' A' ' 73' ' ' GLU . 29.7 ttpp -65.96 105.42 1.32 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 120.803 0.335 . . . . 0.0 110.429 -177.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 110.77 -4.31 29.12 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.143 -177.651 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -97.32 -168.87 1.76 Allowed 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 177.553 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.569 HG12 HG13 ' A' ' 20' ' ' VAL . 3.1 mp -133.78 146.62 31.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 C-N-CA 120.965 -0.294 . . . . 0.0 110.692 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.678 HD11 ' CD2' ' A' ' 108' ' ' TYR . 3.1 tm? -99.3 127.71 45.34 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.432 -179.004 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.633 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 24.2 tm0? -130.72 139.25 50.27 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 112.862 0.69 . . . . 0.0 112.862 -172.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.922 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 38.6 t -134.67 149.05 50.48 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.497 175.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 20.7 m -89.63 -22.9 22.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.822 0.344 . . . . 0.0 111.26 -178.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.404 ' O ' ' HA2' ' A' ' 67' ' ' GLY . 13.6 pt-20 -87.66 164.84 15.81 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.88 -0.328 . . . . 0.0 110.587 -179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.05 173.86 18.43 Favored Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.963 -0.637 . . . . 0.0 111.509 -177.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -63.89 -28.28 67.2 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.825 2.35 . . . . 0.0 111.98 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -139.1 -0.26 1.87 Allowed 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.561 178.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.404 ' HA2' ' O ' ' A' ' 63' ' ' GLU . . . 105.49 -161.09 14.73 Favored Glycine 0 N--CA 1.446 -0.675 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -170.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.922 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 8.5 t-160 -144.1 97.1 3.0 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 117.256 0.528 . . . . 0.0 110.532 178.355 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.615 ' HA ' ' O ' ' A' ' 59' ' ' LEU . 30.8 m -116.29 117.92 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 CA-C-O 121.924 0.868 . . . . 0.0 111.066 169.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . 0.538 ' HB3' HD12 ' A' ' 83' ' ' ILE . . . -129.65 128.48 42.68 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.266 -1.333 . . . . 0.0 109.078 178.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 19.3 t80 -70.58 133.64 46.91 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.061 0.457 . . . . 0.0 110.291 -176.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 22.0 t -86.5 111.61 21.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.265 -176.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.597 ' O ' ' HG3' ' A' ' 55' ' ' LYS . 59.7 mm-40 -78.33 -30.49 48.23 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 13.0 p 178.82 148.51 0.21 Allowed 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.711 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.811 HG23 HG22 ' A' ' 81' ' ' VAL . 8.1 p -106.83 130.55 58.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 172.59 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -81.08 164.25 22.58 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.095 0.474 . . . . 0.0 111.472 -172.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 13.4 m -67.46 -22.56 65.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.605 -177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.14 -2.3 55.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.596 -0.275 . . . . 0.0 111.535 -179.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 98.66 -20.38 50.61 Favored Glycine 0 N--CA 1.448 -0.55 0 C-N-CA 120.611 -0.804 . . . . 0.0 111.978 -178.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.7 m -68.42 144.81 54.57 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 177.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.811 HG22 HG23 ' A' ' 75' ' ' VAL . 54.2 t -114.2 127.65 71.54 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-O 120.728 0.299 . . . . 0.0 111.373 -175.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 95.8 m -93.17 109.2 20.7 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 109.951 178.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 70' ' ' ALA . 39.6 pt -113.69 155.41 14.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.462 179.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 67.2 m -127.11 116.04 20.07 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-O 121.736 0.779 . . . . 0.0 110.346 176.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 5.8 pt-20 -117.98 103.38 9.87 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.54 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.62 ' HA ' ' HA ' ' A' ' 95' ' ' VAL . 56.9 ttm -74.86 126.25 30.54 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.125 -179.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.468 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 47.2 t30 72.35 -64.35 0.4 Allowed 'General case' 0 N--CA 1.466 0.346 0 O-C-N 124.251 0.969 . . . . 0.0 110.833 179.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.698 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 40.6 t80 57.04 40.08 28.82 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.313 0.577 . . . . 0.0 109.604 -179.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 43.4 p 50.42 73.29 0.28 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.125 -172.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -170.02 -97.55 0.11 Allowed Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.76 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -90.68 123.92 7.29 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.908 -0.663 . . . . 0.0 111.828 178.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -56.43 118.8 5.68 Favored 'Trans proline' 0 C--O 1.233 0.249 0 C-N-CA 123.007 2.472 . . . . 0.0 112.712 -176.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 68.1 10.74 8.01 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.194 177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 67.2 m -68.44 89.32 0.35 Allowed 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.62 ' HA ' ' HA ' ' A' ' 86' ' ' MET . 4.0 p -65.69 89.94 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.604 0 CA-C-O 121.628 0.727 . . . . 0.0 109.164 175.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.704 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 26.2 t -68.93 129.32 39.6 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.245 -172.03 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 m -91.39 104.37 16.89 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 114.961 -1.018 . . . . 0.0 109.535 177.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 38.8 ttt180 -125.22 145.36 50.01 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.629 -0.26 . . . . 0.0 110.636 -173.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 51.7 m -121.13 120.03 34.11 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.043 0.449 . . . . 0.0 110.421 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.512 ' HB ' ' HB ' ' A' ' 81' ' ' VAL . 46.9 mm -94.43 119.56 42.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.145 179.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -63.87 148.65 48.88 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 172.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -54.23 -38.65 65.96 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 -176.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 7.5 p -61.53 -47.17 86.81 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.111 0.481 . . . . 0.0 111.052 179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.594 ' HG3' ' CE2' ' A' ' 108' ' ' TYR . 6.3 tp10 -72.65 -24.97 61.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.939 179.277 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -68.91 -28.32 66.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.349 176.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -72.83 -9.44 75.23 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.919 -0.658 . . . . 0.0 111.98 174.179 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . 0.498 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 4.6 t30 -87.78 -48.26 7.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.043 0.449 . . . . 0.0 110.643 177.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.678 ' CD2' HD11 ' A' ' 59' ' ' LEU . 49.2 m-85 -79.42 138.64 37.69 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.775 -172.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.481 ' HA ' ' CB ' ' A' ' 51' ' ' HIS . 47.9 m-80 -84.16 165.88 18.07 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.854 178.385 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.699 ' HE1' ' HB2' ' A' ' 50' ' ' ASN . 0.3 OUTLIER -144.94 146.0 31.79 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.21 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.78 HG22 HG12 ' A' ' 49' ' ' VAL . 44.6 pt -116.78 124.06 72.42 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 CA-C-O 121.041 0.448 . . . . 0.0 110.747 -173.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 32.2 p80 -138.86 159.84 41.15 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.47 177.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.768 ' H ' HD13 ' A' ' 113' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.438 -1.056 0 CA-C-O 118.63 -0.7 . . . . 0.0 109.989 176.364 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.599 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.6 p -122.42 17.45 10.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.98 0.419 . . . . 0.0 111.029 -178.103 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 55.0 m -84.82 106.76 16.59 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.117 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 8.3 tt -172.07 110.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.68 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.2 p -109.98 62.03 0.6 Allowed 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.83 176.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 32.6 p-80 42.44 78.44 0.05 OUTLIER 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 122.109 0.957 . . . . 0.0 110.715 -170.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.5 m -79.2 6.32 10.04 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.667 -173.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 95.79 159.62 32.71 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.724 179.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.616 HD21 ' HB2' ' A' ' 22' ' ' ASP . 83.9 m-20 -125.29 172.23 9.74 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 179.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.7 mt -64.6 -30.36 71.39 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.084 0.469 . . . . 0.0 110.561 174.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . 0.53 ' HB3' ' HD1' ' A' ' 18' ' ' TRP . 3.2 t80 -83.94 -170.14 2.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.855 -173.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.52 ' HB ' ' CG ' ' A' ' 15' ' ' GLN . 2.8 m -69.08 -99.68 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.413 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -169.492 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.445 ' H ' ' HB ' ' A' ' 12' ' ' THR . . . -172.5 107.45 0.19 Allowed 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.246 -177.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.504 ' HA2' ' HE3' ' A' ' 86' ' ' MET . . . 76.22 25.64 65.75 Favored Glycine 0 N--CA 1.449 -0.5 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.824 178.042 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.52 ' CG ' ' HB ' ' A' ' 12' ' ' THR . 9.6 mm100 -92.23 178.21 5.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.771 ' HB3' ' HA ' ' A' ' 88' ' ' TYR . 2.1 p -63.84 -59.86 4.0 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.702 0.26 . . . . 0.0 111.702 -175.519 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 40.2 p -70.51 -21.54 62.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.116 0.484 . . . . 0.0 110.399 179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.53 ' HD1' ' HB3' ' A' ' 11' ' ' TYR . 71.0 t90 -70.31 -50.55 38.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.244 178.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 65.1 t80 -60.29 -44.84 95.03 Favored 'General case' 0 CA--C 1.522 -0.132 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.431 -178.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 88.0 t -56.48 -49.89 75.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.181 176.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 36.6 t80 -64.07 -36.32 83.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.973 -176.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASP . . . . . 0.616 ' HB2' HD21 ' A' ' 9' ' ' ASN . 24.1 t70 -70.23 -45.05 67.3 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.883 0.373 . . . . 0.0 111.001 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 29.4 mmmt -65.96 -24.47 66.81 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.15 -177.091 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.51 HG21 HD13 ' A' ' 28' ' ' ILE . 33.5 m -91.54 1.78 8.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.804 176.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 66.53 26.99 72.9 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 121.209 -0.52 . . . . 0.0 112.492 178.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 71.97 21.1 79.17 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.518 -177.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -59.64 -58.84 6.83 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-O 121.268 0.556 . . . . 0.0 110.64 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.51 HD13 HG21 ' A' ' 24' ' ' VAL . 0.1 OUTLIER -119.23 153.61 21.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.371 177.311 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.583 ' HA2' ' CE3' ' A' ' 32' ' ' TRP . . . 130.33 -146.7 17.76 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.502 171.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 46.1 p 69.23 -42.2 0.49 Allowed 'General case' 0 N--CA 1.472 0.67 0 C-N-CA 125.04 1.336 . . . . 0.0 112.13 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.2 p -104.35 6.49 35.22 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -177.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.583 ' CE3' ' HA2' ' A' ' 29' ' ' GLY . 0.5 OUTLIER -83.42 -7.83 59.49 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.837 -177.192 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 77.59 -120.1 5.45 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 120.258 -0.973 . . . . 0.0 112.115 -178.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.405 ' O ' ' HD1' ' A' ' 38' ' ' TRP . 50.9 m-80 -119.05 -176.57 3.14 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 173.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.449 ' HB3' ' O ' ' A' ' 66' ' ' PHE . . . -57.65 -51.4 69.67 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 113.218 0.821 . . . . 0.0 113.218 -169.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . 0.486 ' HB3' ' CA ' ' A' ' 67' ' ' GLY . 30.7 p-10 -75.58 -3.17 32.78 Favored 'General case' 0 C--N 1.324 -0.542 0 O-C-N 121.815 -0.553 . . . . 0.0 111.693 -175.575 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.533 ' ND2' ' HB2' ' A' ' 41' ' ' ALA . 12.7 t30 -106.11 0.28 25.33 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.337 0.589 . . . . 0.0 109.437 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' TRP . . . . . 0.804 ' CH2' HG21 ' A' ' 58' ' ' ILE . 0.6 OUTLIER -54.81 -70.16 0.11 Allowed 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -172.488 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.478 ' O ' ' HG3' ' A' ' 43' ' ' GLN . . . -50.49 -38.12 42.41 Favored 'General case' 0 C--N 1.33 -0.245 0 O-C-N 123.291 0.37 . . . . 0.0 111.796 -172.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.1 46.71 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.382 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 32' ' ' TRP . . . -69.27 -41.04 77.41 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.491 -177.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.415 ' CB ' HG21 ' A' ' 111' ' ' ILE . . . -55.67 -41.36 73.58 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 -179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLN . . . . . 0.478 ' HG3' ' O ' ' A' ' 39' ' ' ALA . 50.6 mt-30 -67.83 -39.46 83.89 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.685 179.257 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -69.35 -32.06 71.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.798 -0.715 . . . . 0.0 111.825 177.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -70.47 -33.25 71.05 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.816 0.341 . . . . 0.0 110.681 176.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 115.42 24.27 4.16 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.931 177.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PHE . . . . . 0.743 ' HD2' HD12 ' A' ' 111' ' ' ILE . 5.5 m-30 -90.14 151.7 21.47 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.013 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' THR . . . . . . . . . . . . . 9.9 m -83.37 109.98 17.75 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 174.626 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' VAL . . . . . 0.846 HG22 HG22 ' A' ' 111' ' ' ILE . 27.3 t -90.22 119.23 36.99 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-O 121.299 0.571 . . . . 0.0 111.777 -175.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASN . . . . . 0.662 ' HB2' ' CE1' ' A' ' 110' ' ' TYR . 1.7 m-20 -125.07 -161.55 1.03 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.622 -1.621 . . . . 0.0 106.622 176.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 7.7 p80 -157.41 68.3 0.53 Allowed 'General case' 0 C--N 1.309 -1.178 0 CA-C-O 121.878 0.847 . . . . 0.0 110.715 175.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.674 ' H ' ' HD1' ' A' ' 110' ' ' TYR . 39.3 m -157.55 92.35 2.26 Favored Pre-proline 0 C--N 1.323 -0.583 0 CA-C-N 114.858 -1.065 . . . . 0.0 109.285 178.561 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo -59.51 151.53 68.4 Favored 'Trans proline' 0 CA--C 1.53 0.284 0 C-N-CA 122.737 2.292 . . . . 0.0 113.414 -176.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.517 ' H ' ' HB3' ' A' ' 57' ' ' ALA . 33.3 t -166.83 173.9 9.05 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 -179.709 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.586 ' HB2' ' HA ' ' A' ' 74' ' ' SER . 63.5 tttp -61.51 120.65 10.94 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.502 -178.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.84 59.36 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.748 -0.739 . . . . 0.0 111.931 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.686 ' HB1' ' CD2' ' A' ' 110' ' ' TYR . . . -113.2 -168.48 1.33 Allowed 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 110.401 -0.222 . . . . 0.0 110.401 178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.804 HG21 ' CH2' ' A' ' 38' ' ' TRP . 0.2 OUTLIER -134.44 -172.31 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.752 -178.374 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.599 ' H ' HG22 ' A' ' 58' ' ' ILE . 8.2 tp -136.57 161.8 34.87 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 177.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLN . . . . . 0.517 ' HA ' ' O ' ' A' ' 68' ' ' HIS . 0.6 OUTLIER -157.47 128.02 6.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.69 0.757 . . . . 0.0 112.541 -177.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.684 ' HB3' ' HB3' ' A' ' 68' ' ' HIS . 39.5 t -139.83 148.9 42.8 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 114.288 -1.324 . . . . 0.0 108.708 172.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.7 m -112.72 26.12 10.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 121.064 0.459 . . . . 0.0 110.609 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HG2' ' OG ' ' A' ' 61' ' ' SER . 18.1 mm-40 -86.57 30.74 0.7 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.198 -178.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -158.48 164.31 33.44 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.209 -177.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -65.02 -41.98 15.49 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.957 2.438 . . . . 0.0 112.709 -177.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 35' ' ' ALA . 84.2 m-85 -91.13 -20.01 22.48 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.267 177.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.486 ' CA ' ' HB3' ' A' ' 36' ' ' ASN . . . 95.07 178.89 37.41 Favored Glycine 0 N--CA 1.448 -0.519 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.671 -176.418 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.684 ' HB3' ' HB3' ' A' ' 61' ' ' SER . 19.6 t-160 -132.48 96.64 3.89 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.807 0.304 . . . . 0.0 111.246 -178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.584 HG11 ' CD2' ' A' ' 38' ' ' TRP . 33.7 m -117.73 131.36 70.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 C-N-CA 120.318 -0.553 . . . . 0.0 110.448 169.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -135.29 136.55 41.72 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.857 -178.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.632 ' CE2' ' HG2' ' A' ' 73' ' ' GLU . 37.0 t80 -76.65 136.25 39.15 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 120.971 0.415 . . . . 0.0 110.81 -175.795 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.468 HG22 HG22 ' A' ' 83' ' ' ILE . 5.4 t -94.62 122.79 46.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.553 -177.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.632 ' HG2' ' CE2' ' A' ' 71' ' ' TYR . 32.8 mt-10 -97.66 -19.68 18.12 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.469 -176.148 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.586 ' HA ' ' HB2' ' A' ' 55' ' ' LYS . 13.8 p -174.09 157.49 2.89 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.866 0.365 . . . . 0.0 111.502 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.415 HG23 HG12 ' A' ' 81' ' ' VAL . 8.8 p -108.74 138.42 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 172.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 -86.17 174.47 9.11 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.0 0.429 . . . . 0.0 110.911 -173.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 t -74.48 -29.85 61.61 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.367 -176.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -76.36 -24.64 54.19 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.803 0.335 . . . . 0.0 111.013 -178.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.89 -17.56 7.18 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.503 -0.856 . . . . 0.0 112.111 -177.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 91.2 p -73.74 160.14 31.94 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 176.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.611 HG22 ' HB ' ' A' ' 100' ' ' ILE . 35.2 m -117.04 144.82 23.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 121.039 0.447 . . . . 0.0 110.952 178.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . . . . . . . . . 87.5 m -96.22 107.88 20.28 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.817 177.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.549 HD13 HD22 ' A' ' 59' ' ' LEU . 47.1 pt -105.77 158.18 6.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.739 -178.119 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 18.1 p -136.51 136.71 39.61 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 173.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 96' ' ' SER . 11.6 pt-20 -135.81 176.17 8.93 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 114.792 -1.095 . . . . 0.0 108.108 177.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . 0.504 ' HE3' ' HA2' ' A' ' 14' ' ' GLY . 14.3 ttp -147.73 131.33 16.83 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.378 179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 91' ' ' GLY . 5.8 t30 72.69 -55.39 0.68 Allowed 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 123.555 0.742 . . . . 0.0 111.532 179.33 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.771 ' HA ' ' HB3' ' A' ' 16' ' ' CYS . 29.6 t80 67.24 -81.79 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.129 0 O-C-N 123.693 0.62 . . . . 0.0 109.914 -177.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 61.2 p -161.76 21.39 0.11 Allowed 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -133.14 -95.72 0.58 Allowed Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.797 -173.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 87' ' ' ASN . . . -83.93 120.54 5.25 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.885 -0.674 . . . . 0.0 112.462 -175.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.494 ' HA ' ' OD1' ' A' ' 87' ' ' ASN . 42.5 Cg_exo -56.61 122.88 12.58 Favored 'Trans proline' 0 N--CA 1.464 -0.23 0 C-N-CA 122.978 2.452 . . . . 0.0 112.548 -178.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 68.32 17.7 9.21 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.297 -0.865 . . . . 0.0 112.125 176.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 72.5 m -71.27 96.14 1.38 Allowed 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 169.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 44.6 t -66.52 87.66 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 174.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.595 ' HB3' ' HG3' ' A' ' 85' ' ' GLU . 21.9 t -76.93 112.82 13.94 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.791 -0.641 . . . . 0.0 110.537 -172.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 3.1 p -93.08 123.22 36.19 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.692 178.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.402 ' HB2' HD11 ' A' ' 83' ' ' ILE . 35.1 mtt-85 -134.04 155.3 50.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.695 0.284 . . . . 0.0 110.333 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 36.9 m -113.48 117.56 32.03 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.746 174.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.611 ' HB ' HG22 ' A' ' 81' ' ' VAL . 51.7 mm -96.02 109.72 23.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 -179.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 42.2 t -64.91 152.59 42.73 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 177.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . . . -50.89 -29.66 12.57 Favored 'General case' 0 C--O 1.236 0.382 0 CA-C-O 120.962 0.41 . . . . 0.0 110.824 175.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . 0.59 ' HB2' ' OE2' ' A' ' 104' ' ' GLU . 1.2 m -55.75 -51.55 66.99 Favored 'General case' 0 N--CA 1.453 -0.298 0 CA-C-N 115.329 -0.851 . . . . 0.0 110.711 177.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.621 ' HB3' ' CE2' ' A' ' 108' ' ' TYR . 4.2 mp0 -82.79 -26.64 31.61 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.597 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.506 ' HB3' ' HA ' ' A' ' 102' ' ' ALA . . . -59.25 -34.11 71.84 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.34 -178.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -73.39 -14.49 79.34 Favored Glycine 0 CA--C 1.52 0.403 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.524 176.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ASN . . . . . . . . . . . . . 6.6 t30 -92.36 -41.97 10.05 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.812 0.339 . . . . 0.0 111.226 -177.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.621 ' CE2' ' HB3' ' A' ' 104' ' ' GLU . 47.4 m-85 -77.87 137.84 38.6 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.114 -0.493 . . . . 0.0 111.33 -175.2 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASN . . . . . 0.748 ' ND2' HG13 ' A' ' 49' ' ' VAL . 0.0 OUTLIER -83.16 152.45 25.26 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.312 177.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.686 ' CD2' ' HB1' ' A' ' 57' ' ' ALA . 1.9 p90 -141.4 152.72 44.55 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 171.129 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ILE . . . . . 0.846 HG22 HG22 ' A' ' 49' ' ' VAL . 31.0 pt -121.14 129.39 75.71 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.627 -172.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' HIS . . . . . . . . . . . . . 13.8 p80 -133.5 135.58 44.54 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.837 -0.431 . . . . 0.0 109.837 177.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.413 ' H ' HG12 ' A' ' 113' ' ' ILE . 6.5 pt . . . . . 0 C--O 1.25 1.105 0 CA-C-O 118.901 -0.571 . . . . 0.0 111.137 -178.728 . . . . . . . . 1 1 . 1 stop_ save_